<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=us-ascii">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>ema-combined-h-471-en-annotated</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:BISansCond;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:Leelawadee;}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:"Microsoft Uighur";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:"MT Extra";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:PraxisCom-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EUAlbertina;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"\@TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@Batang";
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@BatangChe";}
@font-face
	{font-family:"\@Gungsuh";}
@font-face
	{font-family:"\@GungsuhChe";}
@font-face
	{font-family:"\@DengXian Light";}
@font-face
	{font-family:"\@Gulim";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@GulimChe";}
@font-face
	{font-family:"\@Dotum";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@DotumChe";}
@font-face
	{font-family:"\@Meiryo";}
@font-face
	{font-family:"\@Meiryo UI";}
@font-face
	{font-family:"\@MingLiU";
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"\@MingLiU_HKSCS";}
@font-face
	{font-family:"\@MS PMincho";}
@font-face
	{font-family:"\@STXingkai";}
@font-face
	{font-family:"\@STZhongsong";}
@font-face
	{font-family:"\@Yu Mincho";}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:normal;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
h2
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:normal;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h3
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:normal;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h4
	{mso-style-link:"\00DCberschrift 4 Zchn";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:normal;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
h5
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:normal;}
h6
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:normal;
	font-size:9.0pt;
	font-family:"Arial",sans-serif;
	font-style:italic;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Kommentartext Zchn";
	margin:0in;
	line-height:normal;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpFirst, li.MsoListBulletCxSpFirst, div.MsoListBulletCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpMiddle, li.MsoListBulletCxSpMiddle, div.MsoListBulletCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpLast, li.MsoListBulletCxSpLast, div.MsoListBulletCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{mso-style-link:"Textk\00F6rper 2 Zchn";
	margin:0in;
	line-height:normal;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Verdana",sans-serif;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	line-height:normal;
	background:navy;
	font-size:11.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-link:"Nur Text Zchn";
	margin:0in;
	line-height:normal;
	font-size:10.5pt;
	font-family:Consolas;}
p
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:125%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Kommentarthema Zchn";
	margin:0in;
	line-height:normal;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Sprechblasentext Zchn";
	margin:0in;
	line-height:normal;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEATableCentered, li.EMEATableCentered, div.EMEATableCentered
	{mso-style-name:"EMEA Table Centered";
	margin:0in;
	text-align:center;
	line-height:normal;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEATableLeft, li.EMEATableLeft, div.EMEATableLeft
	{mso-style-name:"EMEA Table Left";
	margin:0in;
	line-height:normal;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEABodyTextIndent, li.EMEABodyTextIndent, div.EMEABodyTextIndent
	{mso-style-name:"EMEA Body Text Indent";
	mso-style-link:"EMEA Body Text Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEABodyText, li.EMEABodyText, div.EMEABodyText
	{mso-style-name:"EMEA Body Text";
	mso-style-link:"EMEA Body Text Char";
	margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEATitle, li.EMEATitle, div.EMEATitle
	{mso-style-name:"EMEA Title";
	margin:0in;
	text-align:center;
	line-height:normal;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.EMEAHeading1NoIndent, li.EMEAHeading1NoIndent, div.EMEAHeading1NoIndent
	{mso-style-name:"EMEA Heading 1 No Indent";
	margin:0in;
	line-height:normal;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.EMEAHeading3, li.EMEAHeading3, div.EMEAHeading3
	{mso-style-name:"EMEA Heading 3";
	margin:0in;
	line-height:normal;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.EMEAHeading1, li.EMEAHeading1, div.EMEAHeading1
	{mso-style-name:"EMEA Heading 1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	line-height:normal;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.EMEAHeading2, li.EMEAHeading2, div.EMEAHeading2
	{mso-style-name:"EMEA Heading 2";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	line-height:normal;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.EMEAAddress, li.EMEAAddress, div.EMEAAddress
	{mso-style-name:"EMEA Address";
	margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEAComment, li.EMEAComment, div.EMEAComment
	{mso-style-name:"EMEA Comment";
	margin:0in;
	line-height:normal;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.EMEAHiddenTitlePIL, li.EMEAHiddenTitlePIL, div.EMEAHiddenTitlePIL
	{mso-style-name:"EMEA Hidden Title PIL";
	margin:0in;
	line-height:normal;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.EMEAHiddenTitlePAC, li.EMEAHiddenTitlePAC, div.EMEAHiddenTitlePAC
	{mso-style-name:"EMEA Hidden Title PAC";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	line-height:normal;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
span.BMSInstructionText
	{mso-style-name:"BMS Instruction Text";
	font-family:"Times New Roman",serif;
	color:red;
	display:none;
	font-style:italic;
	text-decoration:none none;
	vertical-align:baseline;}
span.EMEASubscript
	{mso-style-name:"EMEA Subscript";
	vertical-align:sub;}
span.EMEASuperscript
	{mso-style-name:"EMEA Superscript";
	vertical-align:super;}
p.EMEATableHeader, li.EMEATableHeader, div.EMEATableHeader
	{mso-style-name:"EMEA Table Header";
	margin:0in;
	text-align:center;
	line-height:normal;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.EMEATitlePAC, li.EMEATitlePAC, div.EMEATitlePAC
	{mso-style-name:"EMEA Title PAC";
	margin:0in;
	line-height:normal;
	page-break-after:avoid;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.EMEAHeading0, li.EMEAHeading0, div.EMEAHeading0
	{mso-style-name:"EMEA Heading 0";
	margin:0in;
	line-height:normal;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
span.BMSSubscript
	{mso-style-name:"BMS Subscript";
	vertical-align:sub;}
span.EMEABodyTextChar
	{mso-style-name:"EMEA Body Text Char";
	mso-style-link:"EMEA Body Text";}
span.SprechblasentextZchn
	{mso-style-name:"Sprechblasentext Zchn";
	mso-style-link:Sprechblasentext;
	font-family:"Tahoma",sans-serif;}
p.BMSBodyText, li.BMSBodyText, div.BMSBodyText
	{mso-style-name:"BMS Body Text";
	mso-style-link:"BMS Body Text Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	line-height:125%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
span.KommentartextZchn
	{mso-style-name:"Kommentartext Zchn";
	mso-style-link:Kommentartext;}
span.KommentarthemaZchn
	{mso-style-name:"Kommentarthema Zchn";
	mso-style-link:Kommentarthema;
	font-weight:bold;}
span.NurTextZchn
	{mso-style-name:"Nur Text Zchn";
	mso-style-link:"Nur Text";
	font-family:Consolas;}
span.BMSBodyTextChar
	{mso-style-name:"BMS Body Text Char";
	mso-style-link:"BMS Body Text";
	color:black;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	line-height:normal;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Verdana",sans-serif;
	color:black;}
span.Textkrper2Zchn
	{mso-style-name:"Textk\00F6rper 2 Zchn";
	mso-style-link:"Textk\00F6rper 2";
	font-family:"Verdana",sans-serif;}
span.EMEABodyTextIndentChar
	{mso-style-name:"EMEA Body Text Indent Char";
	mso-style-link:"EMEA Body Text Indent";}
p.TitleA, li.TitleA, div.TitleA
	{mso-style-name:"Title A";
	margin:0in;
	text-align:center;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TitleB, li.TitleB, div.TitleB
	{mso-style-name:"Title B";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.BMSBodyText0
	{mso-style-name:"BMS Body Text \(\6587\5B57\)";
	font-family:"MS Mincho";
	color:black;}
p.BMSTableText, li.BMSTableText, div.BMSTableText
	{mso-style-name:"BMS Table Text";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	line-height:normal;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.BMSHeading1, li.BMSHeading1, div.BMSHeading1
	{mso-style-name:"BMS Heading 1";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:.8in;
	text-indent:-.8in;
	line-height:normal;
	page-break-after:avoid;
	font-size:15.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	text-transform:uppercase;
	font-weight:bold;}
p.BMSHeading2, li.BMSHeading2, div.BMSHeading2
	{mso-style-name:"BMS Heading 2";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:71.8pt;
	text-indent:-.8in;
	line-height:normal;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	font-weight:bold;}
p.BMSHeading3, li.BMSHeading3, div.BMSHeading3
	{mso-style-name:"BMS Heading 3";
	mso-style-link:"BMS Heading 3 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:.8in;
	text-align:justify;
	text-indent:-.8in;
	line-height:normal;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	font-weight:bold;}
p.BMSHeading4, li.BMSHeading4, div.BMSHeading4
	{mso-style-name:"BMS Heading 4";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:100.15pt;
	text-align:justify;
	text-indent:-.8in;
	line-height:normal;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
span.BMSSuperscript
	{mso-style-name:"BMS Superscript";
	vertical-align:super;}
span.BMSHeading3Char
	{mso-style-name:"BMS Heading 3 Char";
	mso-style-link:"BMS Heading 3";
	color:black;
	font-weight:bold;}
span.berschrift4Zchn
	{mso-style-name:"\00DCberschrift 4 Zchn";
	mso-style-link:"\00DCberschrift 4";
	font-weight:bold;
	font-style:italic;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	line-height:normal;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.NormalSingle, li.NormalSingle, div.NormalSingle
	{mso-style-name:"Normal Single";
	margin:0in;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.e24kjd
	{mso-style-name:e24kjd;}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 841.95pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEATitle style='page-break-after:auto'><span lang=EN-GB
style='color:black'>ANNEX I</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB style='color:black'>SUMMARY OF PRODUCT
CHARACTERISTICS</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE
MEDICINAL PRODUCT</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY 5&nbsp;mg
tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY 10&nbsp;mg
tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY 15&nbsp;mg
tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY 30&nbsp;mg
tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE AND
QUANTITATIVE COMPOSITION</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>ABILIFY 5&nbsp;mg
tablets</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Each tablet contains
5&nbsp;mg of aripiprazole.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Excipient with
known effect</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>63.65&nbsp;mg
lactose </span><span lang=EN-GB>(as monohydrate) </span><span lang=EN-GB
style='color:black'>per tablet</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>ABILIFY
10&nbsp;mg tablets</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Each tablet contains
10&nbsp;mg of aripiprazole.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Excipient with
known effect</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>59.07&nbsp;mg
lactose </span><span lang=EN-GB>(as monohydrate) </span><span lang=EN-GB
style='color:black'>per tablet</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>ABILIFY
15&nbsp;mg tablets</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Each tablet contains
15&nbsp;mg of aripiprazole.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Excipient with
known effect</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>54.15&nbsp;mg
lactose </span><span lang=EN-GB>(as monohydrate) </span><span lang=EN-GB
style='color:black'>per tablet</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>ABILIFY
30&nbsp;mg tablets</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Each tablet contains
30&nbsp;mg of aripiprazole.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Excipient with
known effect</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>177.22&nbsp;mg
lactose </span><span lang=EN-GB>(as monohydrate) </span><span lang=EN-GB
style='color:black'>per tablet</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>For the full list of
excipients, see section&nbsp;6.1.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL FORM</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Tablet</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>ABILIFY 5&nbsp;mg
tablets</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Rectangular and
blue, engraved with &quot;A-007&quot; and &quot;5&quot;&nbsp;on one side.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>ABILIFY
10&nbsp;mg tablets</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Rectangular and
pink, engraved with &quot;A-008&quot; and &quot;10&quot;&nbsp;on one side.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>ABILIFY
15&nbsp;mg tablets</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Round and yellow,
engraved with &quot;A-009&quot; and &quot;15&quot;&nbsp;on one side.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>ABILIFY
30&nbsp;mg tablets</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Round and pink,
engraved with &quot;A-011&quot; and &quot;30&quot;&nbsp;on one side.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CLINICAL PARTICULARS</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic indications</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY is indicated
for the treatment of schizophrenia in adults and in adolescents aged
15&nbsp;years and older.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY is indicated
for the treatment of moderate to severe manic episodes in Bipolar I Disorder
and for the prevention of a new manic episode in adults who experienced
predominantly manic episodes and whose manic episodes responded to aripiprazole
treatment (see section&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY is indicated
for the treatment up to 12&nbsp;weeks of moderate to severe manic episodes in
Bipolar I Disorder in adolescents aged 13&nbsp;years and older (see
section&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>4.2&nbsp;&nbsp;&nbsp;&nbsp; Posology and method of
administration</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Posology</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><u><span lang=EN-GB style='color:black'>Adults</span></u></i></p>

<p class=EMEABodyText><i><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Schizophrenia:</span></i><span
lang=EN-GB style='color:black;layout-grid-mode:line'> the recommended starting
dose for ABILIFY is 10&nbsp;mg/day or 15&nbsp;mg/day with a maintenance dose of
15&nbsp;mg/day administered on a once-a-day schedule without regard to meals. ABILIFY
is effective in a dose range of 10&nbsp;mg/day to&nbsp;30&nbsp;mg/day. Enhanced
efficacy at doses higher than a daily dose of 15&nbsp;mg has not been
demonstrated although individual patients may benefit from a higher dose. The maximum
daily dose should not exceed 30&nbsp;mg.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black;layout-grid-mode:
line'>Manic episodes in Bipolar I Disorder:</span></i><span lang=EN-GB
style='color:black'> the recommended starting dose for <span style='layout-grid-mode:
line'>ABILIFY </span>is 15&nbsp;mg administered on a once-a-day schedule
without regard to meals as monotherapy or combination therapy (see section&nbsp;5.1).
Some patients may benefit from a higher dose. <span style='layout-grid-mode:
line'>The maximum daily dose should not exceed 30&nbsp;mg.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black;layout-grid-mode:
line'>Recurrence prevention of manic episodes in Bipolar I Disorder</span></i><i><span
lang=EN-GB style='color:black'>:</span></i><span lang=EN-GB style='color:black'>
for </span><span lang=EN-GB style='color:black'>preventing recurrence of manic
episodes in patients, who have been receiving aripiprazole as monotherapy or
combination therapy, continue therapy at the same dose. </span><span
lang=EN-GB style='color:black'>Adjustments of daily dosage, including dose
reduction should be considered on the basis of clinical status.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><i><u><span lang=EN-GB style='color:black'>Paediatric
population</span></u></i></p>

<p class=EMEABodyText><i><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Schizophrenia in
adolescents aged 15&nbsp;years and older</span></i><span lang=EN-GB
style='color:black'>: the recommended dose for <span style='layout-grid-mode:
line'>ABILIFY</span> is 10&nbsp;mg/day administered on a once-a-day schedule
without regard to meals. Treatment should be initiated at 2&nbsp;mg (using <span
style='layout-grid-mode:line'>ABILIFY</span> oral solution 1&nbsp;mg/mL) for 2&nbsp;days,
titrated to 5&nbsp;mg for 2&nbsp;additional days to reach the recommended daily
dose of 10&nbsp;mg. When appropriate, subsequent dose increases should be
administered in 5&nbsp;mg increments without exceeding the maximum daily dose
of 30&nbsp;mg (see section&nbsp;5.1). ABILIFY is effective in a dose range of
10&nbsp;<span style='layout-grid-mode:line'>mg/day</span> to 30&nbsp;mg/day.
Enhanced efficacy at doses higher than a daily dose of 10&nbsp;mg has not been
demonstrated although individual patients may benefit from a higher dose.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY is not
recommended for use in patients with schizophrenia below 15&nbsp;years of age
due to insufficient data on safety and efficacy (see sections&nbsp;4.8 and
5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Manic episodes in
Bipolar I Disorder in adolescents aged 13&nbsp;years and older</span></i><span
lang=EN-GB style='color:black'>: the recommended dose for ABILIFY is
10&nbsp;mg/day administered on a once-a-day schedule without regard to meals.
Treatment should be initiated at 2&nbsp;mg (using ABILIFY oral solution
1&nbsp;mg/mL) for 2&nbsp;days, titrated to 5&nbsp;mg for 2&nbsp;additional days
to reach the recommended daily dose of 10&nbsp;mg. The treatment duration
should be the minimum necessary for symptom control and must not exceed
12&nbsp;weeks. Enhanced efficacy at doses higher than a daily dose of
10&nbsp;mg has not been demonstrated, and a daily dose of 30&nbsp;mg is
associated with a substantially higher incidence of significant adverse
reactions including EPS related events, somnolence, fatigue and weight gain
(see section&nbsp;4.8). Doses higher than 10&nbsp;mg/day should therefore only
be used in exceptional cases and with close clinical monitoring (see
sections&nbsp;4.4,&nbsp;4.8 and&nbsp;5.1). Younger patients are at increased
risk of experiencing adverse events associated with aripiprazole. Therefore,
ABILIFY is not recommended for use in patients below 13&nbsp;years of age (see
sections&nbsp;4.8 and&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Irritability
associated with autistic disorder:</span></i><span lang=EN-GB style='color:
black'> the safety and efficacy of ABILIFY in children and adolescents aged
below 18&nbsp;years have not yet been established. Currently available data are
described in section&nbsp;5.1 but no recommendation on a posology can be made.</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Tics associated
with Tourette&#8217;s disorder:</span></i><span lang=EN-GB style='color:black'>
the safety and efficacy of ABILIFY in children and adolescents 6 to 18 years of
age have not yet been established. Currently available data are described in
section&nbsp;5.1 but no recommendation on a posology can be made.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><u><span lang=EN-GB style='color:black'>Special
population</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Hepatic
impairment</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>No dosage adjustment
is required for patients with mild to moderate hepatic impairment. In patients
with severe hepatic impairment, the data available are insufficient to
establish recommendations. In these patients dosing should be managed
cautiously. However, the maximum daily dose of 30&nbsp;mg should be used with
caution in patients with severe hepatic impairment (see section&nbsp;5.2).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Renal impairment</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>No dosage adjustment
is required in patients with renal impairment.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Elderly</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The safety and efficacy
of ABILIFY in the treatment of schizophrenia or manic episodes in Bipolar I
Disorder in patients aged 65&nbsp;years and older has not been established.
Owing to the greater sensitivity of this population, a lower starting dose
should be considered when clinical factors warrant (see section&nbsp;4.4).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Gender</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>No dosage adjustment
is required for female patients as compared to male patients
(see&nbsp;section&nbsp;5.2).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Smoking status</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>According to the
metabolic pathway of aripiprazole no dosage adjustment is required for smokers
(see section&nbsp;4.5).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Dose adjustments
due to interactions</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>When concomitant administration of strong CYP3A4 or CYP2D6 inhibitors
with aripiprazole occurs, the aripiprazole dose should be reduced. When the
CYP3A4 or CYP2D6 inhibitor is withdrawn from the combination therapy,
aripiprazole dose should then be increased (see section&nbsp;4.5).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>When concomitant administration of strong CYP3A4 inducers with
aripiprazole occurs, the aripiprazole dose should be increased. When the CYP3A4
inducer is withdrawn from the combination therapy, the aripiprazole dose should
then be reduced to the recommended dose (see section&nbsp;4.5).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Method of
administration</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>ABILIFY</span><span lang=EN-GB style='color:black'> is for oral use.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Orodispersible
tablets or oral solution may be used as an alternative to ABILIFY tablets for
patients who have difficulty swallowing ABILIFY tablets (see section&nbsp;5.2).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Hypersensitivity to
the active substance or to any of the excipients listed in section&nbsp;6.1.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special warnings and
precautions for use</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>During antipsychotic
treatment, improvement in the patient's clinical condition may take several
days to some weeks. Patients should be closely monitored throughout this
period.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Suicidality</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The occurrence of
suicidal behaviour is inherent in psychotic illnesses and mood disorders and in
some cases has been reported early after initiation or switch of antipsychotic <em><span
style='font-style:normal'>treatment</span></em>, including treatment with
aripiprazole (see section&nbsp;4.8). Close supervision of high-risk patients
should accompany antipsychotic treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Cardiovascular
disorders</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole should
be used with caution in patients with known cardiovascular disease (history of
myocardial infarction or ischaemic heart disease, heart failure, or conduction
abnormalities), cerebrovascular disease, conditions which would predispose
patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive
medicinal products) or hypertension, including accelerated or malignant. Cases
of venous thromboembolism (VTE) have been reported with antipsychotic medicinal
products. Since patients treated with antipsychotics often present with
acquired risk factors for VTE, all possible risk factors for VTE should be
identified before and during treatment with aripiprazole and preventive
measures undertaken.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>QT prolongation</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In clinical trials
of aripiprazole, the incidence of QT prolongation was comparable to placebo.
Aripiprazole should be used with caution in patients with a family history of
QT prolongation (see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Tardive
dyskinesia</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In clinical trials
of one year or less duration, there were uncommon reports of treatment emergent
dyskinesia during treatment with aripiprazole. If signs and symptoms of tardive
dyskinesia appear in a patient on aripiprazole, dose reduction or
discontinuation should be considered (see section&nbsp;4.8). These symptoms can
temporally deteriorate or can even arise after discontinuation of treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Other
extrapyramidal symptoms</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In paediatric
clinical trials of aripiprazole akathisia and Parkinsonism were observed. If
signs and symptoms of other EPS appear in a patient taking aripiprazole, dose
reduction and close clinical monitoring should be considered.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Neuroleptic
Malignant Syndrome (NMS)</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>NMS is a potentially
fatal symptom complex associated with antipsychotics. In clinical trials, rare
cases of NMS were reported during treatment with aripiprazole. Clinical
manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status
and evidence of autonomic instability (irregular pulse or blood pressure,
tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs may include
elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute
renal failure. However, elevated creatine phosphokinase and rhabdomyolysis, not
necessarily in association with NMS, have also been reported. If a patient
develops signs and symptoms indicative of NMS, or presents with unexplained
high fever without additional clinical manifestations of NMS, all antipsychotics,
including aripiprazole, must be discontinued.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Seizure</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In clinical trials,
uncommon cases of seizure were reported during treatment with aripiprazole.
Therefore, aripiprazole should be used with caution in patients who have a
history of seizure disorder or have conditions associated with seizures (see
section&nbsp;4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Elderly patients
with dementia-related psychosis</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Increased
mortality</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In three
placebo-controlled trials (n&nbsp;=&nbsp;938; mean age: 82.4&nbsp;years; range:
56 to 99&nbsp;years) of aripiprazole in elderly patients with psychosis
associated with Alzheimer's disease, patients treated with aripiprazole were at
increased risk of death compared to placebo. The rate of death in
aripiprazole-treated patients was 3.5&nbsp;% compared to 1.7&nbsp;% in the
placebo group. Although the causes of deaths were varied, most of the deaths
appeared to be either cardiovascular (e.g. heart failure, sudden death) or
infectious (e.g. pneumonia) in nature (see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Cerebrovascular
adverse reactions</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In the same trials,
cerebrovascular adverse reactions (e.g. stroke, transient ischaemic attack),
including fatalities, were reported in patients (mean age: 84&nbsp;years;
range: 78 to 88&nbsp;years). Overall, 1.3&nbsp;% of aripiprazole-treated
patients reported cerebrovascular adverse reactions compared with 0.6&nbsp;% of
placebo-treated patients in these trials. This difference was not statistically
significant. However, in one of these trials, a fixed-dose trial, there was a
significant dose response relationship for cerebrovascular adverse reactions in
patients treated with aripiprazole (see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole is not
indicated for the treatment of patients with dementia-related psychosis.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Hyperglycaemia
and diabetes mellitus</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Hyperglycaemia, in
some cases extreme and associated with ketoacidosis or hyperosmolar coma or
death, has been reported in patients treated with atypical antipsychotics,
including aripiprazole. Risk factors that may predispose patients to severe
complications include obesity and family history of diabetes. In clinical
trials with aripiprazole, there were no significant differences in the
incidence rates of hyperglycaemia-related adverse reactions (including
diabetes) or in abnormal glycaemia laboratory values compared to placebo.
Precise risk estimates for hyperglycaemia-related adverse reactions in patients
treated with aripiprazole and with other atypical antipsychotics are not
available to allow direct comparisons. Patients treated with any antipsychotics,
including aripiprazole, should be observed for signs and symptoms of
hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness) and
patients with diabetes mellitus or with risk factors for diabetes mellitus
should be monitored regularly for worsening of glucose control (see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Hypersensitivity</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Hypersensitivity
reactions, characterised by allergic symptoms, may occur with aripiprazole (see
section&nbsp;4.8).</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Weight gain</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Weight gain is
commonly seen in schizophrenic and bipolar mania patients due to
co-morbidities, use of antipsychotics known to cause weight gain, poorly
managed life-style, and might lead to severe complications. Weight gain has
been reported post-marketing among patients prescribed aripiprazole. When seen,
it is usually in those with significant risk factors such as history of
diabetes, thyroid disorder or pituitary adenoma. In clinical trials
aripiprazole has not been shown to induce clinically relevant weight gain in
adults (see section&nbsp;5.1). In clinical trials of adolescent patients with
bipolar mania, aripiprazole has been shown to be associated with weight gain
after 4&nbsp;weeks of treatment. Weight gain should be monitored in adolescent
patients with bipolar mania. If weight gain is clinically significant, dose
reduction should be considered (see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Dysphagia</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Oesophageal
dysmotility and aspiration have been associated with the use of antipsychotics,
including aripiprazole. Aripiprazole should be used cautiously in patients at
risk for aspiration pneumonia.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB>Pathological
gambling and other impulse control disorders</span></u></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Patients can experience increased urges,
particularly for gambling, and the inability to control these urges while
taking aripiprazole. Other urges, reported, include: increased sexual urges,
compulsive shopping, binge or compulsive eating, and other impulsive and
compulsive behaviours. It is important for prescribers to ask patients or their
caregivers specifically about the development of new or increased gambling
urges, sexual urges, compulsive shopping, binge or compulsive eating, or other
urges while being treated with aripiprazole. It should be noted that
impulse-control symptoms can be associated with the underlying disorder;
however, in some cases, urges were reported to have stopped when the dose was
reduced or the medication was discontinued. Impulse control disorders may
result in harm to the patient and others if not recognised. Consider dose
reduction or stopping the medication if a patient develops such urges while taking
aripiprazole (see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Lactose</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY tablets
contain lactose. Patients with rare hereditary problems of galactose
intolerance, total lactase deficiency or glucose-galactose malabsorption should
not take this medicinal product.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Patients with attention
deficit hyperactivity disorder (ADHD) comorbidity</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Despite the high
comorbidity frequency of Bipolar I Disorder and ADHD, very limited safety data
are available on concomitant use of aripiprazole and stimulants; therefore,
extreme caution should be taken when these medicinal products are
co-administered.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Falls</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><a name="_Hlk952060"><span
style='color:black'>Aripiprazole may cause somnolence, postural hypotension,
motor and sensory instability, which may lead to falls. Caution should be taken
when treating patients at higher risk, and a lower starting dose should be
considered (e.g., elderly or debilitated patients; see section 4.2).</span></a></p>

<p class=MsoNormal style='margin-left:.1pt;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction with
other medicinal products and other forms of interaction</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>D<span
style='layout-grid-mode:line'>ue to its &#945;</span><span class=BMSSubscript>1</span>-adrenergic
receptor antagonism,<span style='layout-grid-mode:line'> aripiprazole has the
potential to enhance the effect of certain antihypertensive medicinal products.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Given the primary
CNS effects of aripiprazole, caution should be used when aripiprazole is administered
in combination with alcohol or other CNS medicinal products with overlapping
adverse reactions such as sedation (see&nbsp;section&nbsp;4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If aripiprazole is
administered concomitantly with medicinal products known to cause QT
prolongation or electrolyte imbalance, caution should be used.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Potential for
other medicinal products to affect <em><span style='font-style:normal'>aripiprazole</span></em></span></u></p>

<p class=EMEABodyText><em><u><span lang=EN-GB style='color:black;font-style:
normal'><span style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>A gastric acid
blocker, the H<sub>2</sub>&nbsp;antagonist famotidine, reduces aripiprazole
rate of absorption but this effect is deemed not clinically relevant. <span
style='layout-grid-mode:line'>Aripiprazole is metabolised by multiple pathways
involving the CYP2D6 and CYP3A4 enzymes but not CYP1A enzymes. Thus, no dosage
adjustment is required for smokers.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Quinidine and other
CYP2D6 inhibitors</span></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>In a clinical trial in healthy subjects, a strong inhibitor of CYP2D6
(quinidine) increased aripiprazole AUC by 107&nbsp;%, while </span><span
lang=EN-GB style='color:black'>C<span class=EMEASubscript>max</span><span
style='layout-grid-mode:line'> was unchanged. The AUC and </span>C<span
class=EMEASubscript>max</span><span style='layout-grid-mode:line'> of
dehydro-aripiprazole, the active metabolite, decreased by 32&nbsp;% and 47&nbsp;%</span></span><span
lang=EN-GB style='color:black'>, respectively</span><span lang=EN-GB
style='color:black;layout-grid-mode:line'>. Aripiprazole dose should be reduced
to approximately one-half of its prescribed dose when concomitant
administration of aripiprazole with quinidine occurs. Other strong inhibitors
of CYP2D6, such as fluoxetine and paroxetine, may be expected to have similar
effects and similar dose reductions should therefore be applied.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Ketoconazole and
other CYP3A4 inhibitors</span></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>In a clinical trial in healthy subjects, a strong inhibitor of CYP3A4
(ketoconazole) increased aripiprazole AUC and </span><span lang=EN-GB
style='color:black'>C<span class=EMEASubscript>max</span><span
style='layout-grid-mode:line'> by 63&nbsp;% and 37&nbsp;%, respectively. The
AUC and </span>C<span class=EMEASubscript>max</span><span style='layout-grid-mode:
line'> of dehydro-aripiprazole increased by 77&nbsp;% and 43&nbsp;%,
respectively. In CYP2D6 poor metabolisers, concomitant use of strong inhibitors
of CYP3A4 may result in higher plasma concentrations of aripiprazole compared
to that in CYP2D6 extensive metabolizers. When considering concomitant
administration of ketoconazole or other strong CYP3A4 inhibitors with aripiprazole,
potential benefits should </span>outweigh<span style='layout-grid-mode:line'>
the potential risks to the patient. When concomitant administration of ketoconazole
with aripiprazole occurs, aripiprazole dose should be reduced to approximately
one-half of its prescribed dose. Other strong inhibitors of CYP3A4, such as
itraconazole and HIV protease inhibitors may be expected to have similar
effects and similar dose reductions should therefore be applied (see
section&nbsp;4.2). </span>Upon discontinuation of the CYP2D6 or CYP3A4
inhibitor, the dosage of <span style='layout-grid-mode:line'>aripiprazole</span>
should be increased to the level prior to the initiation of the concomitant
therapy. When weak inhibitors of CYP3A4 (e.g. diltiazem) or CYP2D6 (e.g.
escitalopram) are used concomitantly with <span style='layout-grid-mode:line'>aripiprazole</span>,
modest increases in plasma aripiprazole concentrations may be expected.</span></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Carbamazepine and
other CYP3A4 inducers</span></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Following
concomitant administration of carbamazepine, a strong inducer of CYP3A4, and oral
aripiprazole to patients with schizophrenia or schizoaffective disorder, the
geometric means of C<span class=EMEASubscript>max</span> and AUC for
aripiprazole were 68&nbsp;% and 73&nbsp;% lower, respectively, compared to when
<span style='layout-grid-mode:line'>aripiprazole (30&nbsp;mg) was administered
alone</span>. Similarly, for dehydro-aripiprazole the geometric means of C<span
class=EMEASubscript>max</span> and AUC after carbamazepine co-administration
were 69&nbsp;% and 71&nbsp;% lower, respectively, than those following
treatment with aripiprazole alone.<span style='layout-grid-mode:line'> Aripiprazole</span>
dose should be doubled when concomitant administration of <span
style='layout-grid-mode:line'>aripiprazole</span> occurs with carbamazepine. Concomitant
administration of aripiprazole and other inducers of CYP3A4 (such as
rifampicin, rifabutin, phenytoin, phenobarbital, primidone, efavirenz,
nevirapine and St. John's Wort) may be expected to have similar effects and
similar dose increases should therefore be applied. Upon discontinuation of strong
CYP3A4 inducers, the dosage of <span style='layout-grid-mode:line'>aripiprazole</span>
should be reduced to the recommended dose.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Valproate and
lithium</span></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>When either
valproate or lithium was administered concomitantly with aripiprazole, there
was no clinically significant change in aripiprazole concentrations </span><span
lang=EN-GB>and therefore no dose adjustment is necessary when either valproate
or lithium is administered with aripiprazole<span style='color:black'>.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Potential for <span
style='layout-grid-mode:line'>aripiprazole</span> to affect other medicinal
products</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In clinical studies,
10&nbsp;mg/day to 30&nbsp;mg/day doses of aripiprazole had no significant
effect on the metabolism of substrates of CYP2D6
(dextromethorphan/3-methoxymorphinan ratio), CYP2C9&nbsp;(warfarin), CYP2C19
(omeprazole), and CYP3A4 (dextromethorphan). Additionally, aripiprazole and
dehydro-aripiprazole did not show potential for altering CYP1A2-mediated
metabolism <i>in&nbsp;vitro</i>. Thus, aripiprazole is unlikely to cause
clinically important medicinal product interactions mediated by these enzymes.</span></p>

<p class=EMEABodyText><i><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>When aripiprazole
was administered concomitantly with either valproate, lithium or lamotrigine,
there was no clinically important change in valproate, lithium or lamotrigine
concentrations.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Serotonin
syndrome</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Cases of serotonin
syndrome have been reported in patients taking aripiprazole, and possible signs
and symptoms for this condition can occur especially in cases of concomitant
use with other serotonergic medicinal products, such as selective serotonin reuptake
inhibitor/selective serotonin noradrenaline reuptake inhibitor (SSRI/SNRI), or
with medicinal products that are known to increase aripiprazole concentrations
(see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>4.6&nbsp;&nbsp;&nbsp;&nbsp; Fertility, pregnancy
and lactation</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Pregnancy</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>There are no
adequate and well-controlled trials of aripiprazole in pregnant women.
Congenital anomalies have been reported; however, causal relationship with
aripiprazole could not be established. Animal studies could not exclude
potential developmental toxicity (see section&nbsp;5.3). Patients must be
advised to notify their physician if they become pregnant or intend to become
pregnant during treatment with aripiprazole. Due to insufficient safety
information in humans and concerns raised by animal reproductive studies, this
medicinal product should not be used in pregnancy unless the expected benefit
clearly justifies the potential risk to the foetus.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Newborn infants exposed
to antipsychotics (including aripiprazole) during the third trimester of
pregnancy are at risk of adverse reactions including extrapyramidal and/or
withdrawal symptoms that may vary in severity and duration following delivery.
There have been reports of agitation, hypertonia, hypotonia, tremor,
somnolence, respiratory distress, or feeding disorder. Consequently, newborn
infants should be monitored carefully (see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Breast-feeding</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Aripiprazole/metabolites are excreted in
human milk. <em><span style='font-style:normal'>A decision must be made whether
to discontinue breast&#8209;feeding or to discontinue/abstain from </span></em>aripiprazole<em><span
style='font-style:normal'> therapy taking into account the benefit of
breast-feeding for the child and the benefit of therapy for the woman.</span></em></span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='font-style:normal'>Fertility</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=EMEABodyText><span lang=EN-GB>Aripiprazole did not impair fertility
based on data from reproductive toxicity studies.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects on ability
to drive and use machines</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>Aripiprazole </span></em><span
lang=EN-GB>has minor to moderate influence on the ability to drive and use
machines due to potential nervous system and visual effects, such as sedation,
somnolence, syncope, vision blurred, diplopia (see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable effects</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Summary
of the safety profile</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The most commonly
reported adverse reactions in placebo-controlled trials were akathisia and
nausea each occurring in more than 3<b>&nbsp;</b>% of patients treated with
oral aripiprazole.</span></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Tabulated
list of adverse reactions</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>The incidences of the Adverse Drug Reactions (ADRs)
associated with aripiprazole therapy are tabulated below. The table is based on
adverse events reported during clinical trials and/or post-marketing use.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>All ADRs are listed by system organ class and frequency;
very common (&#8805;&nbsp;1/10), common (&#8805;&nbsp;1/100 to &lt;&nbsp;1/10),
uncommon (&#8805;&nbsp;1/1,000 to &lt;&nbsp;1/100), rare (&#8805;&nbsp;1/10,000
to &lt;&nbsp;1/1,000), very rare (&lt;&nbsp;1/10,000) and not known (cannot be
estimated from the available data). Within each frequency grouping, adverse
reactions are presented in order of decreasing seriousness.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The frequency of
adverse reactions reported during post-marketing use cannot be determined as
they are derived from spontaneous reports. Consequently, the frequency of these
adverse events is qualified as &quot;not known&quot;.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
   style='color:black'>&nbsp;</span></b></p>
   </td>
   <td width=123 valign=top style='width:92.15pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
   style='color:black'>Common</span></b></p>
   </td>
   <td width=142 valign=top style='width:106.3pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
   style='color:black'>Uncommon</span></b></p>
   </td>
   <td width=217 valign=top style='width:163.0pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
   style='color:black'>Not known</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Blood and lymphatic system disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Leukopenia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Neutropenia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Thrombocytopenia</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Immune system disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Allergic reaction (e.g. anaphylactic
  reaction, angioedema including swollen tongue, tongue oedema, face oedema,
  pruritus allergic, or urticaria)</span></em></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Endocrine disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hyperprolactinaemia</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=PT style='color:black'>Diabetic hyperosmolar
  coma</span></p>
  <p class=MsoNormal><span lang=PT style='color:black'>Diabetic ketoacidosis</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Metabolism and nutrition disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;text-autospace:none'><span
  lang=EN-GB style='color:black'>Diabetes mellitus</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hyperglycaemia</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Hyponatremia</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Anorexia</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Psychiatric disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Insomnia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Anxiety</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Restlessness</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Depression</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hypersexuality</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Suicide attempt, suicidal ideation and completed suicide
  (see section&nbsp;4.4)</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Pathological gambling</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Impulse-control
  disorder</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Binge eating</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Compulsive
  shopping</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Poriomania</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Aggression</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Agitation</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Nervousness </span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Nervous system disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Akathisia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Extrapyramidal disorder</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Tremor</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Headache</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Sedation</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Somnolence</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Dizziness</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Tardive dyskinesia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Dystonia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=IT
  style='color:black'>Restless legs syndrome</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=FR
  style='color:black'>Neuroleptic Malignant Syndrome</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=FR
  style='color:black'>Grand mal convulsion</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Serotonin syndrome</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Speech disorder</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Eye disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Vision blurred</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Diplopia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Photophobia</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Oculogyric crisis</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Cardiac disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Tachycardia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Sudden death unexplained</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Torsades de pointes</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Ventricular arrhythmia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Cardiac arrest</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Bradycardia</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Vascular disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Orthostatic hypotension</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Venous thromboembolism (including pulmonary embolism and
  deep vein thrombosis)</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hypertension</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Syncope</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Respiratory, thoracic and mediastinal
  disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hiccups</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Aspiration pneumonia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Laryngospasm</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Oropharyngeal spasm</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Gastrointestinal disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Constipation</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Dyspepsia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Nausea</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Salivary hypersecretion</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Vomiting</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Pancreatitis</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Dysphagia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Diarrhoea</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Abdominal discomfort</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Stomach discomfort</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Hepatobiliary disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hepatic failure</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hepatitis</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Jaundice</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
  style='color:black'>Skin and subcutaneous tissue disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Rash</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Photosensitivity reaction</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Alopecia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hyperhidrosis</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Drug Reaction
  with Eosinophilia and Systemic Symptoms (DRESS)</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Musculoskeletal and connective tissue
  disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Rhabdomyolysis</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Myalgia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Stiffness</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Renal and urinary disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Urinary incontinence</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Urinary retention</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Pregnancy, puerperium and perinatal conditions</span></b></em></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Drug withdrawal syndrome neonatal (see section&nbsp;4.6)</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Reproductive system and breast disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Priapism</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>General disorders and administration
  site conditions</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Fatigue</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Temperature regulation disorder (e.g. hypothermia,
  pyrexia)</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Chest pain</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Peripheral oedema</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Investigations</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Weight decreased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Weight gain</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Alanine Aminotransferase </span><span lang=EN-GB
  style='color:black'>increased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Aspartate Aminotransferase increased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Gamma-glutamyltransferase increased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Alkaline phosphatase increased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>QT prolonged</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Blood glucose increased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Glycosylated haemoglobin increased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Blood glucose fluctuation</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Creatine phosphokinase increased</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Description of
selected adverse reactions</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><i><u><span lang=EN-GB style='color:black'>Adults</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Extrapyramidal
symptoms (EPS)</span></i></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Schizophrenia:</span></i><span
lang=EN-GB style='color:black'> in a long-term 52&#8209;week controlled trial,
aripiprazole-treated patients had an overall-lower incidence (25.8&nbsp;%) of
EPS including Parkinsonism, akathisia, dystonia and dyskinesia compared with
those treated with haloperidol (57.3&nbsp;%). In a long-term 26&#8209;week
placebo-controlled trial, the incidence of EPS was 19&nbsp;% for
aripiprazole-treated patients and 13.1&nbsp;% for placebo-treated patients. In
another long-term 26&#8209;week controlled trial, the incidence of EPS was 14.8&nbsp;%
for aripiprazole-treated patients and 15.1&nbsp;% for olanzapine-treated
patients.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Manic episodes in
Bipolar I Disorder: </span></i><span lang=EN-GB style='color:black'>in a 12&#8209;week
controlled trial, the incidence of EPS was 23.5&nbsp;% for aripiprazole-treated
patients and 53.3&nbsp;% for haloperidol-treated patients. In another 12&#8209;week
trial, the incidence of EPS was 26.6&nbsp;% for patients treated with
aripiprazole and 17.6&nbsp;% for those treated with lithium. In the long-term
26&#8209;week maintenance phase of a placebo-controlled trial, the incidence of
EPS was 18.2&nbsp;% for aripiprazole-treated patients and 15.7&nbsp;% for
placebo-treated patients.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Akathisia</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In
placebo-controlled trials, the incidence of akathisia in bipolar patients was
12.1&nbsp;% with aripiprazole and 3.2&nbsp;% with placebo. In schizophrenia
patients the incidence of akathisia was 6.2&nbsp;% with aripiprazole and 3.0&nbsp;%
with placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Dystonia</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Class effect: Symptoms
of dystonia, prolonged abnormal contractions of muscle groups, may occur in
susceptible individuals during the first few days of treatment. Dystonic
symptoms include: spasm of the neck muscles, sometimes progressing to tightness
of the throat, swallowing difficulty, difficulty breathing, and/or protrusion
of the tongue. While these symptoms can occur at low doses, they occur more
frequently and with greater severity with high potency and at higher doses of
first generation antipsychotic medicinal products. An elevated risk of acute
dystonia is observed in males and younger age groups.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Prolactin</span></em></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>In clinical trials for the approved indications and
post-marketing, both increase and decrease in serum prolactin as compared to
baseline was observed with aripiprazole (section&nbsp;5.1).</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Laboratory
parameters</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Comparisons between
aripiprazole and placebo in the proportions of patients experiencing
potentially clinically significant changes in routine laboratory and lipid
parameters (see section&nbsp;5.1) revealed no medically important differences.
Elevations of CPK (Creatine Phosphokinase), generally transient and
asymptomatic, were observed in 3.5&nbsp;% of aripiprazole treated patients as
compared to 2.0&nbsp;% of patients who received placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><u><span lang=EN-GB style='color:black'>Paediatric
population</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Schizophrenia in
adolescents aged 15&nbsp;years and older</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In a short-term
placebo-controlled clinical trial involving 302&nbsp;adolescents (13 to 17&nbsp;years)
with schizophrenia, the frequency and type of adverse reactions were similar to
those in adults except for the following reactions that were reported more
frequently in adolescents receiving aripiprazole than in adults receiving
aripiprazole (and more frequently than placebo):</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Somnolence/sedation
and extrapyramidal disorder were reported very commonly (&#8805;&nbsp;1/10),
and dry mouth, increased appetite, and orthostatic hypotension were reported
commonly (&#8805;&nbsp;1/100, &lt;&nbsp;1/10). The safety profile in a 26&#8209;week
open-label extension trial was similar to that observed in the short-term,
placebo-controlled trial.</span></p>

<p class=MsoNormal><span lang=EN-GB>The safety profile of a long-term,
double-blind, placebo-controlled trial was also similar except for the
following reactions that were reported more frequently than paediatric patients
taking placebo: weight decreased, blood insulin increased, arrhythmia, and
leukopenia were reported commonly (&#8805;&nbsp;1/100, &lt;&nbsp;1/10).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In the pooled
adolescent schizophrenia population (13 to 17&nbsp;years) with exposure up to
2&nbsp;years, incidence of low serum prolactin levels in females (&lt;&nbsp;3&nbsp;ng/mL)
and males (&lt;&nbsp;2&nbsp;ng/mL) was 29.5&nbsp;% and 48.3&nbsp;%,
respectively. In the adolescent (13 to 17&nbsp;years) schizophrenia population
with aripiprazole exposure of 5&nbsp;mg to 30&nbsp;mg up to 72&nbsp;months,
incidence of low serum prolactin levels in females (&lt;&nbsp;3&nbsp;ng/mL) and
males (&lt;&nbsp;2&nbsp;ng/mL) was 25.6&nbsp;% and 45.0&nbsp;%, respectively.</span></p>

<p class=MsoNormal><span lang=EN-GB>In two long-term trials with adolescent (13
to 17&nbsp;years) schizophrenia and bipolar patients treated with aripiprazole,
incidence of low serum prolactin levels in females (&lt;&nbsp;3&nbsp;ng/mL) and
males (&lt;&nbsp;2&nbsp;ng/mL) was 37.0&nbsp;% and 59.4&nbsp;%, respectively.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Manic episodes in
Bipolar I Disorder in adolescents aged 13&nbsp;years and older</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The frequency and
type of adverse reactions in adolescents with Bipolar I Disorder were similar
to those in adults except for the following reactions: very commonly
(&#8805;&nbsp;1/10) somnolence (23.0&nbsp;%), extrapyramidal disorder (18.4&nbsp;%),
akathisia (16.0&nbsp;%), and fatigue (11.8&nbsp;%); and commonly
(&#8805;&nbsp;1/100, &lt;&nbsp;1/10) abdominal pain upper, heart rate
increased, weight increased, increased appetite, muscle twitching, and
dyskinesia.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The following adverse
reactions had a possible dose response relationship; extrapyramidal disorder
(incidences were 10&nbsp;mg, 9.1&nbsp;%; 30&nbsp;mg, 28.8&nbsp;%; placebo, 1.7&nbsp;%);
and akathisia (incidences were 10&nbsp;mg, 12.1&nbsp;%; 30&nbsp;mg, 20.3&nbsp;%;
placebo, 1.7<b>&nbsp;</b>%).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Mean changes in body
weight in adolescents with Bipolar I Disorder at&nbsp;12 and 30&nbsp;weeks for
aripiprazole were 2.4&nbsp;kg and 5.8&nbsp;kg, and for placebo 0.2&nbsp;kg and
2.3&nbsp;kg, respectively.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In the paediatric
population somnolence and fatigue were observed more frequently in patients
with bipolar disorder compared to patients with schizophrenia.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In the paediatric
bipolar population (10 to 17&nbsp;years) with exposure up to 30&nbsp;weeks,
incidence of low serum prolactin levels in females (&lt;&nbsp;3&nbsp;ng/mL) and
males (&lt;&nbsp;2&nbsp;ng/mL) was 28.0&nbsp;% and 53.3&nbsp;%, respectively.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><i><span lang=EN-GB>Pathological
gambling and other impulse control disorders</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>Pathological gambling, hypersexuality,
compulsive shopping and binge or compulsive eating can occur in patients
treated with aripiprazole (see </span><span lang=EN-GB>section&nbsp;4.4).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Reporting of
suspected adverse reactions</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Reporting suspected
adverse reactions after authorisation of the medicinal product is important. It
allows continued monitoring of the benefit/risk balance of the medicinal
product. Healthcare professionals are asked to report any suspected adverse
reactions <span style='background:silver'>via the national reporting system
listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a>.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Signs
and symptoms</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In clinical trials
and post-marketing experience, accidental or intentional acute overdose of
aripiprazole alone was identified in adult patients with reported estimated
doses up to 1,260&nbsp;mg with no fatalities. The potentially medically
important signs and symptoms observed </span><span lang=EN-GB style='color:
black'>included lethargy, increased blood pressure, somnolence, tachycardia,
nausea, </span><span lang=EN-GB style='color:black'>vomiting and diarrhoea. </span><span
lang=EN-GB style='color:black'>In addition, reports of accidental overdose with
aripiprazole alone (up to 195&nbsp;mg) in children have been received with no
fatalities. The potentially medically serious signs and symptoms reported
included somnolence, transient loss of consciousness </span><span lang=EN-GB
style='color:black'>and extrapyramidal symptoms</span><span lang=EN-GB
style='color:black'>.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Management
of overdose</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Management of
overdose should concentrate on supportive therapy, maintaining an adequate
airway, oxygenation and ventilation, and management of symptoms. The
possibility of multiple medicinal product involvement should be considered.
Therefore cardiovascular monitoring should be started immediately and should
include continuous electrocardiographic monitoring to detect possible
arrhythmias. Following any confirmed or suspected overdose with aripiprazole,
close medical supervision and monitoring should continue until the patient
recovers.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Activated charcoal
(50&nbsp;g), administered one hour after aripiprazole, decreased aripiprazole C<span
class=EMEASubscript>max</span> by about 41&nbsp;% and AUC by about 51&nbsp;%,
suggesting that charcoal may be effective in the treatment of overdose.</span></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Haemodialysis</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Although there is no
information on the effect of haemodialysis in treating an overdose with
aripiprazole, haemodialysis is unlikely to be useful in overdose management since
aripiprazole is highly bound to plasma proteins.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading1 style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>5.1&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic properties</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Pharmacotherapeutic
group: Psycholeptics, other antipsychotics, ATC&nbsp;code: N05AX12</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Mechanism of
action</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>It has been proposed
that aripiprazole&#8217;s efficacy in schizophrenia and Bipolar I Disorder is
mediated through a combination of partial agonism at dopamine&nbsp;D<sub>2</sub>
and serotonin 5&#8209;HT<sub>1A</sub> receptors and antagonism of serotonin 5&#8209;HT<sub>2A</sub>
receptors. Aripiprazole exhibited antagonist properties in animal models of
dopaminergic hyperactivity and agonist properties in animal models of
dopaminergic hypoactivity. Aripiprazole exhibited high binding affinity <i>in&nbsp;vitro</i>
for dopamine&nbsp;D<sub>2</sub> and D<sub>3</sub>, serotonin 5&#8209;HT<sub>1A</sub>
and 5&#8209;HT<sub>2A</sub> receptors and moderate affinity for dopamine&nbsp;D<sub>4</sub>,
serotonin 5&#8209;HT<sub>2C</sub> and 5&#8209;HT<sub>7</sub>, alpha&#8209;1
adrenergic and histamine H<sub>1</sub> receptors. Aripiprazole also exhibited
moderate binding affinity for the serotonin reuptake site and no appreciable
affinity for muscarinic receptors. Interaction with receptors other than
dopamine and serotonin subtypes may explain some of the other clinical effects
of aripiprazole.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole doses
ranging from 0.5&nbsp;mg to 30&nbsp;mg administered once a day to healthy
subjects for 2&nbsp;weeks produced a dose-dependent reduction in the binding of
<sup>11</sup>C-raclopride, a D<sub>2</sub>/D<sub>3</sub> receptor ligand, to
the caudate and putamen detected by positron emission tomography.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Clinical efficacy
and safety</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><i><u><span lang=EN-GB style='color:black'>Adults</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Schizophrenia</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In three short-term
(4 to 6&nbsp;weeks) placebo-controlled trials involving
1,228&nbsp;schizophrenic adult patients, presenting with positive or negative
symptoms, aripiprazole was associated with statistically significantly greater
improvements in psychotic symptoms compared to placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>A<em><span
style='font-style:normal'>ripiprazole</span></em> is effective in maintaining
the clinical improvement during continuation therapy in adult patients who have
shown an initial treatment response. In a haloperidol-controlled trial, the
proportion of responder patients maintaining response to medicinal product at
52&#8209;weeks was similar in both groups (aripiprazole 77&nbsp;% and
haloperidol 73&nbsp;%). The overall completion rate was significantly higher
for patients on aripiprazole (43&nbsp;%) than for haloperidol (30&nbsp;%).
Actual scores in rating scales used as secondary endpoints, including PANSS and
the Montgomery-&Aring;sberg Depression Rating Scale (MADRS) showed a
significant improvement over haloperidol.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In a 26&#8209;week,
placebo-controlled trial in adult stabilised patients with chronic
schizophrenia, aripiprazole had significantly greater reduction in relapse
rate, 34&nbsp;% in aripiprazole group and 57&nbsp;% in placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Weight gain</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In clinical trials
aripiprazole has not been shown to induce clinically relevant weight gain. In a
26&#8209;week, olanzapine-controlled, double-blind, multi-national study of
schizophrenia which included 314&nbsp;adult patients and where the primary
endpoint was weight gain, significantly less patients had at least 7&nbsp;%
weight gain over baseline (i.e. a gain of at least 5.6&nbsp;kg for a mean
baseline weight of ~80.5&nbsp;kg) on aripiprazole (n&nbsp;=&nbsp;18, or 13&nbsp;%
of evaluable patients), compared to olanzapine (n&nbsp;=&nbsp;45, or 33&nbsp;%
of evaluable patients).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Lipid parameters</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In a pooled analysis
on lipid parameters from placebo controlled clinical trials in adults,
aripiprazole has not been shown to induce clinically relevant alterations in
levels of total cholesterol, triglycerides, High Density Lipoprotein (HDL) and Low
Density Lipoprotein (LDL).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>Prolactin</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Prolactin levels were
evaluated in all trials of all doses of aripiprazole (n&nbsp;=&nbsp;28,242).
The incidence of hyperprolactinaemia or increased serum prolactin in patients
treated with aripiprazole (0.3&nbsp;%) was similar to that of placebo (0.2&nbsp;%).
For patients receiving aripiprazole, the median time to onset was 42&nbsp;days
and median duration was 34&nbsp;days.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The incidence of
hypoprolactinaemia or decreased serum prolactin in patients treated with
aripiprazole was 0.4&nbsp;%, compared with 0.02&nbsp;% for patients treated
with placebo. For patients receiving aripiprazole, the median time to onset was
30&nbsp;days and median duration was 194&nbsp;days.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Manic episodes in
Bipolar I Disorder</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In two<b> </b>3&#8209;week,
flexible-dose,<b> </b>placebo-controlled monotherapy trials involving<b> </b>patients
with a manic or mixed episode of Bipolar I Disorder, aripiprazole demonstrated
superior efficacy to placebo in reduction of manic symptoms over 3&nbsp;weeks.
These trials included patients with or without psychotic features and with or
without a rapid-cycling course.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In one 3&#8209;week,
fixed-dose, placebo-controlled monotherapy trial involving patients with a
manic or mixed episode of Bipolar I Disorder, aripiprazole failed to
demonstrate superior efficacy to placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In two 12&#8209;week,
placebo- and active-controlled monotherapy trials in patients with a manic or
mixed episode of Bipolar I Disorder, with or without psychotic features,
aripiprazole demonstrated superior efficacy to placebo at week&nbsp;3 and a
maintenance of effect comparable to lithium or haloperidol at week&nbsp;12.
Aripiprazole also demonstrated a comparable proportion of patients in
symptomatic remission from mania as lithium or haloperidol at week&nbsp;12.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In a 6&#8209;week,
placebo-controlled trial involving patients with a manic or mixed episode of
Bipolar I Disorder, with or without psychotic features, who were partially
non-responsive to lithium or valproate monotherapy for 2&nbsp;weeks at
therapeutic serum levels, the addition of aripiprazole as adjunctive therapy
resulted in superior efficacy in reduction of manic symptoms than lithium or
valproate monotherapy.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In a 26&#8209;week,
placebo-controlled trial, followed by a 74&#8209;week extension, in manic
patients who achieved remission on aripiprazole during a stabilization phase
prior to randomisation, aripiprazole demonstrated superiority over placebo in
preventing bipolar recurrence, primarily in preventing recurrence into mania
but failed to demonstrate superiority over placebo in preventing recurrence
into depression.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In a 52&#8209;week,
placebo-controlled trial, in patients with a current manic or mixed episode of
Bipolar I Disorder who achieved sustained remission (Young Mania Rating Scale [YMRS]
and MADRS with total scores &#8804;&nbsp;12) on aripiprazole (10&nbsp;mg/day to
30&nbsp;mg/day) adjunctive to lithium or valproate for 12&nbsp;consecutive
weeks, adjunctive aripiprazole demonstrated superiority over placebo with a 46&nbsp;%
decreased risk (hazard ratio of 0.54) in preventing bipolar recurrence and a 65&nbsp;%
decreased risk (hazard ratio of 0.35) in preventing recurrence into mania over
adjunctive placebo but failed to demonstrate superiority over placebo in
preventing recurrence into depression. Adjunctive aripiprazole demonstrated
superiority over placebo on the secondary outcome measure in Clinical Global
Impression - Bipolar version (CGI-BP) Severity of Illness (SOI; mania) scores. In
this trial, patients were assigned by investigators with either open-label
lithium or valproate monotherapy to determine partial non-response. Patients
were stabilised for at least 12&nbsp;consecutive weeks with the combination of
aripiprazole and the same mood stabilizer. Stabilized patients were then
randomised to continue the same mood stabilizer with double-blind aripiprazole
or placebo. Four mood stabilizer subgroups were assessed in the randomised
phase: aripiprazole + lithium; aripiprazole + valproate; placebo + lithium;
placebo + valproate. The Kaplan-Meier rates for recurrence to any mood episode
for the adjunctive treatment arm were 16&nbsp;% in aripiprazole + lithium and
18&nbsp;% in aripiprazole + valproate compared to 45&nbsp;% in placebo +
lithium and 19&nbsp;% in placebo + valproate.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><u><span lang=EN-GB style='color:black'>Paediatric
population</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Schizophrenia in
adolescents</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In a 6&#8209;week
placebo-controlled trial involving 302&nbsp;schizophrenic adolescent patients
(13 to 17&nbsp;years), presenting with positive or negative symptoms,
aripiprazole was associated with statistically significantly greater
improvements in psychotic symptoms compared to placebo. In a sub-analysis of
the adolescent patients between the ages of 15&nbsp;to 17&nbsp;years,
representing 74&nbsp;% of the total enrolled population, maintenance of effect
was observed over the 26&#8209;week open-label extension trial.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In a 60- to 89-week, randomised,
double-blind, placebo-controlled trial in adolescent subjects (n&nbsp;=&nbsp;146;
ages 13 to 17&nbsp;years) with schizophrenia, there was a statistically
significant difference in the rate of relapse of psychotic symptoms between the
aripiprazole (19.39&nbsp;%) and placebo (37.50&nbsp;%) groups. The point
estimate of the hazard ratio (HR) was 0.461 (95&nbsp;% confidence interval,
0.242 to 0.879) in the full population. In sub-group analyses the point
estimate of the HR was 0.495 for subjects 13 to 14&nbsp;years of age compared
to 0.454 for subjects 15 to 17&nbsp;years of age. However, the estimation of
the HR for the younger (13 to 14&nbsp;years) group was not precise, reflecting
the smaller number of subjects in that group (aripiprazole, n&nbsp;=&nbsp;29;
placebo, n&nbsp;=&nbsp;12), and the confidence interval for this estimation (</span><span
lang=EN-GB style='color:black'>ranging from 0.151 to 1.628</span><span
lang=EN-GB>) did not allow conclusions to be drawn on the presence of a
treatment effect. In contrast the 95&nbsp;% confidence interval for the HR in
the older subgroup (aripiprazole, n&nbsp;=&nbsp;69; placebo, n&nbsp;=&nbsp;36)
was 0.242 to 0.879 and hence a treatment effect could be concluded in the older
patients.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Manic episodes in
Bipolar I Disorder in children and adolescents</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole was
studied in a 30&#8209;week placebo-controlled trial involving 296&nbsp;children
and adolescents (10 to 17&nbsp;years), who met DSM-IV criteria (Diagnostic and
Statistical Manual of Mental Disorders) for Bipolar I Disorder with manic or
mixed episodes with or without psychotic features and had a YMRS score </span><span
lang=EN-GB style='font-family:Symbol;color:black'>&sup3;</span><span
lang=EN-GB style='color:black'>&nbsp;20 at baseline. Among the patients
included in the primary efficacy analysis, 139&nbsp;patients had a current
co-morbid diagnosis of ADHD.</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole was
superior to placebo in change from baseline at week&nbsp;4 and at week&nbsp;12
on the Y-MRS total score. In a post-hoc analysis, the improvement over placebo
was more pronounced in the patients with associated co-morbidity of ADHD compared
to the group without ADHD, where there was no difference from placebo.
Recurrence prevention was not established.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The most common
treatment-emergent adverse events among patients receiving 30&nbsp;mg were
extrapyramidal disorder (28.3&nbsp;%), somnolence (27.3&nbsp;%), headache (23.2&nbsp;%),
and nausea (14.1&nbsp;%). Mean weight gain in the 30&nbsp;weeks
treatment-interval was 2.9&nbsp;kg as compared to 0.98&nbsp;kg in patients
treated with placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Irritability
associated with autistic disorder in paediatric patients (see section&nbsp;4.2)</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole was
studied in patients aged 6&nbsp;to 17&nbsp;years in two 8&#8209;week,
placebo-controlled trials [one flexible-dose (2&nbsp;mg/day to 15&nbsp;mg/day)
and one fixed-dose (5&nbsp;mg/day, 10&nbsp;mg/day, or 15&nbsp;mg/day)] and in
one 52&#8209;week open-label trial. Dosing in these trials was initiated at
2&nbsp;mg/day, increased to 5&nbsp;mg/day after one week, and increased by
5&nbsp;mg/day in weekly increments to the target dose. Over 75&nbsp;% of
patients were less than 13&nbsp;years of age. Aripiprazole demonstrated
statistically superior efficacy compared to placebo on the Aberrant Behaviour
Checklist Irritability subscale. However, the clinical relevance of this
finding has not been established. The safety profile included weight gain and
changes in prolactin levels. The duration of the long-term safety study was
limited to 52&nbsp;weeks. In the pooled trials, the incidence of low serum
prolactin levels in females (&lt;&nbsp;3&nbsp;ng/mL) and males (&lt;&nbsp;2&nbsp;ng/mL)
in aripiprazole-treated patients was 27/46&nbsp;(58.7&nbsp;%) and
258/298&nbsp;(86.6&nbsp;%), respectively. In the placebo-controlled trials, the
mean weight gain was 0.4&nbsp;kg for placebo and 1.6&nbsp;kg for aripiprazole.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole was
also studied in a placebo-controlled, long-term maintenance trial. After a 13
to 26&#8209;week stabilisation on aripiprazole (2&nbsp;mg/day to 15&nbsp;mg/day)
patients with a stable response were either maintained on aripiprazole or
substituted to placebo for further 16&nbsp;weeks. Kaplan-Meier relapse rates at
week&nbsp;16 were 35&nbsp;% for aripiprazole and 52&nbsp;% for placebo; the
hazard ratio for relapse within 16&nbsp;weeks (aripiprazole/placebo) was 0.57
(non-statistically significant difference). The mean weight gain over the
stabilisation phase (up to 26&nbsp;weeks) on aripiprazole was 3.2&nbsp;kg, and
a further mean increase of 2.2&nbsp;kg for aripiprazole as compared to
0.6&nbsp;kg for placebo was observed in the second phase (16&nbsp;weeks) of the
trial. Extrapyramidal symptoms were mainly reported during the stabilisation
phase in 17&nbsp;% of patients, with tremor accounting for 6.5<b>&nbsp;</b>%.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>Tics associated with
Tourette&#8217;s disorder in paediatric patients (see section&nbsp;4.2)</span></i></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>The efficacy of aripiprazole was studied in paediatric subjects
with Tourette&#8217;s disorder (aripiprazole: n&nbsp;=&nbsp;99, placebo:
n&nbsp;=&nbsp;44) in a randomised, double-blind, placebo-controlled,
8&nbsp;week study using a fixed dose weight-based treatment group design over
the dose range of 5&nbsp;mg/day to 20&nbsp;mg/day and a starting dose of
2&nbsp;mg. Patients were 7&nbsp;to&nbsp;17&nbsp;years of age and presented an
average score of 30 on Total Tic Score on the Yale Global Tic Severity Scale
(TTS-YGTSS) at baseline. Aripiprazole showed an improvement on TTS-YGTSS change
from baseline to week&nbsp;8 of 13.35, for the low dose group (5&nbsp;mg or
10&nbsp;mg) and 16.94 for the high dose group (10&nbsp;mg or 20&nbsp;mg) as
compared with an improvement of 7.09 in the placebo group.</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>The efficacy of aripiprazole in paediatric subjects with
Tourette&#8217;s syndrome (aripiprazole: n&nbsp;=&nbsp;32, placebo:
n&nbsp;=&nbsp;29) was also evaluated over a flexible dose range of 2&nbsp;mg/day
to 20&nbsp;mg/day and a starting dose of 2&nbsp;mg, in a 10&nbsp;week,
randomised, double blind, placebo-controlled study conducted in South-Korea. Patients
were 6 to 18&nbsp;years and presented an average score of 29 on
TTS-YGTSS&nbsp;at baseline. Aripiprazole group showed an improvement of 14.97
on TTS-YGTSS change from baseline to week&nbsp;10 as compared with an
improvement of 9.62 in the placebo group.</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>In both of these short-term trials, the clinical relevance of the
efficacy findings has not been established, considering the magnitude of
treatment effect compared to the large placebo effect and the unclear effects
regarding psycho-social functioning. No long-term data are available with
regard to the efficacy and the safety of aripiprazole in this fluctuating
disorder.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The European
Medicines Agency has deferred the obligation to submit the results of studies
with ABILIFY in one or more subsets of the paediatric population in the
treatment of schizophrenia and in the treatment of bipolar affective disorder
(see section&nbsp;4.2 for information on paediatric use).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic
properties</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Absorption</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole is well
absorbed, with peak plasma concentrations occurring within 3 to 5&nbsp;hours
after dosing. Aripiprazole undergoes minimal pre-systemic metabolism. The
absolute oral bioavailability of the tablet formulation is 87&nbsp;%. There is
no effect of a high fat meal on the pharmacokinetics of aripiprazole.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Distribution</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole is
widely distributed throughout the body with an apparent volume of distribution
of 4.9&nbsp;L/kg, indicating extensive extravascular distribution. At
therapeutic concentrations, aripiprazole and dehydro-aripiprazole are greater
than 99&nbsp;% bound to serum proteins, binding primarily to albumin.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Biotransformation</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole is
extensively metabolised by the liver primarily by three biotransformation
pathways: dehydrogenation, hydroxylation, and N-dealkylation. Based on <i>in&nbsp;vitro</i>
studies, CYP3A4 and CYP2D6 enzymes are responsible for dehydrogenation and
hydroxylation of aripiprazole, and N-dealkylation is catalysed by CYP3A4.
Aripiprazole is the predominant medicinal product moiety in systemic
circulation. At steady state, dehydro-aripiprazole, the active metabolite,
represents about 40&nbsp;% of aripiprazole AUC in plasma.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Elimination</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The mean elimination
half-lives for aripiprazole are approximately 75&nbsp;hours in extensive
metabolisers of CYP2D6 and approximately 146&nbsp;hours in poor metabolisers of
CYP2D6.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The total body
clearance of aripiprazole is 0.7&nbsp;mL/min/kg, which is primarily hepatic.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Following a single
oral dose of [<sup>14</sup>C]-labelled aripiprazole, approximately 27&nbsp;% of
the administered radioactivity was recovered in the urine and approximately 60&nbsp;%
in the faeces. Less than 1&nbsp;% of unchanged aripiprazole was excreted in the
urine and approximately 18&nbsp;% was recovered unchanged in the faeces.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Paediatric population</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB>The pharmacokinetics of aripiprazole and
dehydro-aripiprazole in paediatric patients 10&nbsp;to 17&nbsp;years of age
were similar to those in adults after correcting for the differences in body
weights.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Pharmacokinetics
in special patient groups</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Elderly</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>There are no
differences in the pharmacokinetics of aripiprazole between healthy elderly and
younger adult subjects, nor is there any detectable effect of age in a
population pharmacokinetic analysis in schizophrenic patients.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Gender</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>There are no
differences in the pharmacokinetics of aripiprazole between healthy male and female
subjects nor is there any detectable effect of gender in a population
pharmacokinetic analysis in schizophrenic patients.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Smoking</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Population
pharmacokinetic evaluation has revealed no evidence of clinically significant <em><span
style='font-style:normal'>effects from </span></em>smoking on the pharmacokinetics
of aripiprazole.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><i><span lang=EN-GB
style='color:black'>Race</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Population pharmacokinetic evaluation showed no evidence of
race&#8209;related differences on the pharmacokinetics of aripiprazole.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Renal impairment</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The pharmacokinetic
characteristics of aripiprazole and dehydro-aripiprazole were found to be similar
in patients with severe renal disease compared to young healthy subjects.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Hepatic
impairment</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>A single-dose study
in subjects with varying degrees of liver cirrhosis (Child&#8209;Pugh Classes
A, B, and&nbsp;C) did not reveal a significant effect of hepatic impairment on
the pharmacokinetics of aripiprazole and dehydro-aripiprazole, but the study
included only 3&nbsp;patients with Class&nbsp;C liver cirrhosis, which is
insufficient to draw conclusions on their metabolic capacity.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical
safety data</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Non-clinical data
reveal no special hazard for humans based on conventional studies of safety
pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential,
toxicity to reproduction and development.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Toxicologically
significant effects were observed only at doses or exposures that were
sufficiently in excess of the maximum human dose or exposure, indicating that
these effects were limited or of no relevance to clinical use. These included:
dose-dependent adrenocortical toxicity (lipofuscin pigment accumulation and/or
parenchymal cell loss) in rats after 104&nbsp;weeks at&nbsp;20&nbsp;mg/kg/day
to 60&nbsp;mg/kg/day (3&nbsp;to 10&nbsp;times the mean steady-state AUC at the
maximum recommended human dose) and increased adrenocortical carcinomas and
combined adrenocortical adenomas/carcinomas in female rats at 60&nbsp;mg/kg/day
(10&nbsp;times the mean steady-state AUC at the maximum recommended human
dose). The highest nontumorigenic exposure in female rats was 7&nbsp;times the
human exposure at the recommended dose.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>An additional finding
was cholelithiasis as a consequence of precipitation of sulphate conjugates of
hydroxy metabolites of aripiprazole in the bile of monkeys after repeated oral
dosing at&nbsp;25&nbsp;mg/kg/day to 125&nbsp;mg/kg/day (1 to 3&nbsp;times the
mean steady-state AUC at the maximum recommended clinical dose or 16 to
81&nbsp;times the maximum recommended human dose based on&nbsp;mg/m<span
class=EMEASuperscript>2</span>). However, the concentrations of the sulphate
conjugates of hydroxy aripiprazole in human bile at the highest dose proposed,
30&nbsp;mg per day, were no more than 6&nbsp;% of the bile concentrations found
in the monkeys in the 39&#8209;week study and are well below (6&nbsp;%) their
limits of <i>in&nbsp;vitro</i> solubility.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>In repeat-dose studies
in juvenile rats and dogs, the toxicity profile of aripiprazole was comparable
to that observed in adult animals, and there was no evidence of neurotoxicity
or adverse reactions on development.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Based on results of
a full range of standard genotoxicity tests, aripiprazole was considered
non-genotoxic. Aripiprazole did not impair fertility in reproductive toxicity
studies. Developmental toxicity, including dose-dependent delayed foetal
ossification and possible teratogenic effects, were observed in rats at doses
resulting in subtherapeutic exposures (based on AUC) and in rabbits at doses
resulting in exposures 3 and 11&nbsp;times the mean steady-state AUC at the
maximum recommended clinical dose. Maternal toxicity occurred at doses similar
to those eliciting developmental toxicity.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>6.1&nbsp;&nbsp;&nbsp;&nbsp; List of excipients</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Tablet core</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Lactose monohydrate</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Maize starch</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Microcrystalline
cellulose</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Hydroxypropyl
cellulose</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Magnesium stearate</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><u><span lang=NO-BOK style='color:black'>Tablet coat</span></u></p>

<p class=EMEABodyText><span lang=NO-BOK style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=NO-BOK style='color:black'>ABILIFY
5&nbsp;mg tablets</span></u></p>

<p class=EMEABodyText><span lang=NO-BOK style='color:black'>Indigo carmine
aluminium lake (E&nbsp;132)</span></p>

<p class=EMEABodyText><span lang=NO-BOK style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=ES style='color:black'>ABILIFY 10&nbsp;mg
tablets</span></u></p>

<p class=EMEABodyText><span lang=ES style='color:black'>Red iron
oxide&nbsp;(E&nbsp;172)</span></p>

<p class=EMEABodyText><span lang=ES style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>ABILIFY
15&nbsp;mg tablets</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Yellow iron
oxide&nbsp;(E&nbsp;172)</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=ES style='color:black'>ABILIFY 30&nbsp;mg
tablets</span></u></p>

<p class=EMEABodyText><span lang=ES style='color:black'>Red iron
oxide&nbsp;(E&nbsp;172)</span></p>

<p class=EMEABodyText><span lang=ES style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Not applicable.</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf life</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>3&nbsp;years</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>6.4&nbsp;&nbsp;&nbsp;&nbsp; Special precautions
for storage</span></b></p>

<p class=EMEABodyText style='text-align:justify'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Store in the
original package in order to protect from moisture.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>6.5&nbsp;&nbsp;&nbsp;&nbsp; Nature and contents
of container</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aluminium perforated
unit dose blisters in cartons of 14&nbsp;&times;&nbsp;1, 28&nbsp;&times;&nbsp;1,
49&nbsp;&times;&nbsp;1, 56&nbsp;&times;&nbsp;1, 98&nbsp;&times;&nbsp;1&nbsp;tablets.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Not all pack sizes
may be marketed.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>6.6&nbsp;&nbsp;&nbsp;&nbsp; Special precautions
for disposal</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Any unused medicinal
product or waste material should be disposed of in accordance with local requirements.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Otsuka Pharmaceutical
Netherlands B.V.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Herikerbergweg 292</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>1101 CT, Amsterdam</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Netherlands</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>ABILIFY 5&nbsp;mg
tablets</span></u></p>

<p class=MsoCommentText><span lang=DE style='font-size:11.0pt;color:black'>EU/1/04/276/001
(5&nbsp;mg, 14&nbsp;</span><span lang=DE style='color:black'>&times;</span><span
lang=DE style='font-size:11.0pt;color:black'> 1 tablets)</span></p>

<p class=MsoCommentText><span lang=DE style='font-size:11.0pt;color:black'>EU/1/04/276/002
(5&nbsp;mg, 28&nbsp;</span><span lang=DE style='color:black'>&times;</span><span
lang=DE style='font-size:11.0pt;color:black'> 1 tablets)</span></p>

<p class=MsoCommentText><span lang=DE style='font-size:11.0pt;color:black'>EU/1/04/276/003
(5&nbsp;mg, 49&nbsp;</span><span lang=DE style='color:black'>&times;</span><span
lang=DE style='font-size:11.0pt;color:black'> 1 tablets)</span></p>

<p class=MsoCommentText><span lang=DE style='font-size:11.0pt;color:black'>EU/1/04/276/004
(5&nbsp;mg, 56&nbsp;</span><span lang=DE style='color:black'>&times;</span><span
lang=DE style='font-size:11.0pt;color:black'> 1 tablets)</span></p>

<p class=MsoCommentText><span lang=DE style='font-size:11.0pt;color:black'>EU/1/04/276/005
(5&nbsp;mg, 98&nbsp;</span><span lang=DE style='color:black'>&times;</span><span
lang=DE style='font-size:11.0pt;color:black'> 1 tablets)</span></p>

<p class=EMEABodyText><span lang=DE style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=DE style='color:black'>ABILIFY 10&nbsp;mg
tablets</span></u></p>

<p class=MsoCommentText><span lang=DE style='font-size:11.0pt;color:black'>EU/1/04/276/006
(10&nbsp;mg, 14&nbsp;</span><span lang=DE style='color:black'>&times;</span><span
lang=DE style='font-size:11.0pt;color:black'> 1 tablets)</span></p>

<p class=MsoCommentText><span lang=DE style='font-size:11.0pt;color:black'>EU/1/04/276/007
(10&nbsp;mg, 28&nbsp;</span><span lang=DE style='color:black'>&times;</span><span
lang=DE style='font-size:11.0pt;color:black'> 1 tablets)</span></p>

<p class=MsoCommentText><span lang=DE style='font-size:11.0pt;color:black'>EU/1/04/276/008
(10&nbsp;mg, 49&nbsp;</span><span lang=DE style='color:black'>&times;</span><span
lang=DE style='font-size:11.0pt;color:black'> 1 tablets)</span></p>

<p class=MsoCommentText><span lang=DE style='font-size:11.0pt;color:black'>EU/1/04/276/009
(10&nbsp;mg, 56&nbsp;</span><span lang=DE style='color:black'>&times;</span><span
lang=DE style='font-size:11.0pt;color:black'> 1 tablets)</span></p>

<p class=MsoCommentText><span lang=DE style='font-size:11.0pt;color:black'>EU/1/04/276/010
(10&nbsp;mg, 98&nbsp;</span><span lang=DE style='color:black'>&times;</span><span
lang=DE style='font-size:11.0pt;color:black'> 1 tablets)</span></p>

<p class=EMEABodyText><span lang=DE style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=DE style='color:black'>ABILIFY 15&nbsp;mg
tablets</span></u></p>

<p class=MsoCommentText><span lang=DE style='font-size:11.0pt;color:black'>EU/1/04/276/011
(15&nbsp;mg, 14&nbsp;</span><span lang=DE style='color:black'>&times;</span><span
lang=DE style='font-size:11.0pt;color:black'> 1 tablets)</span></p>

<p class=MsoCommentText><span lang=DE style='font-size:11.0pt;color:black'>EU/1/04/276/012
(15&nbsp;mg, 28&nbsp;</span><span lang=DE style='color:black'>&times;</span><span
lang=DE style='font-size:11.0pt;color:black'> 1 tablets)</span></p>

<p class=MsoCommentText><span lang=DE style='font-size:11.0pt;color:black'>EU/1/04/276/013
(15&nbsp;mg, 49&nbsp;</span><span lang=DE style='color:black'>&times;</span><span
lang=DE style='font-size:11.0pt;color:black'> 1 tablets)</span></p>

<p class=MsoCommentText><span lang=DE style='font-size:11.0pt;color:black'>EU/1/04/276/014
(15&nbsp;mg, 56&nbsp;</span><span lang=DE style='color:black'>&times;</span><span
lang=DE style='font-size:11.0pt;color:black'> 1 tablets)</span></p>

<p class=MsoCommentText><span lang=DE style='font-size:11.0pt;color:black'>EU/1/04/276/015
(15&nbsp;mg, 98&nbsp;</span><span lang=DE style='color:black'>&times;</span><span
lang=DE style='font-size:11.0pt;color:black'> 1 tablets)</span></p>

<p class=EMEABodyText><span lang=DE style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=DE style='color:black'>ABILIFY 30&nbsp;mg
tablets</span></u></p>

<p class=MsoCommentText><span lang=DE style='font-size:11.0pt;color:black'>EU/1/04/276/016
(30&nbsp;mg, 14&nbsp;</span><span lang=DE style='color:black'>&times;</span><span
lang=DE style='font-size:11.0pt;color:black'> 1 tablets)</span></p>

<p class=MsoCommentText><span lang=DE style='font-size:11.0pt;color:black'>EU/1/04/276/017
(30&nbsp;mg, 28&nbsp;</span><span lang=DE style='color:black'>&times;</span><span
lang=DE style='font-size:11.0pt;color:black'> 1 tablets)</span></p>

<p class=MsoCommentText><span lang=DE style='font-size:11.0pt;color:black'>EU/1/04/276/018
(30&nbsp;mg, 49&nbsp;</span><span lang=DE style='color:black'>&times;</span><span
lang=DE style='font-size:11.0pt;color:black'> 1 tablets)</span></p>

<p class=MsoCommentText><span lang=DE style='font-size:11.0pt;color:black'>EU/1/04/276/019
(30&nbsp;mg, 56&nbsp;</span><span lang=DE style='color:black'>&times;</span><span
lang=DE style='font-size:11.0pt;color:black'> 1 tablets)</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt;color:black'>EU/1/04/276/020
(30&nbsp;mg, 98&nbsp;</span><span lang=EN-GB style='color:black'>&times;</span><span
lang=EN-GB style='font-size:11.0pt;color:black'> 1 tablets)</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DATE OF
FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Date of first
authorisation: 04&nbsp;June&nbsp;2004</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Date of latest
renewal: 04&nbsp;June&nbsp;2009</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>10.&nbsp;&nbsp;&nbsp;&nbsp; DATE OF REVISION OF
THE TEXT</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>{MM/YYYY}</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Detailed information
on this medicinal product is available on the website of the European Medicines
Agency <a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a>.</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE
MEDICINAL PRODUCT</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY 10&nbsp;mg
orodispersible tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY 15&nbsp;mg orodispersible
tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY 30&nbsp;mg
orodispersible tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE AND
QUANTITATIVE COMPOSITION</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>ABILIFY
10&nbsp;mg orodispersible tablets</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Each orodispersible
tablet contains 10&nbsp;mg of aripiprazole.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Excipient with
known effect</span></u></p>

<p class=EMEABodyText><span lang=IT style='color:black'>2&nbsp;mg aspartame
(E&nbsp;951) and 0.075&nbsp;mg lactose per orodispersible tablet</span></p>

<p class=EMEABodyText><span lang=IT style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=IT style='color:black'>ABILIFY 15&nbsp;mg
orodispersible tablets</span></u></p>

<p class=EMEABodyText><span lang=IT style='color:black'>Each orodispersible
tablet contains 15&nbsp;mg of aripiprazole.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Excipient with
known effect</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>3&nbsp;mg aspartame
(E&nbsp;951) and 0.1125&nbsp;mg lactose per orodispersible tablet</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>ABILIFY
30&nbsp;mg orodispersible tablets</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Each orodispersible
tablet contains 30&nbsp;mg of aripiprazole.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Excipient with
known effect</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>6&nbsp;mg aspartame
(E&nbsp;951) and 0.225&nbsp;mg lactose per orodispersible tablet</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>For the full list of
excipients, see section&nbsp;6.1.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL FORM</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Orodispersible
tablet</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>ABILIFY
10&nbsp;mg orodispersible tablets</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>10&nbsp;mg: Round
and pink, marked with &quot;A&quot; over &quot;640&quot; on one side and
&quot;10&quot; on the other.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>ABILIFY
15&nbsp;mg orodispersible tablets</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>15&nbsp;mg: Round
and yellow, marked with &quot;A&quot; over &quot;641&quot; on one side and
&quot;15&quot; on the other.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>ABILIFY 30&nbsp;mg
orodispersible tablets</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>30&nbsp;mg: Round
and pink, marked with &quot;A&quot; over &quot;643&quot; on one side and
&quot;30&quot; on the other.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CLINICAL PARTICULARS</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic indications</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY is indicated
for the treatment of schizophrenia in adults and in adolescents aged
15&nbsp;years and older.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY is indicated
for the treatment of moderate to severe manic episodes in Bipolar I Disorder
and for the prevention of a new manic episode in adults who experienced
predominantly manic episodes and whose manic episodes responded to aripiprazole
treatment (see section&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY is indicated
for the treatment up to 12&nbsp;weeks of moderate to severe manic episodes in
Bipolar I Disorder in adolescents aged 13&nbsp;years and older (see
section&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>4.2&nbsp;&nbsp;&nbsp;&nbsp; Posology and method of
administration</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Posology</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><u><span lang=EN-GB style='color:black'>Adults</span></u></i></p>

<p class=EMEABodyText><i><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Schizophrenia:</span></i><span
lang=EN-GB style='color:black;layout-grid-mode:line'> the recommended starting
dose for ABILIFY is 10&nbsp;mg/day or 15&nbsp;mg/day with a maintenance dose of
15&nbsp;mg/day administered on a once-a-day schedule without regard to meals.
ABILIFY is effective in a dose range of 10&nbsp;mg/day to&nbsp;30&nbsp;mg/day.
Enhanced efficacy at doses higher than a daily dose of 15&nbsp;mg has not been
demonstrated although individual patients may benefit from a higher dose. The
maximum daily dose should not exceed 30&nbsp;mg.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black;layout-grid-mode:
line'>Manic episodes in Bipolar I Disorder:</span></i><span lang=EN-GB
style='color:black'> the recommended starting dose for <span style='layout-grid-mode:
line'>ABILIFY </span>is 15&nbsp;mg administered on a once-a-day schedule
without regard to meals as monotherapy or combination therapy (see
section&nbsp;5.1). Some patients may benefit from a higher dose. <span
style='layout-grid-mode:line'>The maximum daily dose should not exceed
30&nbsp;mg.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black;layout-grid-mode:
line'>Recurrence prevention of manic episodes in Bipolar I Disorder</span></i><i><span
lang=EN-GB style='color:black'>:</span></i><span lang=EN-GB style='color:black'>
for </span><span lang=EN-GB style='color:black'>preventing recurrence of manic
episodes in patients, who have been receiving aripiprazole as monotherapy or
combination therapy, continue therapy at the same dose. </span><span
lang=EN-GB style='color:black'>Adjustments of daily dosage, including dose
reduction should be considered on the basis of clinical status.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><i><u><span lang=EN-GB style='color:black'>Paediatric
population</span></u></i></p>

<p class=EMEABodyText><i><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Schizophrenia in
adolescents aged 15&nbsp;years and older</span></i><span lang=EN-GB
style='color:black'>: the recommended dose for <span style='layout-grid-mode:
line'>ABILIFY</span> is 10&nbsp;mg/day administered on a once-a-day schedule
without regard to meals. Treatment should be initiated at 2&nbsp;mg (using <span
style='layout-grid-mode:line'>ABILIFY</span> oral solution 1&nbsp;mg/mL) for
2&nbsp;days, titrated to 5&nbsp;mg for 2&nbsp;additional days to reach the
recommended daily dose of 10&nbsp;mg. When appropriate, subsequent dose increases
should be administered in 5&nbsp;mg increments without exceeding the maximum
daily dose of 30&nbsp;mg (see section&nbsp;5.1). ABILIFY is effective in a dose
range of 10&nbsp;mg/day to 30&nbsp;mg/day. Enhanced efficacy at doses higher
than a daily dose of 10&nbsp;mg has not been demonstrated although individual
patients may benefit from a higher dose.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY is not
recommended for use in patients with schizophrenia below 15&nbsp;years of age
due to insufficient data on safety and efficacy (see sections&nbsp;4.8 and
5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Manic episodes in
Bipolar I Disorder in adolescents aged 13&nbsp;years and older</span></i><span
lang=EN-GB style='color:black'>: the recommended dose for ABILIFY is
10&nbsp;mg/day administered on a once-a-day schedule without regard to meals.
Treatment should be initiated at 2&nbsp;mg (using ABILIFY oral solution
1&nbsp;mg/mL) for 2&nbsp;days, titrated to 5&nbsp;mg for 2&nbsp;additional days
to reach the recommended daily dose of 10&nbsp;mg. The treatment duration
should be the minimum necessary for symptom control and must not exceed
12&nbsp;weeks. Enhanced efficacy at doses higher than a daily dose of
10&nbsp;mg has not been demonstrated, and a daily dose of 30&nbsp;mg is
associated with a substantially higher incidence of significant adverse
reactions including EPS related events, somnolence, fatigue and weight gain
(see section&nbsp;4.8). Doses higher than 10&nbsp;mg/day should therefore only
be used in exceptional cases and with close clinical monitoring (see
sections&nbsp;4.4,&nbsp;4.8 and&nbsp;5.1). Younger patients are at increased
risk of experiencing adverse events associated with aripiprazole. Therefore,
ABILIFY is not recommended for use in patients below 13&nbsp;years of age (see
sections&nbsp;4.8 and&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Irritability
associated with autistic disorder:</span></i><span lang=EN-GB style='color:
black'> the safety and efficacy of ABILIFY in children and adolescents aged
below 18&nbsp;years have not yet been established. Currently available data are
described in section&nbsp;5.1 but no recommendation on a posology can be made.</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Tics associated
with Tourette&#8217;s disorder:</span></i><span lang=EN-GB style='color:black'>
the safety and efficacy of ABILIFY in children and adolescents 6 to 18 years of
age have not yet been established. Currently available data are described in
section&nbsp;5.1 but no recommendation on a posology can be made.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><u><span lang=EN-GB style='color:black'>Special
populations</span></u></i></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Hepatic
impairment</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>No dosage adjustment
is required for patients with mild to moderate hepatic impairment. In patients
with severe hepatic impairment, the data available are insufficient to
establish recommendations. In these patients dosing should be managed
cautiously. However, the maximum daily dose of 30&nbsp;mg should be used with
caution in patients with severe hepatic impairment (see section&nbsp;5.2).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Renal impairment</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>No dosage adjustment
is required in patients with renal impairment.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Elderly</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The safety and
efficacy of ABILIFY in the treatment of schizophrenia or manic episodes in
Bipolar I Disorder in patients aged 65&nbsp;years and older has not been
established. Owing to the greater sensitivity of this population, a lower
starting dose should be considered when clinical factors warrant (see
section&nbsp;4.4).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Gender</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>No dosage adjustment
is required for female patients as compared to male patients
(see&nbsp;section&nbsp;5.2).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Smoking status</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>According to the
metabolic pathway of aripiprazole no dosage adjustment is required for smokers
(see section&nbsp;4.5).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Dose adjustments
due to interactions</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>When concomitant administration of strong CYP3A4 or CYP2D6 inhibitors
with aripiprazole occurs, the aripiprazole dose should be reduced. When the
CYP3A4 or CYP2D6 inhibitor is withdrawn from the combination therapy,
aripiprazole dose should then be increased (see section&nbsp;4.5).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>When concomitant administration of strong CYP3A4 inducers with aripiprazole
occurs, the aripiprazole dose should be increased. When the CYP3A4 inducer is
withdrawn from the combination therapy, the aripiprazole dose should then be
reduced to the recommended dose (see section&nbsp;4.5).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Method of
administration</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>ABILIFY</span><span lang=EN-GB style='color:black'> is for oral use.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The orodispersible
tablet should be placed in the mouth on the tongue, where it will rapidly
disperse in saliva. It can be taken with or without liquid. Removal of the
intact orodispersible tablet from the mouth is difficult. Since the
orodispersible tablet is fragile, it should be taken immediately on opening the
blister. Alternatively, disperse the tablet in water and drink the resulting
suspension.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Orodispersible
tablets or oral solution may be used as an alternative to ABILIFY tablets for
patients who have difficulty swallowing ABILIFY tablets (see section&nbsp;5.2).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Hypersensitivity to
the active substance or to any of the excipients listed in section&nbsp;6.1.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special warnings and
precautions for use</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>During antipsychotic
treatment, improvement in the patient's clinical condition may take several
days to some weeks. Patients should be closely monitored throughout this
period.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Suicidality</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The occurrence of
suicidal behaviour is inherent in psychotic illnesses and mood disorders and in
some cases has been reported early after initiation or switch of antipsychotic <em><span
style='font-style:normal'>treatment</span></em>, including treatment with
aripiprazole (see section&nbsp;4.8). Close supervision of high-risk patients
should accompany antipsychotic treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Cardiovascular disorders</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole should
be used with caution in patients with known cardiovascular disease (history of
myocardial infarction or ischaemic heart disease, heart failure, or conduction
abnormalities), cerebrovascular disease, conditions which would predispose
patients to hypotension (dehydration, hypovolemia, and treatment with
antihypertensive medicinal products) or hypertension, including accelerated or
malignant. Cases of venous thromboembolism (VTE) have been reported with
antipsychotic medicinal products. Since patients treated with antipsychotics
often present with acquired risk factors for VTE, all possible risk factors for
VTE should be identified before and during treatment with aripiprazole and
preventive measures undertaken.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>QT prolongation</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In clinical trials
of aripiprazole, the incidence of QT prolongation was comparable to placebo. Aripiprazole
should be used with caution in patients with a family history of QT
prolongation (see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Tardive
dyskinesia</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In clinical trials
of one year or less duration, there were uncommon reports of treatment emergent
dyskinesia during treatment with aripiprazole. If signs and symptoms of tardive
dyskinesia appear in a patient on aripiprazole, dose reduction or
discontinuation should be considered (see section&nbsp;4.8). These symptoms can
temporally deteriorate or can even arise after discontinuation of treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Other
extrapyramidal symptoms</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In paediatric
clinical trials of aripiprazole akathisia and Parkinsonism were observed. If
signs and symptoms of other EPS appear in a patient taking aripiprazole, dose
reduction and close clinical monitoring should be considered.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Neuroleptic
Malignant Syndrome (NMS)</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>NMS is a potentially
fatal symptom complex associated with antipsychotics. In clinical trials, rare
cases of NMS were reported during treatment with aripiprazole. Clinical
manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status
and evidence of autonomic instability (irregular pulse or blood pressure,
tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs may include
elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute
renal failure. However, elevated creatine phosphokinase and rhabdomyolysis, not
necessarily in association with NMS, have also been reported. If a patient
develops signs and symptoms indicative of NMS, or presents with unexplained
high fever without additional clinical manifestations of NMS, all antipsychotics,
including aripiprazole, must be discontinued.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Seizure</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In clinical trials,
uncommon cases of seizure were reported during treatment with aripiprazole.
Therefore, aripiprazole should be used with caution in patients who have a
history of seizure disorder or have conditions associated with seizures (see
section&nbsp;4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Elderly patients
with dementia-related psychosis</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Increased
mortality</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In three
placebo-controlled trials (n&nbsp;=&nbsp;938; mean age: 82.4&nbsp;years; range:
56 to 99&nbsp;years) of aripiprazole in elderly patients with psychosis
associated with Alzheimer's disease, patients treated with aripiprazole were at
increased risk of death compared to placebo. The rate of death in
aripiprazole-treated patients was 3.5&nbsp;% compared to 1.7&nbsp;% in the
placebo group. Although the causes of deaths were varied, most of the deaths
appeared to be either cardiovascular (e.g. heart failure, sudden death) or
infectious (e.g. pneumonia) in nature (see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Cerebrovascular
adverse reactions</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In the same trials,
cerebrovascular adverse reactions (e.g. stroke, transient ischaemic attack),
including fatalities, were reported in patients (mean age: 84&nbsp;years;
range: 78 to 88&nbsp;years). Overall, 1.3&nbsp;% of aripiprazole-treated
patients reported cerebrovascular adverse reactions compared with 0.6&nbsp;% of
placebo-treated patients in these trials. This difference was not statistically
significant. However, in one of these trials, a fixed-dose trial, there was a
significant dose response relationship for cerebrovascular adverse reactions in
patients treated with aripiprazole (see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole is not
indicated for the treatment of patients with dementia-related psychosis.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Hyperglycaemia
and diabetes mellitus</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Hyperglycaemia, in
some cases extreme and associated with ketoacidosis or hyperosmolar coma or
death, has been reported in patients treated with atypical antipsychotics, including
aripiprazole. Risk factors that may predispose patients to severe complications
include obesity and family history of diabetes. In clinical trials with
aripiprazole, there were no significant differences in the incidence rates of
hyperglycaemia-related adverse reactions (including diabetes) or in abnormal
glycaemia laboratory values compared to placebo. Precise risk estimates for
hyperglycaemia-related adverse reactions in patients treated with aripiprazole
and with other atypical antipsychotics are not available to allow direct
comparisons. Patients treated with any antipsychotics, including aripiprazole,
should be observed for signs and symptoms of hyperglycaemia (such as
polydipsia, polyuria, polyphagia and weakness) and patients with diabetes mellitus
or with risk factors for diabetes mellitus should be monitored regularly for
worsening of glucose control (see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Hypersensitivity</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Hypersensitivity
reactions, characterised by allergic symptoms, may occur with aripiprazole (see
section&nbsp;4.8).</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Weight gain</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Weight gain is
commonly seen in schizophrenic and bipolar mania patients due to
co-morbidities, use of antipsychotics known to cause weight gain, poorly
managed life-style, and might lead to severe complications. Weight gain has
been reported post-marketing among patients prescribed aripiprazole. When seen,
it is usually in those with significant risk factors such as history of
diabetes, thyroid disorder or pituitary adenoma. In clinical trials
aripiprazole has not been shown to induce clinically relevant weight gain in
adults (see section&nbsp;5.1). In clinical trials of adolescent patients with
bipolar mania, aripiprazole has been shown to be associated with weight gain
after 4&nbsp;weeks of treatment. Weight gain should be monitored in adolescent
patients with bipolar mania. If weight gain is clinically significant, dose
reduction should be considered (see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Dysphagia</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Oesophageal
dysmotility and aspiration have been associated with the use of antipsychotics,
including aripiprazole. Aripiprazole should be used cautiously in patients at
risk for aspiration pneumonia.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB>Pathological
gambling and other impulse control disorders</span></u></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Patients can experience increased urges,
particularly for gambling, and the inability to control these urges while
taking aripiprazole. Other urges, reported, include: increased sexual urges,
compulsive shopping, binge or compulsive eating, and other impulsive and
compulsive behaviours. It is important for prescribers to ask patients or their
caregivers specifically about the development of new or increased gambling
urges, sexual urges, compulsive shopping, binge or compulsive eating, or other
urges while being treated with aripiprazole. It should be noted that
impulse-control symptoms can be associated with the underlying disorder;
however, in some cases, urges were reported to have stopped when the dose was
reduced or the medication was discontinued. Impulse control disorders may
result in harm to the patient and others if not recognised. Consider dose
reduction or stopping the medication if a patient develops such urges while
taking aripiprazole (see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Aspartame</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY
orodispersible tablets contain aspartame. Aspartame is a source of
phenylalanine. It may be harmful for people with phenylketonuria (PKU), a rare
genetic disorder in which phenylalanine builds up because the body cannot
remove it properly.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Lactose</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY orodispersible
tablets contain lactose. Patients with rare hereditary problems of galactose
intolerance, total lactase deficiency or glucose-galactose malabsorption should
not take this medicinal product.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Sodium</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY
orodispersible tablets contain sodium. This medicinal product contains less
than 1&nbsp;mmol sodium (23&nbsp;mg) per tablet, that is to say essentially &#8216;sodium-free&#8217;.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Patients with attention
deficit hyperactivity disorder (ADHD) comorbidity</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Despite the high
comorbidity frequency of Bipolar I Disorder and ADHD, very limited safety data
are available on concomitant use of aripiprazole and stimulants; therefore,
extreme caution should be taken when these medicinal products are
co-administered.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Falls</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span style='color:black'>Aripiprazole
may cause somnolence, postural hypotension, motor and sensory instability,
which may lead to falls. Caution should be taken when treating patients at
higher risk, and a lower starting dose should be considered (e.g., elderly or
debilitated patients; see section 4.2).</span></p>

<p class=MsoNormal style='margin-left:.1pt;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction with
other medicinal products and other forms of interaction</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>D<span
style='layout-grid-mode:line'>ue to its &#945;</span><span class=BMSSubscript>1</span>-adrenergic
receptor antagonism,<span style='layout-grid-mode:line'> aripiprazole has the
potential to enhance the effect of certain antihypertensive medicinal products.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Given the primary
CNS effects of aripiprazole, caution should be used when aripiprazole is administered
in combination with alcohol or other CNS medicinal products with overlapping
adverse reactions such as sedation (see&nbsp;section&nbsp;4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If aripiprazole is
administered concomitantly with medicinal products known to cause QT
prolongation or electrolyte imbalance, caution should be used.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Potential for
other medicinal products to affect <em><span style='font-style:normal'>aripiprazole</span></em></span></u></p>

<p class=EMEABodyText><em><u><span lang=EN-GB style='color:black;font-style:
normal'><span style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>A gastric acid
blocker, the H<sub>2</sub>&nbsp;antagonist famotidine, reduces aripiprazole
rate of absorption but this effect is deemed not clinically relevant. <span
style='layout-grid-mode:line'>Aripiprazole is metabolised by multiple pathways
involving the CYP2D6 and CYP3A4 enzymes but not CYP1A enzymes. Thus, no dosage
adjustment is required for smokers.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Quinidine and other
CYP2D6 inhibitors</span></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>In a clinical trial in healthy subjects, a strong inhibitor of CYP2D6
(quinidine) increased aripiprazole AUC by 107&nbsp;%, while </span><span
lang=EN-GB style='color:black'>C<span class=EMEASubscript>max</span><span
style='layout-grid-mode:line'> was unchanged. The AUC and </span>C<span
class=EMEASubscript>max</span><span style='layout-grid-mode:line'> of
dehydro-aripiprazole, the active metabolite, decreased by 32&nbsp;% and
47&nbsp;%</span></span><span lang=EN-GB style='color:black'>, respectively</span><span
lang=EN-GB style='color:black;layout-grid-mode:line'>. A</span><span
lang=EN-GB style='color:black'>ripiprazole<span style='layout-grid-mode:line'>
dose should be reduced to approximately one-half of its prescribed dose when
concomitant administration of </span>aripiprazole<span style='layout-grid-mode:
line'> with quinidine occurs. Other strong inhibitors of CYP2D6, such as
fluoxetine and paroxetine, may be expected to have similar effects and similar
dose reductions should therefore be applied.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Ketoconazole and
other CYP3A4 inhibitors</span></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>In a clinical trial in healthy subjects, a strong inhibitor of CYP3A4
(ketoconazole) increased aripiprazole AUC and </span><span lang=EN-GB
style='color:black'>C<span class=EMEASubscript>max</span><span
style='layout-grid-mode:line'> by 63&nbsp;% and 37&nbsp;%, respectively. The
AUC and </span>C<span class=EMEASubscript>max</span><span style='layout-grid-mode:
line'> of dehydro-aripiprazole increased by 77&nbsp;% and 43&nbsp;%,
respectively. In CYP2D6 poor metabolisers, concomitant use of strong inhibitors
of CYP3A4 may result in higher plasma concentrations of aripiprazole compared
to that in CYP2D6 extensive metabolizers. When considering concomitant
administration of ketoconazole or other strong CYP3A4 inhibitors with </span>aripiprazole<span
style='layout-grid-mode:line'>, potential benefits should </span>outweigh<span
style='layout-grid-mode:line'> the potential risks to the patient. When
concomitant administration of ketoconazole with </span>aripiprazole<span
style='layout-grid-mode:line'> occurs, </span>aripiprazole<span
style='layout-grid-mode:line'> dose should be reduced to approximately one-half
of its prescribed dose. Other strong inhibitors of CYP3A4, such as itraconazole
and HIV protease inhibitors may be expected to have similar effects and similar
dose reductions should therefore be applied (see section&nbsp;4.2).</span> Upon
discontinuation of the CYP2D6 or CYP3A4 inhibitor, the dosage of aripiprazole
should be increased to the level prior to the initiation of the concomitant
therapy. When weak inhibitors of CYP3A4 (e.g. diltiazem) or CYP2D6 (e.g.
escitalopram) are used concomitantly with aripiprazole, modest increases in plasma
aripiprazole concentrations may be expected.</span></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Carbamazepine and
other CYP3A4 inducers</span></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Following
concomitant administration of carbamazepine, a strong inducer of CYP3A4, and
oral aripiprazole to patients with schizophrenia or schizoaffective disorder,
the geometric means of C<span class=EMEASubscript>max</span> and AUC for
aripiprazole were 68&nbsp;% and 73&nbsp;% lower, respectively, compared to when
<span style='layout-grid-mode:line'>aripiprazole (30&nbsp;mg) was administered
alone</span>. Similarly, for dehydro-aripiprazole the geometric means of C<span
class=EMEASubscript>max</span> and AUC after carbamazepine co-administration
were 69&nbsp;% and 71&nbsp;% lower, respectively, than those following
treatment with aripiprazole alone. Aripiprazole dose should be doubled when
concomitant administration of aripiprazole occurs with carbamazepine. Concomitant
administration of aripiprazole and other inducers of CYP3A4 (such as
rifampicin, rifabutin, phenytoin, phenobarbital, primidone, efavirenz,
nevirapine and St. John's Wort) may be expected to have similar effects and
similar dose increases should therefore be applied. Upon discontinuation of strong
CYP3A4 inducers, the dosage of aripiprazole should be reduced to the
recommended dose.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Valproate and
lithium</span></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>When either
valproate or lithium was administered concomitantly with aripiprazole, there
was no clinically significant change in aripiprazole concentrations </span><span
lang=EN-GB>and therefore no dose adjustment is necessary when either valproate
or lithium is administered with aripiprazole<span style='color:black'>.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Potential for aripiprazole
to affect other medicinal products</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In clinical studies,
10&nbsp;mg/day to 30&nbsp;mg/day doses of aripiprazole had no significant
effect on the metabolism of substrates of CYP2D6
(dextromethorphan/3-methoxymorphinan ratio), CYP2C9&nbsp;(warfarin), CYP2C19
(omeprazole), and CYP3A4 (dextromethorphan). Additionally, aripiprazole and
dehydro-aripiprazole did not show potential for altering CYP1A2-mediated
metabolism <i>in&nbsp;vitro</i>. Thus, aripiprazole is unlikely to cause
clinically important medicinal product interactions mediated by these enzymes.</span></p>

<p class=EMEABodyText><i><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>When aripiprazole
was administered concomitantly with either valproate, lithium or lamotrigine,
there was no clinically important change in valproate, lithium or lamotrigine
concentrations.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Serotonin
syndrome</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Cases of serotonin
syndrome have been reported in patients taking aripiprazole, and possible signs
and symptoms for this condition can occur especially in cases of concomitant
use with other serotonergic medicinal products, such as selective serotonin reuptake
inhibitor/selective serotonin noradrenaline reuptake inhibitor (SSRI/SNRI), or
with medicinal products that are known to increase aripiprazole concentrations
(see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>4.6&nbsp;&nbsp;&nbsp;&nbsp; Fertility, pregnancy
and lactation</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Pregnancy</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>There are no
adequate and well-controlled trials of aripiprazole in pregnant women.
Congenital anomalies have been reported; however, causal relationship with
aripiprazole could not be established. Animal studies could not exclude
potential developmental toxicity (see section&nbsp;5.3). Patients must be
advised to notify their physician if they become pregnant or intend to become
pregnant during treatment with aripiprazole. Due to insufficient safety
information in humans and concerns raised by animal reproductive studies, this
medicinal product should not be used in pregnancy unless the expected benefit
clearly justifies the potential risk to the foetus.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Newborn infants exposed
to antipsychotics (including aripiprazole) during the third trimester of
pregnancy are at risk of adverse reactions including extrapyramidal and/or
withdrawal symptoms that may vary in severity and duration following delivery.
There have been reports of agitation, hypertonia, hypotonia, tremor,
somnolence, respiratory distress, or feeding disorder. Consequently, newborn
infants should be monitored carefully (see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Breast-feeding</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Aripiprazole/metabolites are excreted in
human milk. <em><span style='font-style:normal'>A decision must be made whether
to discontinue breast&#8209;feeding or to discontinue/abstain from </span></em>aripiprazole<em><span
style='font-style:normal'> therapy taking into account the benefit of
breast-feeding for the child and the benefit of therapy for the woman.</span></em></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='font-style:normal'>Fertility</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=EMEABodyText><span lang=EN-GB>Aripiprazole did not impair fertility
based on data from reproductive toxicity studies.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects on ability
to drive and use machines</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>Aripiprazole </span></em><span
lang=EN-GB>has minor to moderate influence on the ability to drive and use
machines due to potential nervous system and visual effects, such as sedation,
somnolence, syncope, vision blurred, diplopia (see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable effects</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Summary
of the safety profile</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The most commonly
reported adverse reactions in placebo-controlled trials were akathisia and
nausea each occurring in more than 3<b>&nbsp;</b>% of patients treated with
oral aripiprazole.</span></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Tabulated
list of adverse reactions</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>The incidences of the Adverse Drug Reactions (ADRs)
associated with aripiprazole therapy are tabulated below. The table is based on
adverse events reported during clinical trials and/or post-marketing use.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>All ADRs are listed by system organ class and frequency;
very common (&#8805;&nbsp;1/10), common (&#8805;&nbsp;1/100 to &lt;&nbsp;1/10),
uncommon (&#8805;&nbsp;1/1,000 to &lt;&nbsp;1/100), rare (&#8805;&nbsp;1/10,000
to &lt;&nbsp;1/1,000), very rare (&lt;&nbsp;1/10,000) and not known (cannot be
estimated from the available data). Within each frequency grouping, adverse
reactions are presented in order of decreasing seriousness.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The frequency of
adverse reactions reported during post-marketing use cannot be determined as
they are derived from spontaneous reports. Consequently, the frequency of these
adverse events is qualified as &quot;not known&quot;.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
   style='color:black'>&nbsp;</span></b></p>
   </td>
   <td width=123 valign=top style='width:92.15pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
   style='color:black'>Common</span></b></p>
   </td>
   <td width=142 valign=top style='width:106.3pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
   style='color:black'>Uncommon</span></b></p>
   </td>
   <td width=217 valign=top style='width:163.0pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
   style='color:black'>Not known</span></b></p>
   <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
   style='color:black'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Blood and lymphatic system disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Leukopenia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Neutropenia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Thrombocytopenia</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Immune system disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Allergic reaction (e.g. anaphylactic
  reaction, angioedema including swollen tongue, tongue oedema, face oedema,
  pruritus allergic, or urticaria)</span></em></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Endocrine disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hyperprolactinaemia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Diabetic hyperosmolar
  coma</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Diabetic ketoacidosis</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Metabolism and nutrition disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;text-autospace:none'><span
  lang=EN-GB style='color:black'>Diabetes mellitus</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hyperglycaemia</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Hyponatremia</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Anorexia</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Psychiatric disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Insomnia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Anxiety</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Restlessness</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Depression</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hypersexuality</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Suicide attempt, suicidal ideation and completed suicide
  (see section&nbsp;4.4)</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Pathological gambling</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Impulse-control
  disorder</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Binge eating</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Compulsive
  shopping</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Poriomania</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Aggression</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Agitation</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Nervousness </span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Nervous system disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Akathisia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Extrapyramidal disorder</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Tremor</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Headache</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Sedation</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Somnolence</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Dizziness</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Tardive dyskinesia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Dystonia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=IT
  style='color:black'>Restless legs syndrome</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=FR
  style='color:black'>Neuroleptic Malignant Syndrome</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=FR
  style='color:black'>Grand mal convulsion</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Serotonin syndrome</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Speech disorder</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Eye disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Vision blurred</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Diplopia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Photophobia</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Oculogyric crisis</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Cardiac disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Tachycardia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Sudden death unexplained </span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Torsades de pointes</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Ventricular arrhythmia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Cardiac arrest</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Bradycardia</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Vascular disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Orthostatic hypotension</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Venous thromboembolism (including pulmonary embolism and
  deep vein thrombosis)</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hypertension</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Syncope</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Respiratory, thoracic and mediastinal
  disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hiccups</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Aspiration pneumonia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Laryngospasm</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Oropharyngeal spasm</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Gastrointestinal disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Constipation</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Dyspepsia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Nausea</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Salivary hypersecretion</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Vomiting</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Pancreatitis</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Dysphagia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Diarrhoea</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Abdominal discomfort</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Stomach discomfort</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Hepatobiliary disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hepatic failure</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hepatitis</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Jaundice</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
  style='color:black'>Skin and subcutaneous tissue disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Rash</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Photosensitivity reaction</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Alopecia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hyperhidrosis</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Drug Reaction
  with Eosinophilia and Systemic Symptoms (DRESS)</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Musculoskeletal and connective tissue
  disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Rhabdomyolysis</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Myalgia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Stiffness</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Renal and urinary disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Urinary incontinence</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Urinary retention</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Pregnancy, puerperium and perinatal conditions</span></b></em></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Drug withdrawal syndrome neonatal (see section&nbsp;4.6)</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Reproductive system and breast disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Priapism</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>General disorders and administration
  site conditions</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Fatigue</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Temperature regulation disorder (e.g. hypothermia,
  pyrexia)</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Chest pain</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Peripheral oedema</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Investigations</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Weight decreased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Weight gain</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Alanine Aminotransferase </span><span lang=EN-GB
  style='color:black'>increased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Aspartate Aminotransferase increased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Gamma-glutamyltransferase increased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Alkaline phosphatase increased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>QT prolonged</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Blood glucose increased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Glycosylated haemoglobin increased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Blood glucose fluctuation</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Creatine phosphokinase increased</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Description of
selected adverse reactions</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><i><u><span lang=EN-GB style='color:black'>Adults</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Extrapyramidal
symptoms (EPS)</span></i></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Schizophrenia:</span></i><span
lang=EN-GB style='color:black'> in a long-term 52&#8209;week controlled trial,
aripiprazole-treated patients had an overall-lower incidence (25.8&nbsp;%) of
EPS including Parkinsonism, akathisia, dystonia and dyskinesia compared with
those treated with haloperidol (57.3&nbsp;%). In a long-term 26&#8209;week placebo-controlled
trial, the incidence of EPS was 19&nbsp;% for aripiprazole-treated patients and
13.1&nbsp;% for placebo-treated patients. In another long-term 26&#8209;week
controlled trial, the incidence of EPS was 14.8&nbsp;% for aripiprazole-treated
patients and 15.1&nbsp;% for olanzapine-treated patients.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Manic episodes in
Bipolar I Disorder: </span></i><span lang=EN-GB style='color:black'>in a 12&#8209;week
controlled trial, the incidence of EPS was 23.5&nbsp;% for aripiprazole-treated
patients and 53.3&nbsp;% for haloperidol-treated patients. In another 12&#8209;week
trial, the incidence of EPS was 26.6&nbsp;% for patients treated with
aripiprazole and 17.6&nbsp;% for those treated with lithium. In the long-term
26&#8209;week maintenance phase of a placebo-controlled trial, the incidence of
EPS was 18.2&nbsp;% for aripiprazole-treated patients and 15.7&nbsp;% for
placebo-treated patients.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Akathisia</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In
placebo-controlled trials, the incidence of akathisia in bipolar patients was
12.1&nbsp;% with aripiprazole and 3.2&nbsp;% with placebo. In schizophrenia
patients the incidence of akathisia was 6.2&nbsp;% with aripiprazole and
3.0&nbsp;% with placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Dystonia</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Class effect:
Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may
occur in susceptible individuals during the first few days of treatment.
Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to
tightness of the throat, swallowing difficulty, difficulty breathing, and/or
protrusion of the tongue. While these symptoms can occur at low doses, they
occur more frequently and with greater severity with high potency and at higher
doses of first generation antipsychotic medicinal products. An elevated risk of
acute dystonia is observed in males and younger age groups.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Prolactin</span></em></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>In clinical trials for the approved indications and
post-marketing, both increase and decrease in serum prolactin as compared to
baseline was observed with aripiprazole (section&nbsp;5.1).</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Laboratory
parameters</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Comparisons between
aripiprazole and placebo in the proportions of patients experiencing
potentially clinically significant changes in routine laboratory and lipid
parameters (see section&nbsp;5.1) revealed no medically important differences.
Elevations of CPK (Creatine Phosphokinase), generally transient and
asymptomatic, were observed in 3.5&nbsp;% of aripiprazole treated patients as
compared to 2.0&nbsp;% of patients who received placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><u><span lang=EN-GB style='color:black'>Paediatric
population</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Schizophrenia in
adolescents aged 15&nbsp;years and older</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In a short-term
placebo-controlled clinical trial involving 302&nbsp;adolescents (13 to 17&nbsp;years)
with schizophrenia, the frequency and type of adverse reactions were similar to
those in adults except for the following reactions that were reported more
frequently in adolescents receiving aripiprazole than in adults receiving
aripiprazole (and more frequently than placebo):</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Somnolence/sedation
and extrapyramidal disorder were reported very commonly (&#8805;&nbsp;1/10), and
dry mouth, increased appetite, and orthostatic hypotension were reported
commonly (&#8805;&nbsp;1/100, &lt;&nbsp;1/10). The safety profile in a 26&#8209;week
open-label extension trial was similar to that observed in the short-term,
placebo-controlled trial.</span></p>

<p class=MsoNormal><span lang=EN-GB>The safety profile of a long-term,
double-blind, placebo-controlled trial was also similar except for the
following reactions that were reported more frequently than paediatric patients
taking placebo: weight decreased, blood insulin increased, arrhythmia, and
leukopenia were reported commonly (&#8805;&nbsp;1/100, &lt;&nbsp;1/10).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In the pooled
adolescent schizophrenia population (13 to 17&nbsp;years) with exposure up to
2&nbsp;years, incidence of low serum prolactin levels in females (&lt;&nbsp;3&nbsp;ng/mL)
and males (&lt;&nbsp;2&nbsp;ng/mL) was 29.5&nbsp;% and 48.3&nbsp;%, respectively.
In the adolescent (13 to 17&nbsp;years) schizophrenia population with
aripiprazole exposure of 5&nbsp;mg to 30&nbsp;mg up to 72&nbsp;months,
incidence of low serum prolactin levels in females (&lt;&nbsp;3&nbsp;ng/mL) and
males (&lt;&nbsp;2&nbsp;ng/mL) was 25.6&nbsp;% and 45.0&nbsp;%, respectively.</span></p>

<p class=MsoNormal><span lang=EN-GB>In two long-term trials with adolescent (13
to 17&nbsp;years) schizophrenia and bipolar patients treated with aripiprazole,
incidence of low serum prolactin levels in females (&lt;&nbsp;3&nbsp;ng/mL) and
males (&lt;&nbsp;2&nbsp;ng/mL) was 37.0&nbsp;% and 59.4&nbsp;%, respectively.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Manic episodes in
Bipolar I Disorder in adolescents aged 13&nbsp;years and older</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The frequency and
type of adverse reactions in adolescents with Bipolar I Disorder were similar
to those in adults except for the following reactions: very commonly
(&#8805;&nbsp;1/10) somnolence (23.0&nbsp;%), extrapyramidal disorder
(18.4&nbsp;%), akathisia (16.0&nbsp;%), and fatigue (11.8&nbsp;%); and commonly
(&#8805;&nbsp;1/100, &lt;&nbsp;1/10) abdominal pain upper, heart rate
increased, weight increased, increased appetite, muscle twitching, and
dyskinesia.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The following adverse
reactions had a possible dose response relationship; extrapyramidal disorder
(incidences were 10&nbsp;mg, 9.1&nbsp;%; 30&nbsp;mg, 28.8&nbsp;%; placebo,
1.7&nbsp;%); and akathisia (incidences were 10&nbsp;mg, 12.1&nbsp;%;
30&nbsp;mg, 20.3&nbsp;%; placebo, 1.7<b>&nbsp;</b>%).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Mean changes in body
weight in adolescents with Bipolar I Disorder at&nbsp;12 and 30&nbsp;weeks for
aripiprazole were 2.4&nbsp;kg and 5.8&nbsp;kg, and for placebo 0.2&nbsp;kg and
2.3&nbsp;kg, respectively.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In the paediatric
population somnolence and fatigue were observed more frequently in patients
with bipolar disorder compared to patients with schizophrenia.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In the paediatric
bipolar population (10 to 17&nbsp;years) with exposure up to 30&nbsp;weeks,
incidence of low serum prolactin levels in females (&lt;&nbsp;3&nbsp;ng/mL) and
males (&lt;&nbsp;2&nbsp;ng/mL) was 28.0&nbsp;% and 53.3&nbsp;%, respectively.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><i><span lang=EN-GB>Pathological
gambling and other impulse control disorders</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Pathological
gambling, hypersexuality, compulsive shopping and binge or compulsive eating
can occur in patients treated with aripiprazole (see </span><span lang=EN-GB>section&nbsp;4.4).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Reporting of
suspected adverse reactions</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Reporting suspected
adverse reactions after authorisation of the medicinal product is important. It
allows continued monitoring of the benefit/risk balance of the medicinal
product. Healthcare professionals are asked to report any suspected adverse
reactions <span style='background:silver'>via the national reporting system
listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a>.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Signs
and symptoms</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In clinical trials
and post-marketing experience, accidental or intentional acute overdose of
aripiprazole alone was identified in adult patients with reported estimated
doses up to 1,260&nbsp;mg with no fatalities. The potentially medically
important signs and symptoms observed </span><span lang=EN-GB style='color:
black'>included lethargy, increased blood pressure, somnolence, tachycardia,
nausea, </span><span lang=EN-GB style='color:black'>vomiting and diarrhoea. </span><span
lang=EN-GB style='color:black'>In addition, reports of accidental overdose with
aripiprazole alone (up to 195&nbsp;mg) in children have been received with no
fatalities. The potentially medically serious signs and symptoms reported
included somnolence, transient loss of consciousness </span><span lang=EN-GB
style='color:black'>and extrapyramidal symptoms</span><span lang=EN-GB
style='color:black'>.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Management
of overdose</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Management of
overdose should concentrate on supportive therapy, maintaining an adequate
airway, oxygenation and ventilation, and management of symptoms. The possibility
of multiple medicinal product involvement should be considered. Therefore
cardiovascular monitoring should be started immediately and should include
continuous electrocardiographic monitoring to detect possible arrhythmias. Following
any confirmed or suspected overdose with aripiprazole, close medical
supervision and monitoring should continue until the patient recovers.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Activated charcoal
(50&nbsp;g), administered one hour after aripiprazole, decreased aripiprazole C<span
class=EMEASubscript>max</span> by about 41&nbsp;% and AUC by about 51&nbsp;%,
suggesting that charcoal may be effective in the treatment of overdose.</span></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Haemodialysis</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Although there is no
information on the effect of haemodialysis in treating an overdose with
aripiprazole, haemodialysis is unlikely to be useful in overdose management
since aripiprazole is highly bound to plasma proteins.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading1 style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>5.1&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic properties</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Pharmacotherapeutic
group: Psycholeptics, other antipsychotics, ATC&nbsp;code: N05AX12</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Mechanism of
action</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>It has been proposed
that aripiprazole&#8217;s efficacy in schizophrenia and Bipolar I Disorder is
mediated through a combination of partial agonism at dopamine&nbsp;D<sub>2</sub>
and serotonin 5&#8209;HT<sub>1A</sub> receptors and antagonism of serotonin 5&#8209;HT<sub>2A</sub>
receptors. Aripiprazole exhibited antagonist properties in animal models of
dopaminergic hyperactivity and agonist properties in animal models of
dopaminergic hypoactivity. Aripiprazole exhibited high binding affinity <i>in&nbsp;vitro</i>
for dopamine&nbsp;D<sub>2</sub> and D<sub>3</sub>, serotonin 5&#8209;HT<sub>1A</sub>
and 5&#8209;HT<sub>2A</sub> receptors and moderate affinity for dopamine&nbsp;D<sub>4</sub>,
serotonin 5&#8209;HT<sub>2C</sub> and 5&#8209;HT<sub>7</sub>, alpha&#8209;1
adrenergic and histamine H<sub>1</sub> receptors. Aripiprazole also exhibited
moderate binding affinity for the serotonin reuptake site and no appreciable
affinity for muscarinic receptors. Interaction with receptors other than
dopamine and serotonin subtypes may explain some of the other clinical effects
of aripiprazole.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole doses
ranging from 0.5&nbsp;mg to 30&nbsp;mg administered once a day to healthy
subjects for 2&nbsp;weeks produced a dose-dependent reduction in the binding of
<sup>11</sup>C-raclopride, a D<sub>2</sub>/D<sub>3</sub> receptor ligand, to
the caudate and putamen detected by positron emission tomography.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Clinical efficacy
and safety</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><i><u><span lang=EN-GB style='color:black'>Adults</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Schizophrenia</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In three short-term
(4 to 6&nbsp;weeks) placebo-controlled trials involving 1,228&nbsp;schizophrenic
adult patients, presenting with positive or negative symptoms, aripiprazole was
associated with statistically significantly greater improvements in psychotic
symptoms compared to placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole is
effective in maintaining the clinical improvement during continuation therapy
in adult patients who have shown an initial treatment response. In a
haloperidol-controlled trial, the proportion of responder patients maintaining
response to medicinal product at 52&#8209;weeks was similar in both groups
(aripiprazole 77&nbsp;% and haloperidol 73&nbsp;%). The overall completion rate
was significantly higher for patients on aripiprazole (43&nbsp;%) than for
haloperidol (30&nbsp;%). Actual scores in rating scales used as secondary
endpoints, including PANSS and the Montgomery-&Aring;sberg Depression Rating
Scale (MADRS) showed a significant improvement over haloperidol.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In a 26&#8209;week,
placebo-controlled trial in adult stabilised patients with chronic
schizophrenia, aripiprazole had significantly greater reduction in relapse
rate, 34&nbsp;% in aripiprazole group and 57&nbsp;% in placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Weight gain</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In clinical trials
aripiprazole has not been shown to induce clinically relevant weight gain. In a
26&#8209;week, olanzapine-controlled, double-blind, multi-national study of
schizophrenia which included 314&nbsp;adult patients and where the primary
endpoint was weight gain, significantly less patients had at least 7&nbsp;%
weight gain over baseline (i.e. a gain of at least 5.6&nbsp;kg for a mean
baseline weight of ~80.5&nbsp;kg) on aripiprazole (n&nbsp;=&nbsp;18, or 13&nbsp;%
of evaluable patients), compared to olanzapine (n&nbsp;=&nbsp;45, or 33&nbsp;%
of evaluable patients).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Lipid parameters</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In a pooled analysis
on lipid parameters from placebo controlled clinical trials in adults,
aripiprazole has not been shown to induce clinically relevant alterations in levels
of total cholesterol, triglycerides, High Density Lipoprotein (HDL) and Low
Density Lipoprotein (LDL).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>Prolactin</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Prolactin levels were
evaluated in all trials of all doses of aripiprazole (n&nbsp;=&nbsp;28,242).
The incidence of hyperprolactinaemia or increased serum prolactin in patients
treated with aripiprazole (0.3&nbsp;%) was similar to that of placebo
(0.2&nbsp;%). For patients receiving aripiprazole, the median time to onset was
42&nbsp;days and median duration was 34&nbsp;days.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The incidence of hypoprolactinaemia
or decreased serum prolactin in patients treated with aripiprazole was
0.4&nbsp;%, compared with 0.02&nbsp;% for patients treated with placebo. For
patients receiving aripiprazole, the median time to onset was 30&nbsp;days and
median duration was 194&nbsp;days.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Manic episodes in
Bipolar I Disorder</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In two<b> </b>3&#8209;week,
flexible-dose,<b> </b>placebo-controlled monotherapy trials involving<b> </b>patients
with a manic or mixed episode of Bipolar I Disorder, aripiprazole demonstrated
superior efficacy to placebo in reduction of manic symptoms over 3&nbsp;weeks.
These trials included patients with or without psychotic features and with or
without a rapid-cycling course.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In one 3&#8209;week,
fixed-dose, placebo-controlled monotherapy trial involving patients with a
manic or mixed episode of Bipolar I Disorder, aripiprazole failed to
demonstrate superior efficacy to placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In two 12&#8209;week,
placebo- and active-controlled monotherapy trials in patients with a manic or
mixed episode of Bipolar I Disorder, with or without psychotic features,
aripiprazole demonstrated superior efficacy to placebo at week&nbsp;3 and a
maintenance of effect comparable to lithium or haloperidol at week&nbsp;12.
Aripiprazole also demonstrated a comparable proportion of patients in
symptomatic remission from mania as lithium or haloperidol at week&nbsp;12.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In a 6&#8209;week,
placebo-controlled trial involving patients with a manic or mixed episode of
Bipolar I Disorder, with or without psychotic features, who were partially
non-responsive to lithium or valproate monotherapy for 2&nbsp;weeks at therapeutic
serum levels, the addition of aripiprazole as adjunctive therapy resulted in
superior efficacy in reduction of manic symptoms than lithium or valproate
monotherapy.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In a 26&#8209;week,
placebo-controlled trial, followed by a 74&#8209;week extension, in manic patients
who achieved remission on aripiprazole during a stabilization phase prior to randomisation,
aripiprazole demonstrated superiority over placebo in preventing bipolar
recurrence, primarily in preventing recurrence into mania but failed to
demonstrate superiority over placebo in preventing recurrence into depression.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In a 52&#8209;week,
placebo-controlled trial, in patients with a current manic or mixed episode of
Bipolar I Disorder who achieved sustained remission (Young Mania Rating Scale [YMRS]
and MADRS with total scores &#8804;&nbsp;12) on aripiprazole (10&nbsp;mg/day to
30&nbsp;mg/day) adjunctive to lithium or valproate for 12&nbsp;consecutive
weeks, adjunctive aripiprazole demonstrated superiority over placebo with a
46&nbsp;% decreased risk (hazard ratio of 0.54) in preventing bipolar
recurrence and a 65&nbsp;% decreased risk (hazard ratio of 0.35) in preventing
recurrence into mania over adjunctive placebo but failed to demonstrate
superiority over placebo in preventing recurrence into depression. Adjunctive
aripiprazole demonstrated superiority over placebo on the secondary outcome
measure in Clinical Global Impression - Bipolar version (CGI-BP) Severity of
Illness (SOI; mania) scores. In this trial, patients were assigned by
investigators with either open-label lithium or valproate monotherapy to
determine partial non-response. Patients were stabilised for at least
12&nbsp;consecutive weeks with the combination of aripiprazole and the same
mood stabilizer. Stabilized patients were then randomised to continue the same
mood stabilizer with double-blind aripiprazole or placebo. Four mood stabilizer
subgroups were assessed in the randomised phase: aripiprazole + lithium;
aripiprazole + valproate; placebo + lithium; placebo + valproate. The
Kaplan-Meier rates for recurrence to any mood episode for the adjunctive treatment
arm were 16&nbsp;% in aripiprazole + lithium and 18&nbsp;% in aripiprazole +
valproate compared to 45&nbsp;% in placebo + lithium and 19&nbsp;% in placebo +
valproate.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><u><span lang=EN-GB style='color:black'>Paediatric
population</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Schizophrenia in
adolescents</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In a 6&#8209;week
placebo-controlled trial involving 302&nbsp;schizophrenic adolescent patients
(13 to 17&nbsp;years), presenting with positive or negative symptoms,
aripiprazole was associated with statistically significantly greater
improvements in psychotic symptoms compared to placebo. In a sub-analysis of
the adolescent patients between the ages of 15&nbsp;to 17&nbsp;years,
representing 74&nbsp;% of the total enrolled population, maintenance of effect
was observed over the 26&#8209;week open-label extension trial.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In a 60- to 89-week, randomised,
double-blind, placebo-controlled trial in adolescent subjects
(n&nbsp;=&nbsp;146; ages 13 to 17&nbsp;years) with schizophrenia, there was a
statistically significant difference in the rate of relapse of psychotic
symptoms between the aripiprazole (19.39&nbsp;%) and placebo (37.50&nbsp;%)
groups. The point estimate of the hazard ratio (HR) was 0.461 (95&nbsp;%
confidence interval, 0.242 to 0.879) in the full population. In subgroup
analyses the point estimate of the HR was 0.495 for subjects 13 to
14&nbsp;years of age compared to 0.454 for subjects 15 to 17&nbsp;years of age.
However, the estimation of the HR for the younger (13 to 14&nbsp;years) group
was not precise, reflecting the smaller number of subjects in that group
(aripiprazole, n&nbsp;=&nbsp;29; placebo, n&nbsp;=&nbsp;12), and the confidence
interval for this estimation (</span><span lang=EN-GB style='color:black'>ranging
from 0.151 to 1.628</span><span lang=EN-GB>) did not allow conclusions to be
drawn on the presence of a treatment effect. In contrast the 95&nbsp;%
confidence interval for the HR in the older subgroup (aripiprazole,
n&nbsp;=&nbsp;69; placebo, n&nbsp;=&nbsp;36) was 0.242 to 0.879 and hence a
treatment effect could be concluded in the older patients.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Manic episodes in
Bipolar I Disorder in children and adolescents</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole was
studied in a 30&#8209;week placebo-controlled trial involving 296&nbsp;children
and adolescents (10 to 17&nbsp;years), who met DSM-IV criteria (Diagnostic and
Statistical Manual of Mental Disorders) for Bipolar I Disorder with manic or
mixed episodes with or without psychotic features and had a YMRS score </span><span
lang=EN-GB style='font-family:Symbol;color:black'>&sup3;</span><span
lang=EN-GB style='color:black'>&nbsp;20 at baseline. Among the patients
included in the primary efficacy analysis, 139&nbsp;patients had a current
co-morbid diagnosis of ADHD.</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole was
superior to placebo in change from baseline at week&nbsp;4 and at week&nbsp;12
on the Y-MRS total score. In a post-hoc analysis, the improvement over placebo
was more pronounced in the patients with associated co-morbidity of ADHD
compared to the group without ADHD, where there was no difference from placebo.
Recurrence prevention was not established.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The most common
treatment-emergent adverse events among patients receiving 30&nbsp;mg were
extrapyramidal disorder (28.3&nbsp;%), somnolence (27.3&nbsp;%), headache
(23.2&nbsp;%), and nausea (14.1&nbsp;%). Mean weight gain in the 30&nbsp;weeks
treatment-interval was 2.9&nbsp;kg as compared to 0.98&nbsp;kg in patients
treated with placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Irritability
associated with autistic disorder in paediatric patients (see section&nbsp;4.2)</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole was
studied in patients aged 6&nbsp;to 17&nbsp;years in two 8&#8209;week,
placebo-controlled trials [one flexible-dose (2&nbsp;mg/day to 15&nbsp;mg/day)
and one fixed-dose (5&nbsp;mg/day, 10&nbsp;mg/day, or 15&nbsp;mg/day)] and in
one 52&#8209;week open-label trial. Dosing in these trials was initiated at
2&nbsp;mg/day, increased to 5&nbsp;mg/day after one week, and increased by
5&nbsp;mg/day in weekly increments to the target dose. Over 75&nbsp;% of
patients were less than 13&nbsp;years of age. Aripiprazole demonstrated
statistically superior efficacy compared to placebo on the Aberrant Behaviour
Checklist Irritability subscale. However, the clinical relevance of this
finding has not been established. The safety profile included weight gain and
changes in prolactin levels. The duration of the long-term safety study was
limited to 52&nbsp;weeks. In the pooled trials, the incidence of low serum
prolactin levels in females (&lt;&nbsp;3&nbsp;ng/mL) and males
(&lt;&nbsp;2&nbsp;ng/mL) in aripiprazole-treated patients was
27/46&nbsp;(58.7&nbsp;%) and 258/298&nbsp;(86.6&nbsp;%), respectively. In the
placebo-controlled trials, the mean weight gain was 0.4&nbsp;kg for placebo and
1.6&nbsp;kg for aripiprazole.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole was
also studied in a placebo-controlled, long-term maintenance trial. After a 13
to 26&#8209;week stabilisation on aripiprazole (2&nbsp;mg/day to 15&nbsp;mg/day)
patients with a stable response were either maintained on aripiprazole or
substituted to placebo for further 16&nbsp;weeks. Kaplan-Meier relapse rates at
week&nbsp;16 were 35&nbsp;% for aripiprazole and 52&nbsp;% for placebo; the
hazard ratio for relapse within 16&nbsp;weeks (aripiprazole/placebo) was 0.57
(non-statistically significant difference). The mean weight gain over the
stabilisation phase (up to 26&nbsp;weeks) on aripiprazole was 3.2&nbsp;kg, and
a further mean increase of 2.2&nbsp;kg for aripiprazole as compared to
0.6&nbsp;kg for placebo was observed in the second phase (16&nbsp;weeks) of the
trial. Extrapyramidal symptoms were mainly reported during the stabilisation
phase in 17&nbsp;% of patients, with tremor accounting for 6.5<b>&nbsp;</b>%.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>Tics associated with
Tourette&#8217;s disorder in paediatric patients (see section&nbsp;4.2)</span></i></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>The efficacy of aripiprazole was studied in paediatric subjects
with Tourette&#8217;s disorder (aripiprazole: n&nbsp;=&nbsp;99, placebo:
n&nbsp;=&nbsp;44) in a randomised, double-blind, placebo controlled,
8&nbsp;week study using a fixed dose weight-based treatment group design over the
dose range of 5&nbsp;mg/day to 20&nbsp;mg/day and a starting dose of 2&nbsp;mg.
Patients were 7&nbsp;to&nbsp;17&nbsp;years of age and presented an average
score of 30 on Total Tic Score on the Yale Global Tic Severity Scale
(TTS-YGTSS) at baseline. Aripiprazole showed an improvement on TTS-YGTSS change
from baseline to week&nbsp;8 of 13.35, for the low dose group (5&nbsp;mg or
10&nbsp;mg) and 16.94 for the high dose group (10&nbsp;mg or 20&nbsp;mg) as
compared with an improvement of 7.09 in the placebo group.</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>The efficacy of aripiprazole in paediatric subjects with
Tourette&#8217;s syndrome (aripiprazole: n&nbsp;=&nbsp;32, placebo:
n&nbsp;=&nbsp;29) was also evaluated over a flexible dose range of
2&nbsp;mg/day to 20&nbsp;mg/day and a starting dose of 2&nbsp;mg, in a
10&nbsp;week, randomised, double blind, placebo-controlled study conducted in
South-Korea. Patients were 6 to 18&nbsp;years and presented an average score of
29 on TTS-YGTSS&nbsp;at baseline. Aripiprazole group showed an improvement of
14.97 on TTS-YGTSS change from baseline to week&nbsp;10 as compared with an
improvement of 9.62 in the placebo group.</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>In both of these short-term trials, the clinical relevance of the
efficacy findings has not been established, considering the magnitude of
treatment effect compared to the large placebo effect and the unclear effects
regarding psycho-social functioning. No long-term data are available with
regard to the efficacy and the safety of aripiprazole in this fluctuating
disorder.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The European
Medicines Agency has deferred the obligation to submit the results of studies
with ABILIFY in one or more subsets of the paediatric population in the
treatment of schizophrenia and in the treatment of bipolar affective disorder
(see section&nbsp;4.2 for information on paediatric use).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic
properties</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Absorption</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole is well
absorbed, with peak plasma concentrations occurring within 3 to 5&nbsp;hours
after dosing. Aripiprazole undergoes minimal pre-systemic metabolism. The
absolute oral bioavailability of the tablet formulation is 87&nbsp;%. There is
no effect of a high fat meal on the pharmacokinetics of aripiprazole.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Distribution</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole is
widely distributed throughout the body with an apparent volume of distribution
of 4.9&nbsp;L/kg, indicating extensive extravascular distribution. At
therapeutic concentrations, aripiprazole and dehydro-aripiprazole are greater
than 99&nbsp;% bound to serum proteins, binding primarily to albumin.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Biotransformation</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole is
extensively metabolised by the liver primarily by three biotransformation
pathways: dehydrogenation, hydroxylation, and N-dealkylation. Based on <i>in&nbsp;vitro</i>
studies, CYP3A4 and CYP2D6 enzymes are responsible for dehydrogenation and
hydroxylation of aripiprazole, and N-dealkylation is catalysed by CYP3A4.
Aripiprazole is the predominant medicinal product moiety in systemic
circulation. At steady state, dehydro-aripiprazole, the active metabolite,
represents about 40&nbsp;% of aripiprazole AUC in plasma.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Elimination</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The mean elimination
half-lives for aripiprazole are approximately 75&nbsp;hours in extensive
metabolisers of CYP2D6 and approximately 146&nbsp;hours in poor metabolisers of
CYP2D6.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The total body
clearance of aripiprazole is 0.7&nbsp;mL/min/kg, which is primarily hepatic.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Following a single
oral dose of [<sup>14</sup>C]-labelled aripiprazole, approximately 27&nbsp;% of
the administered radioactivity was recovered in the urine and approximately
60&nbsp;% in the faeces. Less than 1&nbsp;% of unchanged aripiprazole was
excreted in the urine and approximately 18&nbsp;% was recovered unchanged in
the faeces.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Paediatric population</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB>The pharmacokinetics of aripiprazole and
dehydro-aripiprazole in paediatric patients 10&nbsp;to 17&nbsp;years of age
were similar to those in adults after correcting for the differences in body
weights.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Pharmacokinetics
in special patient groups</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Elderly</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>There are no
differences in the pharmacokinetics of aripiprazole between healthy elderly and
younger adult subjects, nor is there any detectable effect of age in a
population pharmacokinetic analysis in schizophrenic patients.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Gender</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>There are no
differences in the pharmacokinetics of aripiprazole between healthy male and
female subjects nor is there any detectable effect of gender in a population
pharmacokinetic analysis in schizophrenic patients.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Smoking</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Population
pharmacokinetic evaluation has revealed no evidence of clinically significant <em><span
style='font-style:normal'>effects from </span></em>smoking on the
pharmacokinetics of aripiprazole.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><i><span lang=EN-GB
style='color:black'>Race</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Population pharmacokinetic evaluation showed no evidence of
race&#8209;related differences on the pharmacokinetics of aripiprazole.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Renal impairment</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The pharmacokinetic
characteristics of aripiprazole and dehydro-aripiprazole were found to be
similar in patients with severe renal disease compared to young healthy
subjects.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Hepatic
impairment</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>A single-dose study
in subjects with varying degrees of liver cirrhosis (Child&#8209;Pugh Classes
A, B, and&nbsp;C) did not reveal a significant effect of hepatic impairment on
the pharmacokinetics of aripiprazole and dehydro-aripiprazole, but the study
included only 3&nbsp;patients with Class&nbsp;C liver cirrhosis, which is
insufficient to draw conclusions on their metabolic capacity.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical
safety data</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Non-clinical data
reveal no special hazard for humans based on conventional studies of safety
pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential,
toxicity to reproduction and development.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Toxicologically
significant effects were observed only at doses or exposures that were
sufficiently in excess of the maximum human dose or exposure, indicating that
these effects were limited or of no relevance to clinical use. These included:
dose-dependent adrenocortical toxicity (lipofuscin pigment accumulation and/or
parenchymal cell loss) in rats after 104&nbsp;weeks at&nbsp;20&nbsp;mg/kg/day
to 60&nbsp;mg/kg/day (3&nbsp;to 10&nbsp;times the mean steady-state AUC at the
maximum recommended human dose) and increased adrenocortical carcinomas and
combined adrenocortical adenomas/carcinomas in female rats at 60&nbsp;mg/kg/day
(10&nbsp;times the mean steady-state AUC at the maximum recommended human
dose). The highest nontumorigenic exposure in female rats was 7&nbsp;times the
human exposure at the recommended dose.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>An additional
finding was cholelithiasis as a consequence of precipitation of sulphate
conjugates of hydroxy metabolites of aripiprazole in the bile of monkeys after
repeated oral dosing at&nbsp;25&nbsp;mg/kg/day to 125&nbsp;mg/kg/day (1 to
3&nbsp;times the mean steady-state AUC at the maximum recommended clinical dose
or 16 to 81&nbsp;times the maximum recommended human dose based on&nbsp;mg/m<span
class=EMEASuperscript>2</span>). However, the concentrations of the sulphate
conjugates of hydroxy aripiprazole in human bile at the highest dose proposed,
30&nbsp;mg per day, were no more than 6&nbsp;% of the bile concentrations found
in the monkeys in the 39&#8209;week study and are well below (6&nbsp;%) their
limits of <i>in&nbsp;vitro</i> solubility.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>In repeat-dose studies
in juvenile rats and dogs, the toxicity profile of aripiprazole was comparable
to that observed in adult animals, and there was no evidence of neurotoxicity
or adverse reactions on development.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Based on results of
a full range of standard genotoxicity tests, aripiprazole was considered
non-genotoxic. Aripiprazole did not impair fertility in reproductive toxicity
studies. Developmental toxicity, including dose-dependent delayed foetal
ossification and possible teratogenic effects, were observed in rats at doses
resulting in subtherapeutic exposures (based on AUC) and in rabbits at doses
resulting in exposures 3 and 11&nbsp;times the mean steady-state AUC at the
maximum recommended clinical dose. Maternal toxicity occurred at doses similar
to those eliciting developmental toxicity.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>6.1&nbsp;&nbsp;&nbsp;&nbsp; List of excipients</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Tablet core</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Calcium silicate</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Croscarmellose
sodium</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Crospovidone</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Silicon dioxide</span></p>

<p class=EMEABodyText><span lang=IT style='color:black'>Xylitol</span></p>

<p class=EMEABodyText><span lang=IT style='color:black'>Microcrystalline
cellulose</span></p>

<p class=EMEABodyText><span lang=IT style='color:black'>Aspartame (E&nbsp;951)</span></p>

<p class=EMEABodyText><span lang=IT style='color:black'>Acesulfame potassium</span></p>

<p class=EMEABodyText><span lang=IT style='color:black'>Vanilla flavour
(including vanillin, ethyl vanillin and lactose)</span></p>

<p class=EMEABodyText><span lang=IT style='color:black'>Tartaric acid</span></p>

<p class=EMEABodyText><span lang=IT style='color:black'>Magnesium stearate</span></p>

<p class=EMEABodyText><span lang=IT style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=IT style='color:black'>Tablet coat</span></u></p>

<p class=EMEABodyText><u><span lang=IT style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><u><span lang=IT style='color:black'>ABILIFY 10&nbsp;mg
orodispersible tablets</span></u></p>

<p class=EMEABodyText><span lang=IT style='color:black'>Red iron
oxide&nbsp;(E&nbsp;172)</span></p>

<p class=EMEABodyText><span lang=IT style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=IT style='color:black'>ABILIFY 15&nbsp;mg
orodispersible tablets</span></u></p>

<p class=EMEABodyText><span lang=IT style='color:black'>Yellow iron
oxide&nbsp;(E&nbsp;172)</span></p>

<p class=EMEABodyText><span lang=IT style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=ES style='color:black'>ABILIFY 30&nbsp;mg
orodispersible tablets</span></u></p>

<p class=EMEABodyText><span lang=ES style='color:black'>Red iron
oxide&nbsp;(E&nbsp;172)</span></p>

<p class=EMEABodyText><span lang=ES style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Not applicable.</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf life</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>3&nbsp;years</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>6.4&nbsp;&nbsp;&nbsp;&nbsp; Special precautions
for storage</span></b></p>

<p class=EMEABodyText style='text-align:justify'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Store in the
original package in order to protect from moisture.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>6.5&nbsp;&nbsp;&nbsp;&nbsp; Nature and contents
of container</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aluminium perforated
unit dose blisters in cartons of 14&nbsp;&times;&nbsp;1, 28&nbsp;&times;&nbsp;1,
49&nbsp;&times;&nbsp;1&nbsp;tablets.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Not all pack sizes
may be marketed.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>6.6&nbsp;&nbsp;&nbsp;&nbsp; Special precautions
for disposal</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Any unused medicinal
product or waste material should be disposed of in accordance with local
requirements.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Otsuka Pharmaceutical
Netherlands B.V.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Herikerbergweg 292</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>1101 CT, Amsterdam</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Netherlands</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>ABILIFY
10&nbsp;mg orodispersible tablets</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>EU/1/04/276/024
(10&nbsp;mg, 14&nbsp;&times; 1 orodispersible tablets)</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>EU/1/04/276/025
(10&nbsp;mg, 28&nbsp;&times; 1 orodispersible tablets)</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>EU/1/04/276/026
(10&nbsp;mg, 49&nbsp;&times; 1 orodispersible tablets)</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>ABILIFY
15&nbsp;mg orodispersible tablets</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>EU/1/04/276/027
(15&nbsp;mg, 14&nbsp;&times; 1 orodispersible tablets)</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>EU/1/04/276/028
(15&nbsp;mg, 28&nbsp;&times; 1 orodispersible tablets)</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>EU/1/04/276/029
(15&nbsp;mg, 49&nbsp;&times; 1 orodispersible tablets)</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>ABILIFY
30&nbsp;mg orodispersible tablets</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>EU/1/04/276/030
(30&nbsp;mg, 14&nbsp;&times; 1 orodispersible tablets)</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>EU/1/04/276/031
(30&nbsp;mg, 28&nbsp;&times; 1 orodispersible tablets)</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>EU/1/04/276/032
(30&nbsp;mg, 49&nbsp;&times; 1 orodispersible tablets)</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DATE OF
FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Date of first
authorisation: 04&nbsp;June&nbsp;2004</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Date of latest
renewal: 04&nbsp;June&nbsp;2009</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>10.&nbsp;&nbsp;&nbsp;&nbsp; DATE OF REVISION OF
THE TEXT</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>{MM/YYYY}</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Detailed information
on this medicinal product is available on the website of the European Medicines
Agency <a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a>.</span></p>

<p class=EMEAHeading1 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE MEDICINAL
PRODUCT</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY 1&nbsp;mg/mL
oral solution</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE AND
QUANTITATIVE COMPOSITION</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Each&nbsp;mL oral
solution contains 1&nbsp;mg of aripiprazole.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Excipients with
known effect (per mL)</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>200&nbsp;mg
fructose, 400&nbsp;mg sucrose, 1.8&nbsp;mg methyl parahydroxybenzoate (E218),
0.2&nbsp;mg propyl parahydroxybenzoate (E&nbsp;216)</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>For the full list of
excipients, see section&nbsp;6.1.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL FORM</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Oral solution</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Clear, colourless to
light yellow liquid solution.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CLINICAL PARTICULARS</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic indications</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY is indicated
for the treatment of schizophrenia in adults and in adolescents aged
15&nbsp;years and older.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY is indicated
for the treatment of moderate to severe manic episodes in Bipolar I Disorder
and for the prevention of a new manic episode in adults who experienced
predominantly manic episodes and whose manic episodes responded to aripiprazole
treatment (see section&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY is indicated
for the treatment up to 12&nbsp;weeks of moderate to severe manic episodes in
Bipolar I Disorder in adolescents aged 13&nbsp;years and older (see
section&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>4.2&nbsp;&nbsp;&nbsp;&nbsp; Posology and method of
administration</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Posology</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><u><span lang=EN-GB style='color:black'>Adults</span></u></i></p>

<p class=EMEABodyText><i><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Schizophrenia:</span></i><span
lang=EN-GB style='color:black;layout-grid-mode:line'> the recommended starting
dose for ABILIFY is 10&nbsp;mg/day or 15&nbsp;mg/day (i.e. 10&nbsp;mL or
15&nbsp;mL solution/day) with a maintenance dose of 15&nbsp;mg/day administered
on a once-a-day schedule without regard to meals. ABILIFY is effective in a
dose range of 10&nbsp;mg/day to&nbsp;30&nbsp;mg/day (i.e. 10&nbsp;mL to
30&nbsp;mL solution/day). Enhanced efficacy at doses higher than a daily dose
of 15&nbsp;mg has not been demonstrated although individual patients may
benefit from a higher dose. The maximum daily dose should not exceed
30&nbsp;mg.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black;layout-grid-mode:
line'>Manic episodes in Bipolar I Disorder:</span></i><span lang=EN-GB
style='color:black'> the recommended starting dose for <span style='layout-grid-mode:
line'>ABILIFY </span>is 15&nbsp;mg (i.e. 15&nbsp;mL solution/day) administered
on a once-a-day schedule without regard to meals as monotherapy or combination
therapy (see section&nbsp;5.1). Some patients may benefit from a higher dose. <span
style='layout-grid-mode:line'>The maximum daily dose should not exceed
30&nbsp;mg.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black;layout-grid-mode:
line'>Recurrence prevention of manic episodes in Bipolar I Disorder</span></i><i><span
lang=EN-GB style='color:black'>:</span></i><span lang=EN-GB style='color:black'>
for </span><span lang=EN-GB style='color:black'>preventing recurrence of manic
episodes in patients, who have been receiving aripiprazole as monotherapy or
combination therapy, continue therapy at the same dose. </span><span
lang=EN-GB style='color:black'>Adjustments of daily dosage, including dose
reduction should be considered on the basis of clinical status.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><i><u><span lang=EN-GB style='color:black'>Paediatric
population</span></u></i></p>

<p class=EMEABodyText><i><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Schizophrenia in
adolescents aged 15&nbsp;years and older</span></i><span lang=EN-GB
style='color:black'>: the recommended dose for <span style='layout-grid-mode:
line'>ABILIFY</span> is 10&nbsp;mg/day administered on a once-a-day schedule
without regard to meals. Treatment should be initiated at 2&nbsp;mg (using <span
style='layout-grid-mode:line'>ABILIFY</span> oral solution 1 mg/mL) for
2&nbsp;days, titrated to 5&nbsp;mg for 2&nbsp;additional days to reach the
recommended daily dose of 10&nbsp;mg. When appropriate, subsequent dose
increases should be administered in 5&nbsp;mg increments without exceeding the
maximum daily dose of 30&nbsp;mg (see section&nbsp;5.1). ABILIFY is effective
in a dose range of 10&nbsp;mg/day to 30&nbsp;mg/day. Enhanced efficacy at doses
higher than a daily dose of 10&nbsp;mg has not been demonstrated although
individual patients may benefit from a higher dose.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY is not recommended
for use in patients with schizophrenia below 15&nbsp;years of age due to
insufficient data on safety and efficacy (see sections&nbsp;4.8 and 5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Manic episodes in
Bipolar I Disorder in adolescents aged 13&nbsp;years and older</span></i><span
lang=EN-GB style='color:black'>: the recommended dose for ABILIFY is
10&nbsp;mg/day administered on a once-a-day schedule without regard to meals.
Treatment should be initiated at 2&nbsp;mg (using ABILIFY oral solution
1&nbsp;mg/mL) for 2&nbsp;days, titrated to 5&nbsp;mg for 2&nbsp;additional days
to reach the recommended daily dose of 10&nbsp;mg. The treatment duration should
be the minimum necessary for symptom control and must not exceed 12&nbsp;weeks.
Enhanced efficacy at doses higher than a daily dose of 10&nbsp;mg has not been
demonstrated, and a daily dose of 30&nbsp;mg is associated with a substantially
higher incidence of significant adverse reactions including EPS related events,
somnolence, fatigue and weight gain (see section&nbsp;4.8). Doses higher than
10&nbsp;mg/day should therefore only be used in exceptional cases and with
close clinical monitoring (see sections&nbsp;4.4,&nbsp;4.8 and&nbsp;5.1). Younger
patients are at increased risk of experiencing adverse events associated with
aripiprazole. Therefore, ABILIFY is not recommended for use in patients below
13&nbsp;years of age (see sections&nbsp;4.8 and&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Irritability
associated with autistic disorder:</span></i><span lang=EN-GB style='color:
black'> the safety and efficacy of ABILIFY in children and adolescents aged
below 18&nbsp;years have not yet been established. Currently available data are
described in section&nbsp;5.1 but no recommendation on a posology can be made.</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Tics associated with
Tourette&#8217;s disorder:</span></i><span lang=EN-GB style='color:black'> the
safety and efficacy of ABILIFY in children and adolescents 6 to 18 years of age
have not yet been established. Currently available data are described in
section&nbsp;5.1 but no recommendation on a posology can be made.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><u><span lang=EN-GB style='color:black'>Special populations</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Hepatic impairment</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>No dosage adjustment
is required for patients with mild to moderate hepatic impairment. In patients
with severe hepatic impairment, the data available are insufficient to
establish recommendations. In these patients dosing should be managed
cautiously. However, the maximum daily dose of 30&nbsp;mg should be used with
caution in patients with severe hepatic impairment (see section&nbsp;5.2).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Renal impairment</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>No dosage adjustment
is required in patients with renal impairment.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Elderly</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The safety and
efficacy of ABILIFY in the treatment of schizophrenia or manic episodes in
Bipolar I Disorder in patients aged 65&nbsp;years and older has not been
established. Owing to the greater sensitivity of this population, a lower
starting dose should be considered when clinical factors warrant (see
section&nbsp;4.4).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Gender</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>No dosage adjustment
is required for female patients as compared to male patients
(see&nbsp;section&nbsp;5.2).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Smoking status</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>According to the
metabolic pathway of aripiprazole no dosage adjustment is required for smokers
(see section&nbsp;4.5).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Dose adjustments
due to interactions</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>When concomitant administration of strong CYP3A4 or CYP2D6 inhibitors
with aripiprazole occurs, the aripiprazole dose should be reduced. When the
CYP3A4 or CYP2D6 inhibitor is withdrawn from the combination therapy,
aripiprazole dose should then be increased (see section&nbsp;4.5).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>When concomitant administration of strong CYP3A4 inducers with
aripiprazole occurs, the aripiprazole dose should be increased. When the CYP3A4
inducer is withdrawn from the combination therapy, the aripiprazole dose should
then be reduced to the recommended dose (see section&nbsp;4.5).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Method of
administration</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>ABILIFY</span><span lang=EN-GB style='color:black'> is for oral use.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Orodispersible
tablets or oral solution may be used as an alternative to ABILIFY tablets for
patients who have difficulty swallowing ABILIFY tablets (see section&nbsp;5.2).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Hypersensitivity to
the active substance or to any of the excipients listed in section&nbsp;6.1.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special warnings and
precautions for use</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>During antipsychotic
treatment, improvement in the patient's clinical condition may take several
days to some weeks. Patients should be closely monitored throughout this
period.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Suicidality</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The occurrence of
suicidal behaviour is inherent in psychotic illnesses and mood disorders and in
some cases has been reported early after initiation or switch of antipsychotic <em><span
style='font-style:normal'>treatment</span></em>, including treatment with
aripiprazole (see section&nbsp;4.8). Close supervision of high-risk patients
should accompany antipsychotic treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Cardiovascular
disorders</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole should
be used with caution in patients with known cardiovascular disease (history of
myocardial infarction or ischaemic heart disease, heart failure, or conduction
abnormalities), cerebrovascular disease, conditions which would predispose
patients to hypotension (dehydration, hypovolemia, and treatment with
antihypertensive medicinal products) or hypertension, including accelerated or
malignant. Cases of venous thromboembolism (VTE) have been reported with antipsychotic
medicinal products. Since patients treated with antipsychotics often present
with acquired risk factors for VTE, all possible risk factors for VTE should be
identified before and during treatment with aripiprazole and preventive
measures undertaken.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>QT prolongation</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In clinical trials
of aripiprazole, the incidence of QT prolongation was comparable to placebo.
Aripiprazole should be used with caution in patients with a family history of
QT prolongation (see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Tardive
dyskinesia</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In clinical trials
of one year or less duration, there were uncommon reports of treatment emergent
dyskinesia during treatment with aripiprazole. If signs and symptoms of tardive
dyskinesia appear in a patient on aripiprazole, dose reduction or
discontinuation should be considered (see section&nbsp;4.8). These symptoms can
temporally deteriorate or can even arise after discontinuation of treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Other
extrapyramidal symptoms</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In paediatric
clinical trials of aripiprazole akathisia and Parkinsonism were observed. If
signs and symptoms of other EPS appear in a patient taking aripiprazole, dose
reduction and close clinical monitoring should be considered.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Neuroleptic
Malignant Syndrome (NMS)</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>NMS is a potentially
fatal symptom complex associated with antipsychotics. In clinical trials, rare
cases of NMS were reported during treatment with aripiprazole. Clinical
manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status
and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia,
diaphoresis and cardiac dysrhythmia). Additional signs may include elevated
creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal
failure. However, elevated creatine phosphokinase and rhabdomyolysis, not
necessarily in association with NMS, have also been reported. If a patient
develops signs and symptoms indicative of NMS, or presents with unexplained
high fever without additional clinical manifestations of NMS, all antipsychotics,
including aripiprazole, must be discontinued.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Seizure</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In clinical trials,
uncommon cases of seizure were reported during treatment with aripiprazole.
Therefore, aripiprazole should be used with caution in patients who have a
history of seizure disorder or have conditions associated with seizures (see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Elderly patients
with dementia-related psychosis</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Increased
mortality</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In three
placebo-controlled trials (n&nbsp;=&nbsp;938; mean age: 82.4&nbsp;years; range:
56 to 99&nbsp;years) of aripiprazole in elderly patients with psychosis
associated with Alzheimer's disease, patients treated with aripiprazole were at
increased risk of death compared to placebo. The rate of death in
aripiprazole-treated patients was 3.5&nbsp;% compared to 1.7&nbsp;% in the
placebo group. Although the causes of deaths were varied, most of the deaths
appeared to be either cardiovascular (e.g. heart failure, sudden death) or
infectious (e.g. pneumonia) in nature (see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Cerebrovascular
adverse reactions</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In the same trials,
cerebrovascular adverse reactions (e.g. stroke, transient ischaemic attack),
including fatalities, were reported in patients (mean age: 84&nbsp;years;
range: 78 to 88&nbsp;years). Overall, 1.3&nbsp;% of aripiprazole-treated
patients reported cerebrovascular adverse reactions compared with 0.6&nbsp;% of
placebo-treated patients in these trials. This difference was not statistically
significant. However, in one of these trials, a fixed-dose trial, there was a
significant dose response relationship for cerebrovascular adverse reactions in
patients treated with aripiprazole (see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole is not
indicated for the treatment of patients with dementia-related psychosis.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Hyperglycaemia
and diabetes mellitus</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Hyperglycaemia, in
some cases extreme and associated with ketoacidosis or hyperosmolar coma or
death, has been reported in patients treated with atypical antipsychotics,
including aripiprazole. Risk factors that may predispose patients to severe
complications include obesity and family history of diabetes. In clinical
trials with aripiprazole, there were no significant differences in the
incidence rates of hyperglycaemia-related adverse reactions (including
diabetes) or in abnormal glycaemia laboratory values compared to placebo.
Precise risk estimates for hyperglycaemia-related adverse reactions in patients
treated with aripiprazole and with other atypical antipsychotics are not
available to allow direct comparisons. Patients treated with any antipsychotics,
including aripiprazole, should be observed for signs and symptoms of
hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness) and
patients with diabetes mellitus or with risk factors for diabetes mellitus
should be monitored regularly for worsening of glucose control (see
section&nbsp;4.8).</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Hypersensitivity</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Hypersensitivity
reactions, characterised by allergic symptoms, may occur with aripiprazole (see
section&nbsp;4.8).</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Weight gain</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Weight gain is
commonly seen in schizophrenic and bipolar mania patients due to
co-morbidities, use of antipsychotics known to cause weight gain, poorly
managed life-style, and might lead to severe complications. Weight gain has
been reported post-marketing among patients prescribed aripiprazole. When seen,
it is usually in those with significant risk factors such as history of
diabetes, thyroid disorder or pituitary adenoma. In clinical trials
aripiprazole has not been shown to induce clinically relevant weight gain in
adults (see section&nbsp;5.1). In clinical trials of adolescent patients with
bipolar mania, aripiprazole has been shown to be associated with weight gain
after 4&nbsp;weeks of treatment. Weight gain should be monitored in adolescent
patients with bipolar mania. If weight gain is clinically significant, dose
reduction should be considered (see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Dysphagia</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Oesophageal
dysmotility and aspiration have been associated with the use of antipsychotics,
including aripiprazole. Aripiprazole should be used cautiously in patients at
risk for aspiration pneumonia.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB>Pathological
gambling and other impulse control disorders</span></u></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Patients can experience increased urges,
particularly for gambling, and the inability to control these urges while
taking aripiprazole. Other urges, reported, include: increased sexual urges,
compulsive shopping, binge or compulsive eating, and other impulsive and
compulsive behaviours. It is important for prescribers to ask patients or their
caregivers specifically about the development of new or increased gambling
urges, sexual urges, compulsive shopping, binge or compulsive eating, or other
urges while being treated with aripiprazole. It should be noted that
impulse-control symptoms can be associated with the underlying disorder;
however, in some cases, urges were reported to have stopped when the dose was
reduced or the medication was discontinued. Impulse control disorders may
result in harm to the patient and others if not recognised. Consider dose
reduction or stopping the medication if a patient develops such urges while
taking aripiprazole (see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Fructose and
sucrose</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The oral solution
contains fructose and sucrose. Fructose may damage teeth. Sucrose may be
harmful to the teeth. Patients with rare hereditary problems of fructose
intolerance, glucose-galactose malabsorption or sucrase-isomaltase
insufficiency should not take this medicinal product.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Parahydroxybenzoate</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The oral solution
contains methyl parahydroxybenzoate and propyl parahydroxybenzoate. May cause
allergic reactions (possibly delayed).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Sodium</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The oral solution
contains sodium. This medicinal product contains less than 1&nbsp;mmol sodium
(23&nbsp;mg) per dosage unit, that is to say essentially &#8216;sodium-free&#8217;.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Patients with attention
deficit hyperactivity disorder (ADHD) comorbidity</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Despite the high
comorbidity frequency of Bipolar I Disorder and ADHD, very limited safety data
are available on concomitant use of aripiprazole and stimulants; therefore,
extreme caution should be taken when these medicinal products are
co-administered.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Falls</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span style='color:black'>Aripiprazole
may cause somnolence, postural hypotension, motor and sensory instability,
which may lead to falls. Caution should be taken when treating patients at
higher risk, and a lower starting dose should be considered (e.g., elderly or
debilitated patients; see section 4.2).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction
with other medicinal products and other forms of interaction</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>D<span
style='layout-grid-mode:line'>ue to its &#945;</span><span class=BMSSubscript>1</span>-adrenergic
receptor antagonism,<span style='layout-grid-mode:line'> aripiprazole has the
potential to enhance the effect of certain antihypertensive medicinal products.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Given the primary
CNS effects of aripiprazole, caution should be used when aripiprazole is administered
in combination with alcohol or other CNS medicinal products with overlapping
adverse reactions such as sedation (see&nbsp;section&nbsp;4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If aripiprazole is
administered concomitantly with medicinal products known to cause QT
prolongation or electrolyte imbalance, caution should be used.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Potential for
other medicinal products to affect aripiprazole</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>A gastric acid
blocker, the H<sub>2</sub>&nbsp;antagonist famotidine, reduces aripiprazole
rate of absorption but this effect is deemed not clinically relevant. <span
style='layout-grid-mode:line'>Aripiprazole is metabolised by multiple pathways
involving the CYP2D6 and CYP3A4 enzymes but not CYP1A enzymes. Thus, no dosage
adjustment is required for smokers.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Quinidine and other
CYP2D6 inhibitors</span></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>In a clinical trial in healthy subjects, a strong inhibitor of CYP2D6
(quinidine) increased aripiprazole AUC by 107&nbsp;%, while </span><span
lang=EN-GB style='color:black'>C<span class=EMEASubscript>max</span><span
style='layout-grid-mode:line'> was unchanged. The AUC and </span>C<span
class=EMEASubscript>max</span><span style='layout-grid-mode:line'> of
dehydro-aripiprazole, the active metabolite, decreased by 32&nbsp;% and
47&nbsp;%</span></span><span lang=EN-GB style='color:black'>, respectively</span><span
lang=EN-GB style='color:black;layout-grid-mode:line'>. A</span><span
lang=EN-GB style='color:black'>ripiprazole<span style='layout-grid-mode:line'>
dose should be reduced to approximately one-half of its prescribed dose when
concomitant administration of </span>aripiprazole<span style='layout-grid-mode:
line'> with quinidine occurs. Other strong inhibitors of CYP2D6, such as
fluoxetine and paroxetine, may be expected to have similar effects and similar
dose reductions should therefore be applied.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Ketoconazole and
other CYP3A4 inhibitors</span></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>In a clinical trial in healthy subjects, a strong inhibitor of CYP3A4
(ketoconazole) increased aripiprazole AUC and </span><span lang=EN-GB
style='color:black'>C<span class=EMEASubscript>max</span><span
style='layout-grid-mode:line'> by 63&nbsp;% and 37&nbsp;%, respectively. The
AUC and </span>C<span class=EMEASubscript>max</span><span style='layout-grid-mode:
line'> of dehydro-aripiprazole increased by 77&nbsp;% and 43&nbsp;%, respectively.
In CYP2D6 poor metabolisers, concomitant use of strong inhibitors of CYP3A4 may
result in higher plasma concentrations of aripiprazole compared to that in
CYP2D6 extensive metabolizers. When considering concomitant administration of
ketoconazole or other strong CYP3A4 inhibitors with </span>aripiprazole<span
style='layout-grid-mode:line'>, potential benefits should </span>outweigh<span
style='layout-grid-mode:line'> the potential risks to the patient. When
concomitant administration of ketoconazole with </span>aripiprazole<span
style='layout-grid-mode:line'> occurs, </span>aripiprazole<span
style='layout-grid-mode:line'> dose should be reduced to approximately one-half
of its prescribed dose. Other strong inhibitors of CYP3A4, such as itraconazole
and HIV protease inhibitors may be expected to have similar effects and similar
dose reductions should therefore be applied (see section&nbsp;4.2).</span> Upon
discontinuation of the CYP2D6 or CYP3A4 inhibitor, the dosage of aripiprazole
should be increased to the level prior to the initiation of the concomitant
therapy. When weak inhibitors of CYP3A4 (e.g. diltiazem) or CYP2D6 (e.g.
escitalopram) are used concomitantly with aripiprazole, modest increases in plasma
aripiprazole concentrations may be expected.</span></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Carbamazepine and
other CYP3A4 inducers</span></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Following
concomitant administration of carbamazepine, a strong inducer of CYP3A4, and
oral aripiprazole to patients with schizophrenia or schizoaffective disorder, the
geometric means of C<span class=EMEASubscript>max</span> and AUC for
aripiprazole were 68&nbsp;% and 73&nbsp;% lower, respectively, compared to when
<span style='layout-grid-mode:line'>aripiprazole (30&nbsp;mg) was administered
alone</span>. Similarly, for dehydro-aripiprazole the geometric means of C<span
class=EMEASubscript>max</span> and AUC after carbamazepine co-administration
were 69&nbsp;% and 71&nbsp;% lower, respectively, than those following
treatment with aripiprazole alone. Aripiprazole dose should be doubled when
concomitant administration of aripiprazole occurs with carbamazepine. Concomitant
administration of aripiprazole and other inducers of CYP3A4 (such as
rifampicin, rifabutin, phenytoin, phenobarbital, primidone, efavirenz,
nevirapine and St. John's Wort) may be expected to have similar effects and
similar dose increases should therefore be applied. Upon discontinuation of strong
CYP3A4 inducers, the dosage of aripiprazole should be reduced to the
recommended dose.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Valproate and
lithium</span></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>When either
valproate or lithium was administered concomitantly with aripiprazole, there
was no clinically significant change in aripiprazole concentrations </span><span
lang=EN-GB>and therefore no dose adjustment is necessary when either valproate
or lithium is administered with aripiprazole<span style='color:black'>.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Potential for aripiprazole
to affect other medicinal products</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In clinical studies,
10&nbsp;mg/day to 30&nbsp;mg/day doses of aripiprazole had no significant
effect on the metabolism of substrates of CYP2D6
(dextromethorphan/3-methoxymorphinan ratio), CYP2C9&nbsp;(warfarin), CYP2C19
(omeprazole), and CYP3A4 (dextromethorphan). Additionally, aripiprazole and
dehydro-aripiprazole did not show potential for altering CYP1A2-mediated
metabolism <i>in&nbsp;vitro</i>. Thus, aripiprazole is unlikely to cause
clinically important medicinal product interactions mediated by these enzymes.</span></p>

<p class=EMEABodyText><i><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>When aripiprazole
was administered concomitantly with either valproate, lithium or lamotrigine,
there was no clinically important change in valproate, lithium or lamotrigine
concentrations.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Serotonin
syndrome</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Cases of serotonin
syndrome have been reported in patients taking aripiprazole, and possible signs
and symptoms for this condition can occur especially in cases of concomitant
use with other serotonergic medicinal products, such as selective serotonin reuptake
inhibitor/selective serotonin noradrenaline reuptake inhibitor (SSRI/SNRI), or
with medicinal products that are known to increase aripiprazole concentrations
(see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>4.6&nbsp;&nbsp;&nbsp;&nbsp; Fertility, pregnancy
and lactation</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Pregnancy</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>There are no
adequate and well-controlled trials of aripiprazole in pregnant women.
Congenital anomalies have been reported; however, causal relationship with
aripiprazole could not be established. Animal studies could not exclude
potential developmental toxicity (see section&nbsp;5.3). Patients must be
advised to notify their physician if they become pregnant or intend to become
pregnant during treatment with aripiprazole. Due to insufficient safety information
in humans and concerns raised by animal reproductive studies, this medicinal
product should not be used in pregnancy unless the expected benefit clearly
justifies the potential risk to the foetus.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Newborn infants
exposed to antipsychotics (including aripiprazole) during the third trimester
of pregnancy are at risk of adverse reactions including extrapyramidal and/or
withdrawal symptoms that may vary in severity and duration following delivery.
There have been reports of agitation, hypertonia, hypotonia, tremor,
somnolence, respiratory distress, or feeding disorder. Consequently, newborn
infants should be monitored carefully (see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Breast-feeding</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole/</span><span
lang=EN-GB>metabolites are<span style='color:black'> excreted in human milk. </span><em><span
style='font-style:normal'>A decision must be made whether to discontinue breast&#8209;feeding
or to discontinue/abstain from </span></em>aripiprazole<em><span
style='font-style:normal'> therapy taking into account the benefit of
breast-feeding for the child and the benefit of therapy for the woman.</span></em></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='font-style:normal'>Fertility</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=EMEABodyText><span lang=EN-GB>Aripiprazole did not impair fertility
based on data from reproductive toxicity studies.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects on ability
to drive and use machines</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>Aripiprazole </span></em><span
lang=EN-GB>has minor to moderate influence on the ability to drive and use
machines due to potential nervous system and visual effects, such as sedation,
somnolence, syncope, vision blurred, diplopia (see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable effects</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Summary
of the safety profile</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The most commonly
reported adverse reactions in placebo-controlled trials were akathisia and
nausea each occurring in more than 3<b>&nbsp;</b>% of patients treated with
oral aripiprazole.</span></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Tabulated
list of adverse reactions</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>The incidences of the Adverse Drug Reactions (ADRs)
associated with aripiprazole therapy are tabulated below. The table is based on
adverse events reported during clinical trials and/or post-marketing use.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>All ADRs are listed by system organ class and frequency;
very common (&#8805;&nbsp;1/10), common (&#8805;&nbsp;1/100 to &lt;&nbsp;1/10),
uncommon (&#8805;&nbsp;1/1,000 to &lt;&nbsp;1/100), rare (&#8805;&nbsp;1/10,000
to &lt;&nbsp;1/1,000), very rare (&lt;&nbsp;1/10,000) and not known (cannot be
estimated from the available data). Within each frequency grouping, adverse
reactions are presented in order of decreasing seriousness.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The frequency of
adverse reactions reported during post-marketing use cannot be determined as
they are derived from spontaneous reports. Consequently, the frequency of these
adverse events is qualified as &quot;not known&quot;.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
   style='color:black'>&nbsp;</span></b></p>
   </td>
   <td width=123 valign=top style='width:92.15pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
   style='color:black'>Common</span></b></p>
   </td>
   <td width=142 valign=top style='width:106.3pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
   style='color:black'>Uncommon</span></b></p>
   </td>
   <td width=217 valign=top style='width:163.0pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
   style='color:black'>Not known</span></b></p>
   <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
   style='color:black'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Blood and lymphatic system disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Leukopenia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Neutropenia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Thrombocytopenia</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Immune system disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Allergic reaction (e.g. anaphylactic
  reaction, angioedema including swollen tongue, tongue oedema, face oedema,
  pruritus allergic, or urticaria)</span></em></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Endocrine disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hyperprolactinaemia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Diabetic hyperosmolar
  coma</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Diabetic ketoacidosis</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Metabolism and nutrition disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;text-autospace:none'><span
  lang=EN-GB style='color:black'>Diabetes mellitus</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hyperglycaemia</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Hyponatremia</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Anorexia</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Psychiatric disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Insomnia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Anxiety</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Restlessness</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Depression</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hypersexuality</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Suicide attempt, suicidal ideation and completed suicide
  (see section&nbsp;4.4)</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Pathological gambling</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Impulse-control
  disorder</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Binge eating</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Compulsive
  shopping</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Poriomania</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Aggression</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Agitation</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Nervousness </span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Nervous system disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Akathisia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Extrapyramidal disorder</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Tremor</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Headache</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Sedation</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Somnolence</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Dizziness</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Tardive dyskinesia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Dystonia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=IT
  style='color:black'>Restless legs syndrome</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=FR
  style='color:black'>Neuroleptic Malignant Syndrome</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=FR
  style='color:black'>Grand mal convulsion</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Serotonin syndrome</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Speech disorder</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Eye disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Vision blurred</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Diplopia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Photophobia</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Oculogyric crisis</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Cardiac disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Tachycardia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Sudden death unexplained </span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Torsades de pointes</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Ventricular arrhythmia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Cardiac arrest</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Bradycardia</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Vascular disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Orthostatic hypotension</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Venous thromboembolism (including pulmonary embolism and
  deep vein thrombosis)</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hypertension</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Syncope</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Respiratory, thoracic and mediastinal
  disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hiccups</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Aspiration pneumonia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Laryngospasm</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Oropharyngeal spasm</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Gastrointestinal disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Constipation</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Dyspepsia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Nausea</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Salivary hypersecretion</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Vomiting</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Pancreatitis</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Dysphagia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Diarrhoea</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Abdominal discomfort</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Stomach discomfort</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Hepatobiliary disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hepatic failure</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hepatitis</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Jaundice</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
  style='color:black'>Skin and subcutaneous tissue disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Rash</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Photosensitivity reaction</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Alopecia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hyperhidrosis</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Drug Reaction
  with Eosinophilia and Systemic Symptoms (DRESS)</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Musculoskeletal and connective tissue
  disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Rhabdomyolysis</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Myalgia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Stiffness</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Renal and urinary disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Urinary incontinence</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Urinary retention</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Pregnancy, puerperium and perinatal conditions</span></b></em></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Drug withdrawal syndrome neonatal (see section&nbsp;4.6)</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Reproductive system and breast disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Priapism</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>General disorders and administration
  site conditions</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Fatigue</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Temperature regulation disorder (e.g. hypothermia,
  pyrexia)</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Chest pain</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Peripheral oedema</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Investigations</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Weight decreased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Weight gain</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Alanine Aminotransferase </span><span lang=EN-GB
  style='color:black'>increased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Aspartate Aminotransferase increased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Gamma-glutamyltransferase increased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Alkaline phosphatase increased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>QT prolonged</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Blood glucose increased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Glycosylated haemoglobin increased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Blood glucose fluctuation</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Creatine phosphokinase increased</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Description of
selected adverse reactions</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><i><u><span lang=EN-GB style='color:black'>Adults</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Extrapyramidal
symptoms (EPS)</span></i></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Schizophrenia:</span></i><span
lang=EN-GB style='color:black'> in a long-term 52&#8209;week controlled trial,
aripiprazole-treated patients had an overall-lower incidence (25.8&nbsp;%) of
EPS including Parkinsonism, akathisia, dystonia and dyskinesia compared with
those treated with haloperidol (57.3&nbsp;%). In a long-term 26&#8209;week
placebo-controlled trial, the incidence of EPS was 19&nbsp;% for
aripiprazole-treated patients and 13.1&nbsp;% for placebo-treated patients. In
another long-term 26&#8209;week controlled trial, the incidence of EPS was
14.8&nbsp;% for aripiprazole-treated patients and 15.1&nbsp;% for
olanzapine-treated patients.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Manic episodes in
Bipolar I Disorder: </span></i><span lang=EN-GB style='color:black'>in a 12&#8209;week
controlled trial, the incidence of EPS was 23.5&nbsp;% for aripiprazole-treated
patients and 53.3&nbsp;% for haloperidol-treated patients. In another 12&#8209;week
trial, the incidence of EPS was 26.6&nbsp;% for patients treated with aripiprazole
and 17.6&nbsp;% for those treated with lithium. In the long-term 26&#8209;week
maintenance phase of a placebo-controlled trial, the incidence of EPS was
18.2&nbsp;% for aripiprazole-treated patients and 15.7&nbsp;% for
placebo-treated patients.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Akathisia</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In placebo-controlled
trials, the incidence of akathisia in bipolar patients was 12.1&nbsp;% with
aripiprazole and 3.2&nbsp;% with placebo. In schizophrenia patients the
incidence of akathisia was 6.2&nbsp;% with aripiprazole and 3.0&nbsp;% with
placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Dystonia</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Class effect:
Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may
occur in susceptible individuals during the first few days of treatment.
Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to
tightness of the throat, swallowing difficulty, difficulty breathing, and/or
protrusion of the tongue. While these symptoms can occur at low doses, they
occur more frequently and with greater severity with high potency and at higher
doses of first generation antipsychotic medicinal products. An elevated risk of
acute dystonia is observed in males and younger age groups.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Prolactin</span></em></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>In clinical trials for the approved indications and
post-marketing, both increase and decrease in serum prolactin as compared to
baseline was observed with aripiprazole (section&nbsp;5.1).</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Laboratory
parameters</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Comparisons between
aripiprazole and placebo in the proportions of patients experiencing
potentially clinically significant changes in routine laboratory and lipid
parameters (see section&nbsp;5.1) revealed no medically important differences.
Elevations of CPK (Creatine Phosphokinase), generally transient and
asymptomatic, were observed in 3.5&nbsp;% of aripiprazole treated patients as
compared to 2.0&nbsp;% of patients who received placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><u><span lang=EN-GB style='color:black'>Paediatric
population</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Schizophrenia in
adolescents aged 15&nbsp;years and older</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In a short-term
placebo-controlled clinical trial involving 302&nbsp;adolescents (13 to 17&nbsp;years)
with schizophrenia, the frequency and type of adverse reactions were similar to
those in adults except for the following reactions that were reported more
frequently in adolescents receiving aripiprazole than in adults receiving
aripiprazole (and more frequently than placebo):</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Somnolence/sedation
and extrapyramidal disorder were reported very commonly (&#8805;&nbsp;1/10),
and dry mouth, increased appetite, and orthostatic hypotension were reported
commonly (&#8805;&nbsp;1/100, &lt;&nbsp;1/10). The safety profile in a 26&#8209;week
open-label extension trial was similar to that observed in the short-term,
placebo-controlled trial.</span></p>

<p class=MsoNormal><span lang=EN-GB>The safety profile of a long-term,
double-blind, placebo-controlled trial was also similar except for the
following reactions that were reported more frequently than paediatric patients
taking placebo: weight decreased, blood insulin increased, arrhythmia, and
leukopenia were reported commonly (&#8805;&nbsp;1/100, &lt;&nbsp;1/10).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In the pooled
adolescent schizophrenia population (13 to 17&nbsp;years) with exposure up to
2&nbsp;years, incidence of low serum prolactin levels in females (&lt;&nbsp;3&nbsp;ng/mL)
and males (&lt;&nbsp;2&nbsp;ng/mL) was 29.5&nbsp;% and 48.3&nbsp;%,
respectively. In the adolescent (13 to 17&nbsp;years) schizophrenia population
with aripiprazole exposure of 5&nbsp;mg to 30&nbsp;mg up to 72&nbsp;months,
incidence of low serum prolactin levels in females (&lt;&nbsp;3&nbsp;ng/mL) and
males (&lt;&nbsp;2&nbsp;ng/mL) was 25.6&nbsp;% and 45.0&nbsp;%, respectively.</span></p>

<p class=MsoNormal><span lang=EN-GB>In two long-term trials with adolescent (13
to 17&nbsp;years) schizophrenia and bipolar patients treated with aripiprazole,
incidence of low serum prolactin levels in females (&lt;&nbsp;3&nbsp;ng/mL) and
males (&lt;&nbsp;2&nbsp;ng/mL) was 37.0&nbsp;% and 59.4&nbsp;%, respectively.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Manic episodes in
Bipolar I Disorder in adolescents aged 13&nbsp;years and older</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The frequency and
type of adverse reactions in adolescents with Bipolar I Disorder were similar
to those in adults except for the following reactions: very commonly
(&#8805;&nbsp;1/10) somnolence (23.0&nbsp;%), extrapyramidal disorder
(18.4&nbsp;%), akathisia (16.0&nbsp;%), and fatigue (11.8&nbsp;%); and commonly
(&#8805;&nbsp;1/100, &lt;&nbsp;1/10) abdominal pain upper, heart rate
increased, weight increased, increased appetite, muscle twitching, and
dyskinesia.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The following adverse
reactions had a possible dose response relationship; extrapyramidal disorder
(incidences were 10&nbsp;mg, 9.1&nbsp;%; 30&nbsp;mg, 28.8&nbsp;%; placebo,
1.7&nbsp;%); and akathisia (incidences were 10&nbsp;mg, 12.1&nbsp;%;
30&nbsp;mg, 20.3&nbsp;%; placebo, 1.7<b>&nbsp;</b>%).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Mean changes in body
weight in adolescents with Bipolar I Disorder at&nbsp;12 and 30&nbsp;weeks for
aripiprazole were 2.4&nbsp;kg and 5.8&nbsp;kg, and for placebo 0.2&nbsp;kg and
2.3&nbsp;kg, respectively.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In the paediatric
population somnolence and fatigue were observed more frequently in patients
with bipolar disorder compared to patients with schizophrenia.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In the paediatric
bipolar population (10 to 17&nbsp;years) with exposure up to 30&nbsp;weeks,
incidence of low serum prolactin levels in females (&lt;&nbsp;3&nbsp;ng/mL) and
males (&lt;&nbsp;2&nbsp;ng/mL) was 28.0&nbsp;% and 53.3&nbsp;%, respectively.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><i><span lang=EN-GB>Pathological
gambling and other impulse control disorders</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Pathological
gambling, hypersexuality, compulsive shopping and binge or compulsive eating
can occur in patients treated with aripiprazole (see </span><span lang=EN-GB>section&nbsp;4.4).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Reporting of
suspected adverse reactions</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Reporting suspected
adverse reactions after authorisation of the medicinal product is important. It
allows continued monitoring of the benefit/risk balance of the medicinal
product. Healthcare professionals are asked to report any suspected adverse
reactions <span style='background:silver'>via the national reporting system
listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a>.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Signs
and symptoms</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In clinical trials
and post-marketing experience, accidental or intentional acute overdose of
aripiprazole alone was identified in adult patients with reported estimated
doses up to 1,260&nbsp;mg with no fatalities. The potentially medically
important signs and symptoms observed </span><span lang=EN-GB style='color:
black'>included lethargy, increased blood pressure, somnolence, tachycardia,
nausea, </span><span lang=EN-GB style='color:black'>vomiting and diarrhoea. </span><span
lang=EN-GB style='color:black'>In addition, reports of accidental overdose with
aripiprazole alone (up to 195&nbsp;mg) in children have been received with no
fatalities. The potentially medically serious signs and symptoms reported
included somnolence, transient loss of consciousness </span><span lang=EN-GB
style='color:black'>and extrapyramidal symptoms</span><span lang=EN-GB
style='color:black'>.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Management
of overdose</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Management of
overdose should concentrate on supportive therapy, maintaining an adequate
airway, oxygenation and ventilation, and management of symptoms. The
possibility of multiple medicinal product involvement should be considered.
Therefore cardiovascular monitoring should be started immediately and should
include continuous electrocardiographic monitoring to detect possible
arrhythmias. Following any confirmed or suspected overdose with aripiprazole,
close medical supervision and monitoring should continue until the patient
recovers.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Activated charcoal
(50&nbsp;g), administered one hour after aripiprazole, decreased aripiprazole C<span
class=EMEASubscript>max</span> by about 41&nbsp;% and AUC by about 51&nbsp;%,
suggesting that charcoal may be effective in the treatment of overdose.</span></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Haemodialysis</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Although there is no
information on the effect of haemodialysis in treating an overdose with
aripiprazole, haemodialysis is unlikely to be useful in overdose management since
aripiprazole is highly bound to plasma proteins.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading1 style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>5.1&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic properties</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Pharmacotherapeutic
group: Psycholeptics, other antipsychotics, ATC&nbsp;code: N05AX12</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Mechanism of
action</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>It has been proposed
that aripiprazole&#8217;s efficacy in schizophrenia and Bipolar I Disorder is
mediated through a combination of partial agonism at dopamine&nbsp;D<sub>2</sub>
and serotonin 5&#8209;HT<sub>1A</sub> receptors and antagonism of serotonin 5&#8209;HT<sub>2A</sub>
receptors. Aripiprazole exhibited antagonist properties in animal models of
dopaminergic hyperactivity and agonist properties in animal models of
dopaminergic hypoactivity. Aripiprazole exhibited high binding affinity <i>in&nbsp;vitro</i>
for dopamine&nbsp;D<sub>2</sub> and D<sub>3</sub>, serotonin 5&#8209;HT<sub>1A</sub>
and 5&#8209;HT<sub>2A</sub> receptors and moderate affinity for dopamine&nbsp;D<sub>4</sub>,
serotonin 5&#8209;HT<sub>2C</sub> and 5&#8209;HT<sub>7</sub>, alpha&#8209;1
adrenergic and histamine H<sub>1</sub> receptors. Aripiprazole also exhibited
moderate binding affinity for the serotonin reuptake site and no appreciable
affinity for muscarinic receptors. Interaction with receptors other than
dopamine and serotonin subtypes may explain some of the other clinical effects
of aripiprazole.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole doses
ranging from 0.5&nbsp;mg to 30&nbsp;mg administered once a day to healthy
subjects for 2&nbsp;weeks produced a dose-dependent reduction in the binding of
<sup>11</sup>C-raclopride, a D<sub>2</sub>/D<sub>3</sub> receptor ligand, to
the caudate and putamen detected by positron emission tomography.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Clinical efficacy
and safety</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><i><u><span lang=EN-GB style='color:black'>Adults</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Schizophrenia</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In three short-term
(4 to 6&nbsp;weeks) placebo-controlled trials involving
1,228&nbsp;schizophrenic adult patients, presenting with positive or negative
symptoms, aripiprazole was associated with statistically significantly greater
improvements in psychotic symptoms compared to placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>A<em><span
style='font-style:normal'>ripiprazole</span></em> is effective in maintaining
the clinical improvement during continuation therapy in adult patients who have
shown an initial treatment response. In a haloperidol-controlled trial, the
proportion of responder patients maintaining response to medicinal product at
52&#8209;weeks was similar in both groups (aripiprazole 77&nbsp;% and
haloperidol 73&nbsp;%). The overall completion rate was significantly higher
for patients on aripiprazole (43&nbsp;%) than for haloperidol (30&nbsp;%).
Actual scores in rating scales used as secondary endpoints, including PANSS and
the Montgomery-&Aring;sberg Depression Rating Scale (MADRS) showed a
significant improvement over haloperidol.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In a 26&#8209;week,
placebo-controlled trial in adult stabilised patients with chronic
schizophrenia, aripiprazole had significantly greater reduction in relapse
rate, 34&nbsp;% in aripiprazole group and 57&nbsp;% in placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Weight gain</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In clinical trials
aripiprazole has not been shown to induce clinically relevant weight gain. In a
26&#8209;week, olanzapine-controlled, double-blind, multi-national study of
schizophrenia which included 314&nbsp;adult patients and where the primary
endpoint was weight gain, significantly less patients had at least 7&nbsp;%
weight gain over baseline (i.e. a gain of at least 5.6&nbsp;kg for a mean
baseline weight of ~80.5&nbsp;kg) on aripiprazole (n&nbsp;=&nbsp;18, or
13&nbsp;% of evaluable patients), compared to olanzapine (n&nbsp;=&nbsp;45, or
33&nbsp;% of evaluable patients).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Lipid parameters</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In a pooled analysis
on lipid parameters from placebo controlled clinical trials in adults, aripiprazole
has not been shown to induce clinically relevant alterations in levels of total
cholesterol, triglycerides, High Density Lipoprotein (HDL) and Low Density
Lipoprotein (LDL).</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>Prolactin</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Prolactin levels were
evaluated in all trials of all doses of aripiprazole (n&nbsp;=&nbsp;28,242).
The incidence of hyperprolactinaemia or increased serum prolactin in patients
treated with aripiprazole (0.3&nbsp;%) was similar to that of placebo
(0.2&nbsp;%). For patients receiving aripiprazole, the median time to onset was
42&nbsp;days and median duration was 34&nbsp;days.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The incidence of
hypoprolactinaemia or decreased serum prolactin in patients treated with
aripiprazole was 0.4&nbsp;%, compared with 0.02&nbsp;% for patients treated
with placebo. For patients receiving aripiprazole, the median time to onset was
30&nbsp;days and median duration was 194&nbsp;days.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Manic episodes in
Bipolar I Disorder</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In two<b> </b>3&#8209;week,
flexible-dose,<b> </b>placebo-controlled monotherapy trials involving<b> </b>patients
with a manic or mixed episode of Bipolar I Disorder, aripiprazole demonstrated
superior efficacy to placebo in reduction of manic symptoms over 3&nbsp;weeks.
These trials included patients with or without psychotic features and with or
without a rapid-cycling course.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In one 3&#8209;week,
fixed-dose, placebo-controlled monotherapy trial involving patients with a
manic or mixed episode of Bipolar I Disorder, aripiprazole failed to
demonstrate superior efficacy to placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In two 12&#8209;week,
placebo- and active-controlled monotherapy trials in patients with a manic or
mixed episode of Bipolar I Disorder, with or without psychotic features,
aripiprazole demonstrated superior efficacy to placebo at week&nbsp;3 and a
maintenance of effect comparable to lithium or haloperidol at week&nbsp;12.
Aripiprazole also demonstrated a comparable proportion of patients in
symptomatic remission from mania as lithium or haloperidol at week&nbsp;12.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In a 6&#8209;week,
placebo-controlled trial involving patients with a manic or mixed episode of
Bipolar I Disorder, with or without psychotic features, who were partially
non-responsive to lithium or valproate monotherapy for 2&nbsp;weeks at
therapeutic serum levels, the addition of aripiprazole as adjunctive therapy
resulted in superior efficacy in reduction of manic symptoms than lithium or
valproate monotherapy.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In a 26&#8209;week,
placebo-controlled trial, followed by a 74&#8209;week extension, in manic
patients who achieved remission on aripiprazole during a stabilization phase
prior to randomisation, aripiprazole demonstrated superiority over placebo in
preventing bipolar recurrence, primarily in preventing recurrence into mania
but failed to demonstrate superiority over placebo in preventing recurrence
into depression.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In a 52&#8209;week,
placebo-controlled trial, in patients with a current manic or mixed episode of
Bipolar I Disorder who achieved sustained remission (Young Mania Rating Scale [YMRS]
and MADRS with total scores &#8804;&nbsp;12) on aripiprazole (10&nbsp;mg/day to
30&nbsp;mg/day) adjunctive to lithium or valproate for 12&nbsp;consecutive
weeks, adjunctive aripiprazole demonstrated superiority over placebo with a
46&nbsp;% decreased risk (hazard ratio of 0.54) in preventing bipolar recurrence
and a 65&nbsp;% decreased risk (hazard ratio of 0.35) in preventing recurrence
into mania over adjunctive placebo but failed to demonstrate superiority over
placebo in preventing recurrence into depression. Adjunctive aripiprazole
demonstrated superiority over placebo on the secondary outcome measure in Clinical
Global Impression - Bipolar version (CGI-BP) Severity of Illness (SOI; mania)
scores. In this trial, patients were assigned by investigators with either
open-label lithium or valproate monotherapy to determine partial non-response.
Patients were stabilised for at least 12&nbsp;consecutive weeks with the
combination of aripiprazole and the same mood stabilizer. Stabilized patients
were then randomised to continue the same mood stabilizer with double-blind
aripiprazole or placebo. Four mood stabilizer subgroups were assessed in the
randomised phase: aripiprazole + lithium; aripiprazole + valproate; placebo +
lithium; placebo + valproate. The Kaplan-Meier rates for recurrence to any mood
episode for the adjunctive treatment arm were 16&nbsp;% in aripiprazole +
lithium and 18&nbsp;% in aripiprazole + valproate compared to 45&nbsp;% in
placebo + lithium and 19&nbsp;% in placebo + valproate.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><u><span lang=EN-GB style='color:black'>Paediatric
population</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Schizophrenia in
adolescents</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In a 6&#8209;week
placebo-controlled trial involving 302&nbsp;schizophrenic adolescent patients
(13 to 17&nbsp;years), presenting with positive or negative symptoms,
aripiprazole was associated with statistically significantly greater
improvements in psychotic symptoms compared to placebo. In a sub-analysis of
the adolescent patients between the ages of 15&nbsp;to 17&nbsp;years,
representing 74&nbsp;% of the total enrolled population, maintenance of effect
was observed over the 26&#8209;week open-label extension trial.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In a 60- to 89-week, randomised,
double-blind, placebo-controlled trial in adolescent subjects
(n&nbsp;=&nbsp;146; ages 13 to 17&nbsp;years) with schizophrenia, there was a
statistically significant difference in the rate of relapse of psychotic
symptoms between the aripiprazole (19.39&nbsp;%) and placebo (37.50&nbsp;%)
groups. The point estimate of the hazard ratio (HR) was 0.461 (95&nbsp;%
confidence interval, 0.242 to 0.879) in the full population. In subgroup
analyses the point estimate of the HR was 0.495 for subjects 13 to
14&nbsp;years of age compared to 0.454 for subjects 15 to 17&nbsp;years of age.
However, the estimation of the HR for the younger (13 to 14&nbsp;years) group
was not precise, reflecting the smaller number of subjects in that group
(aripiprazole, n&nbsp;=&nbsp;29; placebo, n&nbsp;=&nbsp;12), and the confidence
interval for this estimation (</span><span lang=EN-GB style='color:black'>ranging
from 0.151 to 1.628</span><span lang=EN-GB>) did not allow conclusions to be
drawn on the presence of a treatment effect. In contrast the 95&nbsp;%
confidence interval for the HR in the older subgroup (aripiprazole,
n&nbsp;=&nbsp;69; placebo, n&nbsp;=&nbsp;36) was 0.242 to 0.879 and hence a
treatment effect could be concluded in the older patients.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Manic episodes in
Bipolar I Disorder in children and adolescents</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole was
studied in a 30&#8209;week placebo-controlled trial involving 296&nbsp;children
and adolescents (10 to 17&nbsp;years), who met DSM-IV criteria (Diagnostic and
Statistical Manual of Mental Disorders) for Bipolar I Disorder with manic or
mixed episodes with or without psychotic features and had a YMRS score </span><span
lang=EN-GB style='font-family:Symbol;color:black'>&sup3;</span><span
lang=EN-GB style='color:black'>&nbsp;20 at baseline. Among the patients
included in the primary efficacy analysis, 139&nbsp;patients had a current
co-morbid diagnosis of ADHD.</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole was
superior to placebo in change from baseline at week&nbsp;4 and at week&nbsp;12
on the Y-MRS total score. In a post-hoc analysis, the improvement over placebo
was more pronounced in the patients with associated co-morbidity of ADHD compared
to the group without ADHD, where there was no difference from placebo.
Recurrence prevention was not established.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The most common
treatment-emergent adverse events among patients receiving 30&nbsp;mg were
extrapyramidal disorder (28.3&nbsp;%), somnolence (27.3&nbsp;%), headache
(23.2&nbsp;%), and nausea (14.1&nbsp;%). Mean weight gain in the 30&nbsp;weeks
treatment-interval was 2.9&nbsp;kg as compared to 0.98&nbsp;kg in patients
treated with placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Irritability
associated with autistic disorder in paediatric patients (see section&nbsp;4.2)</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole was
studied in patients aged 6&nbsp;to 17&nbsp;years in two 8&#8209;week,
placebo-controlled trials [one flexible-dose (2&nbsp;mg/day to 15&nbsp;mg/day)
and one fixed-dose (5&nbsp;mg/day, 10&nbsp;mg/day, or 15&nbsp;mg/day)] and in
one 52&#8209;week open-label trial. Dosing in these trials was initiated at
2&nbsp;mg/day, increased to 5&nbsp;mg/day after one week, and increased by
5&nbsp;mg/day in weekly increments to the target dose. Over 75&nbsp;% of
patients were less than 13&nbsp;years of age. Aripiprazole demonstrated
statistically superior efficacy compared to placebo on the Aberrant Behaviour
Checklist Irritability subscale. However, the clinical relevance of this
finding has not been established. The safety profile included weight gain and
changes in prolactin levels. The duration of the long-term safety study was
limited to 52&nbsp;weeks. In the pooled trials, the incidence of low serum
prolactin levels in females (&lt;&nbsp;3&nbsp;ng/mL) and males
(&lt;&nbsp;2&nbsp;ng/mL) in aripiprazole-treated patients was
27/46&nbsp;(58.7&nbsp;%) and 258/298&nbsp;(86.6&nbsp;%), respectively. In the
placebo-controlled trials, the mean weight gain was 0.4&nbsp;kg for placebo and
1.6&nbsp;kg for aripiprazole.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole was
also studied in a placebo-controlled, long-term maintenance trial. After a 13
to 26&#8209;week stabilisation on aripiprazole (2&nbsp;mg/day to 15&nbsp;mg/day)
patients with a stable response were either maintained on aripiprazole or
substituted to placebo for further 16&nbsp;weeks. Kaplan-Meier relapse rates at
week&nbsp;16 were 35&nbsp;% for aripiprazole and 52&nbsp;% for placebo; the
hazard ratio for relapse within 16&nbsp;weeks (aripiprazole/placebo) was 0.57
(non-statistically significant difference). The mean weight gain over the
stabilisation phase (up to 26&nbsp;weeks) on aripiprazole was 3.2&nbsp;kg, and
a further mean increase of 2.2&nbsp;kg for aripiprazole as compared to
0.6&nbsp;kg for placebo was observed in the second phase (16&nbsp;weeks) of the
trial. Extrapyramidal symptoms were mainly reported during the stabilisation
phase in 17&nbsp;% of patients, with tremor accounting for 6.5<b>&nbsp;</b>%.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>Tics associated with
Tourette&#8217;s disorder in paediatric patients (see section&nbsp;4.2)</span></i></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>The efficacy of aripiprazole was studied in paediatric subjects
with Tourette&#8217;s disorder (aripiprazole: n&nbsp;=&nbsp;99, placebo:
n&nbsp;=&nbsp;44) in a randomised, double-blind, placebo controlled,
8&nbsp;week study using a fixed dose weight-based treatment group design over
the dose range of 5&nbsp;mg/day to 20&nbsp;mg/day and a starting dose of
2&nbsp;mg. Patients were 7&nbsp;to&nbsp;17&nbsp;years of age and presented an
average score of 30 on Total Tic Score on the Yale Global Tic Severity Scale
(TTS-YGTSS) at baseline. Aripiprazole showed an improvement on TTS-YGTSS change
from baseline to week&nbsp;8 of 13.35, for the low dose group (5&nbsp;mg or
10&nbsp;mg) and 16.94 for the high dose group (10&nbsp;mg or 20&nbsp;mg) as
compared with an improvement of 7.09 in the placebo group.</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>The efficacy of aripiprazole in paediatric subjects with
Tourette&#8217;s syndrome (aripiprazole: n&nbsp;=&nbsp;32, placebo:
n&nbsp;=&nbsp;29) was also evaluated over a flexible dose range of
2&nbsp;mg/day to 20&nbsp;mg/day and a starting dose of 2&nbsp;mg, in a
10&nbsp;week, randomised, double blind, placebo-controlled study conducted in
South-Korea. Patients were 6 to 18&nbsp;years and presented an average score of
29 on TTS-YGTSS&nbsp;at baseline. Aripiprazole group showed an improvement of
14.97 on TTS-YGTSS change from baseline to week&nbsp;10 as compared with an
improvement of 9.62 in the placebo group.</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>In both of these short-term trials, the clinical relevance of the
efficacy findings has not been established, considering the magnitude of
treatment effect compared to the large placebo effect and the unclear effects
regarding psycho-social functioning. No long-term data are available with
regard to the efficacy and the safety of aripiprazole in this fluctuating
disorder.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The European
Medicines Agency has deferred the obligation to submit the results of studies
with ABILIFY in one or more subsets of the paediatric population in the
treatment of schizophrenia and in the treatment of bipolar affective disorder
(see section&nbsp;4.2 for information on paediatric use).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic
properties</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Absorption</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole is well
absorbed, with peak plasma concentrations occurring within 3 to 5&nbsp;hours
after dosing. Aripiprazole undergoes minimal pre-systemic metabolism. The
absolute oral bioavailability of the tablet formulation is 87&nbsp;%. There is
no effect of a high fat meal on the pharmacokinetics of aripiprazole.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Distribution</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole is
widely distributed throughout the body with an apparent volume of distribution
of 4.9&nbsp;L/kg, indicating extensive extravascular distribution. At
therapeutic concentrations, aripiprazole and dehydro-aripiprazole are greater
than 99&nbsp;% bound to serum proteins, binding primarily to albumin.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Biotransformation</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole is
extensively metabolised by the liver primarily by three biotransformation
pathways: dehydrogenation, hydroxylation, and N-dealkylation. Based on <i>in&nbsp;vitro</i>
studies, CYP3A4 and CYP2D6 enzymes are responsible for dehydrogenation and
hydroxylation of aripiprazole, and N-dealkylation is catalysed by CYP3A4.
Aripiprazole is the predominant medicinal product moiety in systemic
circulation. At steady state, dehydro-aripiprazole, the active metabolite,
represents about 40&nbsp;% of aripiprazole AUC in plasma.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Elimination</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The mean elimination
half-lives for aripiprazole are approximately 75&nbsp;hours in extensive
metabolisers of CYP2D6 and approximately 146&nbsp;hours in poor metabolisers of
CYP2D6.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The total body
clearance of aripiprazole is 0.7&nbsp;mL/min/kg, which is primarily hepatic.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Following a single
oral dose of [<sup>14</sup>C]-labelled aripiprazole, approximately 27&nbsp;% of
the administered radioactivity was recovered in the urine and approximately
60&nbsp;% in the faeces. Less than 1&nbsp;% of unchanged aripiprazole was
excreted in the urine and approximately 18&nbsp;% was recovered unchanged in
the faeces.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Oral Solution</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole is well
absorbed when administered orally as the solution. At equivalent doses, the
peak plasma concentrations of aripiprazole (</span><span lang=EN-GB
style='color:black'>C<span class=EMEASubscript>max</span></span><span
lang=EN-GB style='color:black'>) from the solution were somewhat higher but the
systemic exposure (AUC) was equivalent to tablets. In a relative
bioavailability study comparing the pharmacokinetics of 30</span><i><span
lang=EN-GB style='color:black'>&nbsp;</span></i><span lang=EN-GB
style='color:black'>mg aripiprazole as the oral solution to 30</span><i><span
lang=EN-GB style='color:black'>&nbsp;</span></i><span lang=EN-GB
style='color:black'>mg aripiprazole tablets in healthy subjects, the solution
to the tablet ratio of geometric mean </span><span lang=EN-GB style='color:
black'>C<span class=EMEASubscript>max</span></span><span lang=EN-GB
style='color:black'> values was 122&nbsp;% (n&nbsp;=&nbsp;30). The single-dose
pharmacokinetics of aripiprazole was linear and dose-proportional.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Paediatric population</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB>The pharmacokinetics of aripiprazole and
dehydro-aripiprazole in paediatric patients 10&nbsp;to 17&nbsp;years of age
were similar to those in adults after correcting for the differences in body
weights.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Pharmacokinetics
in special patient groups</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Elderly</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>There are no differences
in the pharmacokinetics of aripiprazole between healthy elderly and younger
adult subjects, nor is there any detectable effect of age in a population
pharmacokinetic analysis in schizophrenic patients.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Gender</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>There are no differences
in the pharmacokinetics of aripiprazole between healthy male and female
subjects nor is there any detectable effect of gender in a population
pharmacokinetic analysis in schizophrenic patients.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Smoking</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Population
pharmacokinetic evaluation has revealed no evidence of clinically significant <em><span
style='font-style:normal'>effects from </span></em>smoking on the
pharmacokinetics of aripiprazole.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><i><span lang=EN-GB
style='color:black'>Race</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Population pharmacokinetic evaluation showed no evidence of
race&#8209;related differences on the pharmacokinetics of aripiprazole.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Renal impairment</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The pharmacokinetic
characteristics of aripiprazole and dehydro-aripiprazole were found to be
similar in patients with severe renal disease compared to young healthy
subjects.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Hepatic
impairment</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>A single-dose study
in subjects with varying degrees of liver cirrhosis (Child&#8209;Pugh Classes
A, B, and&nbsp;C) did not reveal a significant effect of hepatic impairment on
the pharmacokinetics of aripiprazole and dehydro-aripiprazole, but the study
included only 3&nbsp;patients with Class&nbsp;C liver cirrhosis, which is
insufficient to draw conclusions on their metabolic capacity.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical
safety data</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Non-clinical data
reveal no special hazard for humans based on conventional studies of safety
pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity
to reproduction and development.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Toxicologically
significant effects were observed only at doses or exposures that were
sufficiently in excess of the maximum human dose or exposure, indicating that
these effects were limited or of no relevance to clinical use. These included:
dose-dependent adrenocortical toxicity (lipofuscin pigment accumulation and/or
parenchymal cell loss) in rats after 104&nbsp;weeks at&nbsp;20&nbsp;mg/kg/day
to 60&nbsp;mg/kg/day (3&nbsp;to 10&nbsp;times the mean steady-state AUC at the
maximum recommended human dose) and increased adrenocortical carcinomas and
combined adrenocortical adenomas/carcinomas in female rats at 60&nbsp;mg/kg/day
(10&nbsp;times the mean steady-state AUC at the maximum recommended human
dose). The highest nontumorigenic exposure in female rats was 7&nbsp;times the
human exposure at the recommended dose.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>An additional
finding was cholelithiasis as a consequence of precipitation of sulphate
conjugates of hydroxy metabolites of aripiprazole in the bile of monkeys after
repeated oral dosing at&nbsp;25&nbsp;mg/kg/day to 125&nbsp;mg/kg/day (1 to
3&nbsp;times the mean steady-state AUC at the maximum recommended clinical dose
or 16 to 81&nbsp;times the maximum recommended human dose based on&nbsp;mg/m<span
class=EMEASuperscript>2</span>). However, the concentrations of the sulphate
conjugates of hydroxy aripiprazole in human bile at the highest dose proposed,
30&nbsp;mg per day, were no more than 6&nbsp;% of the bile concentrations found
in the monkeys in the 39&#8209;week study and are well below (6&nbsp;%) their
limits of <i>in&nbsp;vitro</i> solubility.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>In repeat-dose studies
in juvenile rats and dogs, the toxicity profile of aripiprazole was comparable
to that observed in adult animals, and there was no evidence of neurotoxicity
or adverse reactions on development.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Based on results of
a full range of standard genotoxicity tests, aripiprazole was considered
non-genotoxic. Aripiprazole did not impair fertility in reproductive toxicity
studies. Developmental toxicity, including dose-dependent delayed foetal
ossification and possible teratogenic effects, were observed in rats at doses
resulting in subtherapeutic exposures (based on AUC) and in rabbits at doses
resulting in exposures 3 and 11&nbsp;times the mean steady-state AUC at the
maximum recommended clinical dose. Maternal toxicity occurred at doses similar
to those eliciting developmental toxicity.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>6.1&nbsp;&nbsp;&nbsp;&nbsp; List of excipients</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Disodium edetate</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Fructose</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Glycerin</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Lactic acid</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Methyl
parahydroxybenzoate (E&nbsp;218)</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Propylene glycol</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Propyl
parahydroxybenzoate (E&nbsp;216)</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Sodium hydroxide</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Sucrose</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Purified water</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Orange flavour</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The <span
style='layout-grid-mode:line'>oral solution should not be diluted with other
liquids or mixed with any food prior to administration.</span></span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf life</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>3&nbsp;years</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>After first opening:
6&nbsp;months.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>6.4&nbsp;&nbsp;&nbsp;&nbsp; Special precautions
for storage</span></b></p>

<p class=EMEABodyText style='text-align:justify'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>This medicinal
product does not require any special storage conditions.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>For storage
conditions after first opening of the medicinal product, see section&nbsp;6.3.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>6.5&nbsp;&nbsp;&nbsp;&nbsp; Nature and contents
of container</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>PET-bottles with
polypropylene child-resistant closure containing 50&nbsp;mL, 150&nbsp;mL or
480&nbsp;mL per bottle.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Each carton contains
1&nbsp;bottle and both a calibrated polypropylene measuring cup </span><span
lang=EN style='color:black'>with a graduation interval of 2.5&nbsp;mL</span><span
lang=EN style='color:black'> </span><span lang=EN-GB style='color:black'>and a
calibrated polypropylene low-density polyethylene <a name="_Hlk11317764">dropping
pipette</a></span><span lang=EN-GB style='color:black'> </span><span lang=EN
style='color:black'>with a graduation interval of 0.5&nbsp;mL</span><span
lang=EN-GB style='color:black'>.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Not all pack sizes
may be marketed.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>6.6&nbsp;&nbsp;&nbsp;&nbsp; Special precautions
for disposal</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Any unused medicinal
product or waste material should be disposed of in accordance with local
requirements.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Otsuka Pharmaceutical
Netherlands B.V.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Herikerbergweg 292</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>1101 CT, Amsterdam</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Netherlands</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=SV style='color:black'>EU/1/04/276/033
(1&nbsp;mg/mL, 50&nbsp;mL per bottle)</span></p>

<p class=EMEABodyText><span lang=SV style='color:black'>EU/1/04/276/034
(1&nbsp;mg/mL, 150&nbsp;mL per bottle)</span></p>

<p class=EMEABodyText><span lang=SV style='color:black'>EU/1/04/276/035
(1&nbsp;mg/mL, 480&nbsp;mL per bottle)</span></p>

<p class=EMEABodyText><span lang=SV style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=SV style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DATE OF
FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Date of first authorisation:
04&nbsp;June&nbsp;2004</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Date of latest
renewal: 04&nbsp;June&nbsp;2009</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>10.&nbsp;&nbsp;&nbsp;&nbsp; DATE OF REVISION OF
THE TEXT</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>{MM/YYYY}</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Detailed information
on this medicinal product is available on the website of the European Medicines
Agency <a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a>.</span></p>

<p class=EMEAHeading1 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading1 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;text-transform:uppercase'><br clear=all style='page-break-before:
always'>
</span></b>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black;text-transform:uppercase'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY&nbsp;7.5&nbsp;mg/mL
solution for injection</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading1 style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Each&nbsp;mL
contains 7.5&nbsp;mg of aripiprazole. Each vial contains 9.75&nbsp;mg
aripiprazole.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>For the full list of
excipients, see section&nbsp;6.1.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading1 style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Solution for
injection</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Clear, colourless,
aqueous solution.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading1 style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CLINICAL
PARTICULARS</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading1 style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic
indications</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY solution for
injection is indicated for the rapid control of agitation and disturbed
behaviours in adult patients with schizophrenia or with manic episodes in
Bipolar I Disorder, when oral therapy is not appropriate.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Treatment with ABILIFY
solution for injection should be discontinued as soon as clinically appropriate
and the use of oral aripiprazole should be initiated.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading1 style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>4.2&nbsp;&nbsp;&nbsp;&nbsp; Posology
and method of administration</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Posology</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The recommended
initial dose for ABILIFY solution for injection is 9.75&nbsp;mg (1.3&nbsp;mL),
administered as a single intramuscular injection. The effective dose range of ABILIFY
solution for injection is 5.25&nbsp;mg to 15&nbsp;mg as a single injection. A
lower dose of 5.25&nbsp;mg (0.7&nbsp;mL) may be given, on the basis of
individual clinical status, which should also include consideration of
medicinal products already administered either for maintenance or acute
treatment (see section&nbsp;4.5).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>A second injection
may be administered 2&nbsp;hours after the first injection, on the basis of
individual clinical status and no more than three injections should be given in
any 24-hour period.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The maximum daily
dose of aripiprazole is 30&nbsp;mg (including all formulations of ABILIFY).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If continued
treatment is indicated with oral aripiprazole, see the Summary of Product
Characteristics for ABILIFY tablets, ABILIFY orodispersible tablets, or ABILIFY
oral solution.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Special
populations</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Paediatric
population</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>The safety and efficacy of ABILIFY solution for injection
in children and adolescents aged 0 to 17&nbsp;years have not been established.
No data are available.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Hepatic
impairment</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>No dosage adjustment
is required for patients with mild to moderate hepatic impairment. In patients
with severe hepatic impairment, the data available are insufficient to
establish recommendations. In these patients dosing should be managed
cautiously. However, the maximum daily dose of 30&nbsp;mg should be used with
caution in patients with severe hepatic impairment (see section&nbsp;5.2).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>R<i>enal impairment</i></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>No dosage adjustment
is required in patients with renal impairment.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Elderly</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The safety and
efficacy of ABILIFY </span><span lang=EN-GB>in the treatment of schizophrenia
or manic episodes in Bipolar I Disorder<span style='color:black'> in patients
aged 65</span></span><span lang=EN-GB style='color:black'>&nbsp;</span><span
lang=EN-GB style='color:black'>years and older has not been established. Owing
to the greater sensitivity of this population, a lower starting dose should be
considered when clinical factors warrant (see section</span><span lang=EN-GB
style='color:black'>&nbsp;</span><span lang=EN-GB style='color:black'>4.4).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Gender</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>No dosage adjustment
is required for female patients as compared to male patients (see
section&nbsp;5.2).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Smoking status</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>According to the
metabolic pathway of <span style='layout-grid-mode:line'>aripiprazole </span>no
dosage adjustment is required for smokers (see section&nbsp;4.5).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Dose adjustments
due to interactions</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>When concomitant administration of strong CYP3A4 or CYP2D6 inhibitors
with aripiprazole occurs, the aripiprazole dose should be reduced. When the
CYP3A4 or CYP2D6 inhibitor is withdrawn from the combination therapy,
aripiprazole dose should then be increased (see section&nbsp;4.5).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>When concomitant administration of strong CYP3A4 inducers with
aripiprazole occurs, the aripiprazole dose should be increased. When the CYP3A4
inducer is withdrawn from the combination therapy, the aripiprazole dose should
then be reduced to the recommended dose (see section&nbsp;4.5).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Method of
administration</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY solution for
injection is for intramuscular use.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>To enhance
absorption and minimise variability, injection into the deltoid or deep within
the gluteus maximus muscle, avoiding adipose regions, is recommended.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY solution for
injection should not be administered intravenously or subcutaneously.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>It is ready to use
and intended for short-term use only (see section</span><span lang=EN-GB
style='color:black'>&nbsp;</span><span lang=EN-GB style='color:black'>5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading1 style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Hypersensitivity to
the active substance or to any of the excipients listed in section&nbsp;6.1.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading1 style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special
warnings and precautions for use</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The efficacy of ABILIFY
solution for injection in patients with agitation and disturbed behaviours has
not been established related to conditions other than schizophrenia and manic
episodes in Bipolar I Disorder.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Simultaneous
administration of injectable antipsychotics and parenteral benzodiazepine may
be associated with excessive sedation and cardiorespiratory depression. If
parenteral benzodiazepine therapy is deemed necessary in addition to
aripiprazole solution for injection, patients should be monitored for excessive
sedation and for orthostatic hypotension (see section</span><span lang=EN-GB
style='color:black'>&nbsp;</span><span lang=EN-GB style='color:black'>4.5).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Patients receiving ABILIFY
solution for injection should be observed for orthostatic hypotension. Blood
pressure, pulse, respiratory rate and level of consciousness should be
monitored regularly.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The safety and
efficacy of ABILIFY solution for injection has not been evaluated in patients
with alcohol or medicinal product intoxication (either with prescribed or
illicit medicinal products).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>During antipsychotic
treatment, improvement in the patient's clinical condition may take several
days to some weeks. Patients should be closely monitored throughout this
period.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Suicidality</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The occurrence of
suicidal behaviour is inherent in psychotic illnesses and mood disorders and in
some cases has been reported early after initiation or switch of antipsychotic <em><span
style='font-style:normal'>treatment</span></em>, including treatment with
aripiprazole (see section&nbsp;4.8). Close supervision of high-risk patients
should accompany antipsychotic treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Cardiovascular
disorders</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole should
be used with caution in patients with known cardiovascular disease (history of
myocardial infarction or ischaemic heart disease, heart failure, or conduction
abnormalities), cerebrovascular disease, conditions which would predispose
patients to hypotension (dehydration, hypovolemia, and treatment with
antihypertensive medicinal products) or hypertension, including accelerated or
malignant. Cases of venous thromboembolism (VTE) have been reported with
antipsychotic medicinal products. Since patients treated with antipsychotics
often present with acquired risk factors for VTE, all possible risk factors for
VTE should be identified before and during treatment with aripiprazole and
preventive measures undertaken (see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>QT prolongation</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In clinical trials
of treatment with oral aripiprazole, the incidence of QT prolongation was
comparable to placebo. Aripiprazole should be used with caution in patients
with a family history of QT prolongation (see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Tardive
dyskinesia</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In clinical trials
of one year or less duration, there were uncommon reports of treatment emergent
dyskinesia during treatment with aripiprazole. If signs and symptoms of tardive
dyskinesia appear in a patient on <em><span style='font-style:normal'>aripiprazole</span></em>,
dose reduction or discontinuation should be considered (see section&nbsp;4.8). These
symptoms can temporally deteriorate or can even arise after discontinuation of
treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Other
extrapyramidal symptoms</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In paediatric
clinical trials of aripiprazole akathisia and Parkinsonism were observed. If
signs and symptoms of other EPS appear in a patient taking aripiprazole, dose
reduction and close clinical monitoring should be considered.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Neuroleptic
Malignant Syndrome (NMS)</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>NMS is a potentially
fatal symptom complex associated with antipsychotics. In clinical trials, rare
cases of NMS were reported during treatment with aripiprazole. Clinical manifestations
of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of
autonomic instability (irregular pulse or blood pressure, tachycardia,
diaphoresis and cardiac dysrhythmia). Additional signs may include elevated
creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal
failure. However, elevated creatine phosphokinase and rhabdomyolysis, not
necessarily in association with NMS, have also been reported. If a patient
develops signs and symptoms indicative of NMS, or presents with unexplained
high fever without additional clinical manifestations of NMS, all antipsychotics,
including aripiprazole, must be discontinued.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Seizure</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In clinical trials,
uncommon cases of seizure were reported during treatment with aripiprazole.
Therefore, aripiprazole should be used with caution in patients who have a
history of seizure disorder or have conditions associated with seizures (see
section</span><span lang=EN-GB style='color:black'>&nbsp;</span><span
lang=EN-GB style='color:black'>4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Elderly patients
with dementia-related psychosis</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Increased
mortality</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In three placebo-controlled
trials (n&nbsp;=&nbsp;938; mean age: 82.4</span><span lang=EN-GB
style='color:black'>&nbsp;</span><span lang=EN-GB style='color:black'>years;
range: 56 to 99</span><span lang=EN-GB style='color:black'>&nbsp;</span><span
lang=EN-GB style='color:black'>years) of aripiprazole in elderly patients with
psychosis associated with Alzheimer's disease, patients treated with
aripiprazole were at increased risk of death compared to placebo. The rate of
death in aripiprazole-treated patients was 3.5&nbsp;% compared to 1.7&nbsp;% in
the placebo group. Although the causes of deaths were varied, most of the
deaths appeared to be either cardiovascular (e.g. heart failure, sudden death)
or infectious (e.g. pneumonia) in nature (see section</span><span lang=EN-GB
style='color:black'>&nbsp;</span><span lang=EN-GB style='color:black'>4.8).</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Cerebrovascular
adverse reactions</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In the same trials,
cerebrovascular adverse reactions (e.g. stroke, transient ischaemic attack),
including fatalities, were reported in patients (mean age: 84</span><span
lang=EN-GB style='color:black'>&nbsp;</span><span lang=EN-GB style='color:black'>years;
range: 78 to 88</span><span lang=EN-GB style='color:black'>&nbsp;</span><span
lang=EN-GB style='color:black'>years). Overall, 1.3&nbsp;% of aripiprazole-treated
patients reported cerebrovascular adverse reactions compared with 0.6&nbsp;% of
placebo-treated patients in these trials. This difference was not statistically
significant. However, in one of these trials, a fixed-dose trial, there was a
significant dose response relationship for cerebrovascular adverse reactions in
patients treated with aripiprazole (see section</span><span lang=EN-GB
style='color:black'>&nbsp;</span><span lang=EN-GB style='color:black'>4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole is not
indicated for the treatment of patients with dementia-related psychosis.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Hyperglycaemia
and diabetes mellitus</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Hyperglycaemia, in
some cases extreme and associated with ketoacidosis or hyperosmolar coma or
death, has been reported in patients treated with atypical antipsychotics</span><span
lang=EN-GB style='color:black'>, including aripiprazole. Risk factors that may
predispose patients to severe complications include obesity and family history
of diabetes. In clinical trials with aripiprazole, there were no significant
differences in the incidence rates of hyperglycaemia-related adverse reactions
(including diabetes) or in abnormal glycaemia laboratory values compared to
placebo. Precise risk estimates for hyperglycaemia-related adverse reactions in
patients treated with aripiprazole and with other atypical antipsychotics are
not available to allow direct comparisons. Patients treated with any antipsychotics,
including aripiprazole, should be observed for signs and symptoms of
hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness) and
patients with diabetes mellitus or with risk factors for diabetes mellitus
should be monitored regularly for worsening of glucose control (see section</span><span
lang=EN-GB style='color:black'>&nbsp;</span><span lang=EN-GB style='color:black'>4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Hypersensitivity</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Hypersensitivity
reactions, characterised by allergic symptoms, may occur with aripiprazole (see
section&nbsp;4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Weight gain</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Weight gain is
commonly seen in schizophrenic and bipolar mania patients due to
co-morbidities, use of antipsychotics known to cause weight gain, poorly
managed life-style, and might lead to severe complications. Weight gain has
been reported post-marketing among patients prescribed oral aripiprazole. When
seen, it is usually in those with significant risk factors such as history of
diabetes, thyroid disorder or pituitary adenoma. In clinical trials
aripiprazole has not been shown to induce clinically relevant weight gain in
adults (see section&nbsp;5.1). In clinical trials of adolescent patients with
bipolar mania, aripiprazole has been shown to be associated with weight gain
after 4&nbsp;weeks of treatment. Weight gain should be monitored in adolescent
patients with bipolar mania. If weight gain is clinically significant, dose
reduction should be considered (see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Dysphagia</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Oesophageal
dysmotility and aspiration have been associated with the use of antipsychotics,
including aripiprazole. Aripiprazole should be used cautiously in patients at
risk for aspiration pneumonia.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB>Pathological
gambling and other impulse control disorders</span></u></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Patients can experience increased urges,
particularly for gambling, and the inability to control these urges while
taking aripiprazole. Other urges, reported, include: increased sexual urges,
compulsive shopping, binge or compulsive eating, and other impulsive and
compulsive behaviours. It is important for prescribers to ask patients or their
caregivers specifically about the development of new or increased gambling
urges, sexual urges, compulsive shopping, binge or compulsive eating, or other
urges while being treated with aripiprazole. It should be noted that
impulse-control symptoms can be associated with the underlying disorder;
however, in some cases, urges were reported to have stopped when the dose was
reduced or the medication was discontinued. Impulse control disorders may
result in harm to the patient and others if not recognised. Consider dose
reduction or stopping the medication if a patient develops such urges while
taking aripiprazole (see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Sodium</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY solution for
injection contains sodium. This medicinal product contains less than
1&nbsp;mmol sodium (23&nbsp;mg) per dosage unit, that is to say essentially
&#8216;sodium-free&#8217;.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Patients with attention
deficit hyperactivity disorder (ADHD) comorbidity</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Despite the high
comorbidity frequency of Bipolar I Disorder and ADHD, very limited safety data
are available on concomitant use of aripiprazole and stimulants; therefore,
extreme caution should be taken when these medicinal products are
co-administered.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Falls</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span style='color:black'>Aripiprazole
may cause somnolence, postural hypotension, motor and sensory instability,
which may lead to falls. Caution should be taken when treating patients at
higher risk, and a lower starting dose should be considered (e.g., elderly or
debilitated patients; see section 4.2).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction
with other medicinal products and other forms of interaction</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>No
specific interaction studies have been performed with ABILIFY solution for
injection. The information below is obtained from studies with oral
aripiprazole.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>D<span
style='layout-grid-mode:line'>ue to its &#945;</span><span class=BMSSubscript>1</span>-adrenergic
receptor antagonism,<span style='layout-grid-mode:line'> aripiprazole has the
potential to enhance the effect of certain antihypertensive medicinal products.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Given the primary
CNS effects of aripiprazole, caution should be used when aripiprazole is administered
in combination with alcohol or other CNS medicinal products with overlapping
adverse reactions such as sedation (see&nbsp;section&nbsp;4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If aripiprazole is
administered concomitantly with medicinal products known to cause QT
prolongation or electrolyte imbalance, caution should be used.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Potential for
other medicinal products to affect ABILIFY solution for injection</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The administration
of lorazepam solution for injection had no effect on the pharmacokinetics of ABILIFY
solution for injection when administered concomitantly. However, in a
single-dose, intramuscular study of aripiprazole (dose 15&nbsp;mg) in healthy
subjects, administered simultaneously with intramuscular lorazepam (dose
2&nbsp;mg), the intensity of sedation was greater with the combination as
compared to that observed with aripiprazole alone.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>A gastric acid
blocker, the H<sub>2</sub>&nbsp;antagonist famotidine, reduces aripiprazole
rate of absorption but this effect is deemed not clinically relevant.<span
style='layout-grid-mode:line'> Aripiprazole is metabolised by multiple pathways
involving the CYP2D6 and CYP3A4 enzymes but not CYP1A enzymes. Thus, no dosage
adjustment is required for smokers.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Quinidine and other
CYP2D6 inhibitors</span></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>In a clinical trial of oral aripiprazole in healthy subjects, a strong
inhibitor of CYP2D6 (quinidine) increased aripiprazole AUC by 107&nbsp;%, while
</span><span lang=EN-GB style='color:black'>C<span class=EMEASubscript>max</span><span
style='layout-grid-mode:line'> was unchanged. The AUC and </span>C<span
class=EMEASubscript>max</span><span style='layout-grid-mode:line'> of
dehydro-aripiprazole, the active metabolite, decreased by 32&nbsp;% and
47&nbsp;%</span><em><span style='font-style:normal'>, respectively</span></em><span
style='layout-grid-mode:line'>. A</span>ripiprazole<span style='layout-grid-mode:
line'> dose should be reduced to approximately one-half of its prescribed dose
when concomitant administration of </span>aripiprazole<span style='layout-grid-mode:
line'> with quinidine occurs. Other strong inhibitors of CYP2D6, such as
fluoxetine and paroxetine, may be expected to have similar effects and similar
dose reductions should therefore be applied.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Ketoconazole and
other CYP3A4 inhibitors</span></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>In a clinical trial of oral aripiprazole in healthy subjects, a strong
inhibitor of CYP3A4 (ketoconazole) increased aripiprazole AUC and </span><span
lang=EN-GB style='color:black'>C<span class=EMEASubscript>max</span><span
style='layout-grid-mode:line'> by 63&nbsp;% and 37&nbsp;%, respectively. The
AUC and </span>C<span class=EMEASubscript>max</span><span style='layout-grid-mode:
line'> of dehydro-aripiprazole increased by 77&nbsp;% and 43&nbsp;%,
respectively. In CYP2D6 poor metabolisers, concomitant use of strong inhibitors
of CYP3A4 may result in higher plasma concentrations of aripiprazole compared
to that in CYP2D6 extensive metabolizers. When considering concomitant
administration of ketoconazole or other strong CYP3A4 inhibitors with </span>aripiprazole<span
style='layout-grid-mode:line'>, potential benefits should </span>outweigh<span
style='layout-grid-mode:line'> the potential risks to the patient. When
concomitant administration of ketoconazole with </span>aripiprazole<span
style='layout-grid-mode:line'> occurs, </span>aripiprazole<span
style='layout-grid-mode:line'> dose should be reduced to approximately one-half
of its prescribed dose. Other strong inhibitors of CYP3A4, such as itraconazole
and HIV protease inhibitors may be expected to have similar effects and similar
dose reductions should therefore be applied (see section&nbsp;4.2).</span> Upon
discontinuation of the CYP2D6 or CYP3A4 inhibitor, the dosage of aripiprazole
should be increased to the level prior to the initiation of the concomitant
therapy. When weak inhibitors of CYP3A4 (e.g. diltiazem) or CYP2D6 (e.g.
escitalopram) are used concomitantly with aripiprazole, modest increases in plasma
aripiprazole concentrations may be expected.</span></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Carbamazepine and
other CYP3A4 inducers</span></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Following
concomitant administration of carbamazepine, a strong inducer of CYP3A4, and
oral aripiprazole to patients with schizophrenia or schizoaffective disorder, the
geometric means of C<span class=EMEASubscript>max</span> and AUC for
aripiprazole were 68&nbsp;% and 73&nbsp;% lower, respectively, compared to when
<span style='layout-grid-mode:line'>aripiprazole (30&nbsp;mg) was administered
alone</span>. Similarly, for dehydro-aripiprazole the geometric means of C<span
class=EMEASubscript>max</span> and AUC after carbamazepine co-administration
were 69&nbsp;% and 71&nbsp;% lower, respectively, than those following
treatment with aripiprazole alone. Aripiprazole dose should be doubled when
concomitant administration of aripiprazole occurs with carbamazepine. Concomitant
administration of aripiprazole and other inducers of CYP3A4 (such as
rifampicin, rifabutin, phenytoin, phenobarbital, primidone, efavirenz,
nevirapine and St. John's Wort) may be expected to have similar effects and
similar dose increases should therefore be applied. Upon discontinuation of strong
CYP3A4 inducers, the dosage of aripiprazole should be reduced to the
recommended dose.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Valproate and
lithium</span></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>When either
valproate or lithium was administered concomitantly with aripiprazole, there
was no clinically significant change in aripiprazole concentrations </span><span
lang=EN-GB>and therefore no dose adjustment is necessary when either valproate
or lithium is administered with aripiprazole<span style='color:black'>.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Potential for aripiprazole
to affect other medicinal products</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The administration
of ABILIFY solution for injection had no effect on the pharmacokinetics of
lorazepam solution for injection when administered concomitantly. However, in a
single-dose, intramuscular study of aripiprazole (dose 15&nbsp;mg) in healthy
subjects, administered simultaneously with intramuscular lorazepam (dose
2&nbsp;mg), the orthostatic hypotension observed was greater with the
combination as compared to that observed with lorazepam alone.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In clinical studies,
oral doses of 10&nbsp;mg/day to 30&nbsp;mg/day of aripiprazole had no
significant effect on the metabolism of substrates of CYP2D6
(dextromethorphan/3-methoxymorphinan ratio), CYP2C9&nbsp;(warfarin), CYP2C19
(omeprazole), and CYP3A4 (dextromethorphan). Additionally, aripiprazole and
dehydro-aripiprazole did not show potential for altering CYP1A2-mediated
metabolism <i>in&nbsp;vitro</i>. Thus, aripiprazole is unlikely to cause
clinically important medicinal product interactions mediated by these enzymes.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>When aripiprazole
was administered concomitantly with either valproate, lithium or lamotrigine,
there was no clinically important change in valproate, lithium or lamotrigine
concentrations.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Serotonin
syndrome</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Cases of serotonin
syndrome have been reported in patients taking aripiprazole, and possible signs
and symptoms for this condition can occur especially in cases of concomitant
use with other serotonergic medicinal products, such as selective serotonin reuptake
inhibitor/selective serotonin noradrenaline reuptake inhibitor (SSRI/SNRI), or
with medicinal products that are known to increase aripiprazole concentrations
(see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading1 style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>4.6&nbsp;&nbsp;&nbsp;&nbsp; Fertility,
pregnancy and lactation</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Pregnancy</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>There are no
adequate and well-controlled trials of aripiprazole in pregnant women.
Congenital anomalies have been reported; however, causal relationship with
aripiprazole could not be established. Animal studies could not exclude
potential developmental toxicity (see section&nbsp;5.3). Patients must be
advised to notify their physician if they become pregnant or intend to become
pregnant during treatment with aripiprazole. Due to insufficient safety
information in humans and concerns raised by animal reproductive studies, this
medicinal product should not be used in pregnancy unless the expected benefit
clearly justifies the potential risk to the foetus.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Newborn infants
exposed to antipsychotics (including aripiprazole) during the third trimester
of pregnancy are at risk of adverse reactions including extrapyramidal and/or
withdrawal symptoms that may vary in severity and duration following delivery.
There have been reports of agitation, hypertonia, hypotonia, tremor,
somnolence, respiratory distress, or feeding disorder. Consequently, newborn
infants should be monitored carefully (see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Breast-feeding</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole/</span><span
lang=EN-GB>metabolites are <span style='color:black'>excreted in human milk. </span><em><span
style='font-style:normal'>A decision must be made whether to discontinue breast-feeding
or to discontinue/abstain from </span></em>aripiprazole<em><span
style='font-style:normal'> therapy taking into account the benefit of
breast-feeding for the child and the benefit of therapy for the woman.</span></em></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='font-style:normal'>Fertility</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=EMEABodyText><span lang=EN-GB>Aripiprazole did not impair fertility
based on data from reproductive toxicity studies.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading1 style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects on
ability to drive and use machines</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>Aripiprazole </span></em><span
lang=EN-GB>has minor to moderate influence on the ability to drive and use
machines due to potential nervous system and visual effects, such as sedation,
somnolence, syncope, vision blurred, diplopia (see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading1 style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable
effects</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Summary
of the safety profile</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The most commonly
reported adverse reactions in placebo-controlled trials were nausea, dizziness
and somnolence each occurring in more than 3&nbsp;% of patients treated with
aripiprazole solution for injection.</span></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Tabulated
list of adverse reactions</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>The incidences of the Adverse Drug Reactions (ADRs)
associated with aripiprazole therapy are tabulated below. The table is based on
adverse events reported during clinical trials and/or post-marketing use.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>All ADRs are listed by system organ class and frequency;
very common (&#8805;&nbsp;1/10), common (&#8805;&nbsp;1/100 to &lt;&nbsp;1/10),
uncommon (&#8805;&nbsp;1/1,000 to &lt;&nbsp;1/100), rare (&#8805;&nbsp;1/10,000
to &lt;&nbsp;1/1,000), very rare (&lt;&nbsp;1/10,000) and not known (cannot be
estimated from the available data). Within each frequency grouping, adverse
reactions are presented in order of decreasing seriousness.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The frequency of
adverse reactions reported during post-marketing use cannot be determined as
they are derived from spontaneous reports. Consequently, the frequency of these
adverse events is qualified as &quot;not known&quot;.</span></p>

<p class=EMEABodyText><em><u><span lang=EN-GB style='color:black;font-style:
normal'><span style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
   style='color:black'>&nbsp;</span></b></p>
   </td>
   <td width=123 valign=top style='width:92.15pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
   style='color:black'>Common</span></b></p>
   </td>
   <td width=142 valign=top style='width:106.3pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
   style='color:black'>Uncommon</span></b></p>
   </td>
   <td width=217 valign=top style='width:163.0pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
   style='color:black'>Not known</span></b></p>
   <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
   style='color:black'>&nbsp;</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Blood and lymphatic system disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Leukopenia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Neutropenia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Thrombocytopenia</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Immune system disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
  style='color:black;font-style:normal'>Allergic reaction (e.g. anaphylactic
  reaction, angioedema including swollen tongue, tongue oedema, face oedema,
  pruritus allergic, or urticaria)</span></em></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Endocrine disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hyperprolactinaemia</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Diabetic hyperosmolar
  coma</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Diabetic ketoacidosis</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Metabolism and nutrition disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;text-autospace:none'><span
  lang=EN-GB style='color:black'>Diabetes mellitus</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hyperglycaemia</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Hyponatremia</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Anorexia</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Psychiatric disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Insomnia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Anxiety</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Restlessness</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Depression</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hypersexuality</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Suicide attempt, suicidal ideation and completed suicide
  (see section&nbsp;4.4)</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Pathological gambling</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Impulse-control
  disorder</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Binge eating</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Compulsive
  shopping</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Poriomania</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Aggression</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Agitation</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Nervousness </span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Nervous system disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Akathisia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Extrapyramidal disorder</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Tremor</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Headache</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Sedation</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Somnolence</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Dizziness</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Tardive dyskinesia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Dystonia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=IT
  style='color:black'>Restless legs syndrome</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=FR
  style='color:black'>Neuroleptic Malignant Syndrome</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=FR
  style='color:black'>Grand mal convulsion</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Serotonin syndrome</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Speech disorder</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Eye disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Vision blurred</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Diplopia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Photophobia</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Oculogyric crisis</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Cardiac disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Tachycardia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Sudden death unexplained </span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Torsades de pointes</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Ventricular arrhythmia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Cardiac arrest</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Bradycardia</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Vascular disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Orthostatic hypotension</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Venous thromboembolism (including pulmonary embolism and
  deep vein thrombosis)</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hypertension</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Syncope</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Respiratory, thoracic and mediastinal disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hiccups</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Aspiration pneumonia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Laryngospasm</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Oropharyngeal spasm</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Gastrointestinal disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Constipation</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Dyspepsia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Nausea</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Salivary hypersecretion</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Vomiting</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Mouth dry</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Pancreatitis</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Dysphagia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Diarrhoea</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Abdominal discomfort</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Stomach discomfort</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Hepatobiliary disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hepatic failure</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hepatitis</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Jaundice</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
  style='color:black'>Skin and subcutaneous tissue disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Rash</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Photosensitivity reaction</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Alopecia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Hyperhidrosis</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Drug Reaction
  with Eosinophilia and Systemic Symptoms (DRESS)</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Musculoskeletal and connective tissue
  disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Rhabdomyolysis</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Myalgia</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Stiffness</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Renal and urinary disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Urinary incontinence</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Urinary retention</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:
  normal'>Pregnancy, puerperium and perinatal conditions</span></b></em></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Drug withdrawal syndrome neonatal (see section&nbsp;4.6)</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Reproductive system and breast disorders</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Priapism</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>General disorders and administration
  site conditions</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Fatigue</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Temperature regulation disorder (e.g. hypothermia,
  pyrexia)</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Chest pain</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Peripheral oedema</span></p>
  </td>
 </tr>
 <tr>
  <td width=142 valign=top style='width:106.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin-bottom:0in;line-height:normal'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Investigations</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Diastolic blood pressure increased</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Weight decreased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Weight gain</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Alanine Aminotransferase </span><span lang=EN-GB
  style='color:black'>increased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Aspartate Aminotransferase increased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Gamma-glutamyltransferase increased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Alkaline phosphatase increased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>QT prolonged</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Blood glucose increased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Glycosylated haemoglobin increased</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Blood glucose fluctuation</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Creatine phosphokinase increased</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Description of
selected adverse reactions</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Extrapyramidal
symptoms (EPS)</span></i></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Schizophrenia: </span></i><span
lang=EN-GB style='color:black'>in a long-term 52&#8209;week controlled trial,
aripiprazole-treated patients had an overall-lower incidence (25.8&nbsp;%) of
EPS including Parkinsonism, akathisia, dystonia and dyskinesia compared with
those treated with haloperidol (57.3&nbsp;%). In a long-term 26&#8209;week
placebo-controlled trial, the incidence of EPS was 19&nbsp;% for
aripiprazole-treated patients and 13.1&nbsp;% for placebo-treated patients. In
another long-term 26&#8209;week controlled trial, the incidence of EPS was 14.8&nbsp;%
for aripiprazole-treated patients and 15.1&nbsp;% for olanzapine-treated
patients.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Manic episodes in
Bipolar I Disorder: </span></i><span lang=EN-GB style='color:black'>in a 12&#8209;week
controlled trial, the incidence of EPS was 23.5&nbsp;% for aripiprazole-treated
patients and 53.3&nbsp;% for haloperidol-treated patients. In another 12&#8209;week
trial, the incidence of EPS was 26.6&nbsp;% for patients treated with
aripiprazole and 17.6&nbsp;% for those treated with lithium. In the long-term
26&#8209;week maintenance phase of a placebo-controlled trial, the incidence of
EPS was 18.2&nbsp;% for aripiprazole-treated patients and 15.7&nbsp;% for
placebo-treated patients.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Akathisia</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In
placebo-controlled trials, the incidence of akathisia in bipolar patients was
12.1&nbsp;% with aripiprazole and 3.2&nbsp;% with placebo. In schizophrenia
patients the incidence of akathisia was 6.2&nbsp;% with aripiprazole and 3.0&nbsp;%
with placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Dystonia</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Class effect: Symptoms
of dystonia, prolonged abnormal contractions of muscle groups, may occur in
susceptible individuals during the first few days of treatment. Dystonic
symptoms include: spasm of the neck muscles, sometimes progressing to tightness
of the throat, swallowing difficulty, difficulty breathing, and/or protrusion
of the tongue. While these symptoms can occur at low doses, they occur more
frequently and with greater severity with high potency and at higher doses of
first generation antipsychotic medicinal products. An elevated risk of acute
dystonia is observed in males and younger age groups.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>Prolactin</span></em></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>In clinical trials for the approved indications and
post-marketing, both increase and decrease in serum prolactin as compared to
baseline was observed with aripiprazole (section&nbsp;5.1).</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Laboratory
parameters</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Comparisons between
aripiprazole and placebo in the proportions of patients experiencing
potentially clinically significant changes in routine laboratory and lipid
parameters (see section&nbsp;5.1) revealed no medically important differences.
Elevations of CPK (Creatine Phosphokinase), generally transient and
asymptomatic, were observed in 3.5&nbsp;% of aripiprazole treated patients as
compared to 2.0&nbsp;% of patients who received placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><i><span lang=EN-GB>Pathological
gambling and other impulse control disorders</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Pathological
gambling, hypersexuality, compulsive shopping and binge or compulsive eating
can occur in patients treated with aripiprazole (see </span><span lang=EN-GB>section&nbsp;4.4).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Reporting of
suspected adverse reactions</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Reporting suspected
adverse reactions after authorisation of the medicinal product is important. It
allows continued monitoring of the benefit/risk balance of the medicinal
product. Healthcare professionals are asked to report any suspected adverse
reactions <span style='background:silver'>via the national reporting system
listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a>.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></b></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>No cases of overdose associated with
adverse reactions were reported in clinical studies with ABILIFY solution for injection.
Care must be taken to avoid inadvertent injection of this medicinal product
into a blood vessel. Following any confirmed or suspected accidental
overdose/inadvertent intravenous administration, close observation of the
patient is needed and if any potentially medically serious sign or symptom
develops, monitoring, which should include continuous electrocardiographic
monitoring, is required. The medical supervision and monitoring should continue
until the patient recovers.</span></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Signs
and symptoms</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In clinical trials
and post-marketing experience, accidental or intentional acute overdose of
aripiprazole alone was identified in adult patients with reported estimated
doses up to 1,260&nbsp;mg with no fatalities. The potentially medically
important signs and symptoms observed </span><span lang=EN-GB style='color:
black'>included lethargy, increased blood pressure, somnolence, tachycardia,
nausea, </span><span lang=EN-GB style='color:black'>vomiting and diarrhoea. </span><span
lang=EN-GB style='color:black'>In addition, reports of accidental overdose with
aripiprazole alone (up to 195&nbsp;mg) in children have been received with no
fatalities. The potentially medically serious signs and symptoms reported
included somnolence, transient loss of consciousness </span><span lang=EN-GB
style='color:black'>and extrapyramidal symptoms</span><span lang=EN-GB
style='color:black'>.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Management
of overdose</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Management of
overdose should concentrate on supportive therapy, maintaining an adequate
airway, oxygenation and ventilation, and management of symptoms. The
possibility of multiple medicinal product involvement should be considered.
Therefore cardiovascular monitoring should be started immediately and should
include continuous electrocardiographic monitoring to detect possible
arrhythmias. Following any confirmed or suspected overdose with aripiprazole,
close medical supervision and monitoring should continue until the patient
recovers.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Activated charcoal
(50&nbsp;g), administered one hour after aripiprazole, decreased aripiprazole C<span
class=EMEASubscript>max</span> by about 41&nbsp;% and AUC by about 51&nbsp;%,
suggesting that charcoal may be effective in the treatment of overdose.</span></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'>Haemodialysis</span></u></em></p>

<p class=MsoNormal><em><u><span lang=EN-GB style='color:black;font-style:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Although there is no
information on the effect of haemodialysis in treating an overdose with
aripiprazole, haemodialysis is unlikely to be useful in overdose management
since aripiprazole is highly bound to plasma proteins.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>5.1&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic
properties</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Pharmacotherapeutic
group: Psycholeptics, other antipsychotics, ATC&nbsp;code: N05AX12</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Mechanism of
action</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>It has been proposed
that aripiprazole&#8217;s efficacy in schizophrenia and Bipolar I Disorder is
mediated through a combination of partial agonism at dopamine&nbsp;D<sub>2</sub>
and serotonin 5&#8209;HT<sub>1A</sub> receptors and antagonism of serotonin 5&#8209;HT<sub>2A</sub>
receptors. Aripiprazole exhibited antagonist properties in animal models of
dopaminergic hyperactivity and agonist properties in animal models of
dopaminergic hypoactivity. Aripiprazole exhibited high binding affinity <i>in&nbsp;vitro</i>
for dopamine&nbsp;D<sub>2</sub> and D<sub>3</sub>, serotonin 5&#8209;HT<sub>1A</sub>
and 5&#8209;HT<sub>2A</sub> receptors and moderate affinity for dopamine&nbsp;D<sub>4</sub>,
serotonin 5&#8209;HT<sub>2C</sub> and 5&#8209;HT<sub>7</sub>, alpha&#8209;1
adrenergic and histamine H<sub>1</sub> receptors. Aripiprazole also exhibited
moderate binding affinity for the serotonin reuptake site and no appreciable
affinity for muscarinic receptors. Interaction with receptors other than
dopamine and serotonin subtypes may explain some of the other clinical effects
of aripiprazole.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole doses
ranging from 0.5&nbsp;mg to 30&nbsp;mg administered once a day to healthy
subjects for 2&nbsp;weeks produced a dose-dependent reduction in the binding of
<sup>11</sup>C-raclopride, a D<sub>2</sub>/D<sub>3</sub> receptor ligand, to
the caudate and putamen detected by positron emission tomography.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Clinical efficacy
and safety</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Agitation in
schizophrenia and Bipolar I Disorder with ABILIFY solution for injection</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In two short- term
(24-hour) placebo-controlled trials involving 554</span><span lang=EN-GB
style='color:black'>&nbsp;</span><span lang=EN-GB style='color:black'>schizophrenic
adult patients presenting with agitation and disturbed behaviours, ABILIFYsolution
for injection was associated with statistically significant greater
improvements in agitation/behavioural symptoms compared to placebo and was
similar to haloperidol.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In one short-term
(24-hour) placebo-controlled trial involving 291&nbsp;patients with bipolar
disorder presenting with agitation and disturbed behaviours, ABILIFY solution
for injection was associated with statistically significant greater improvements
in agitation/behavioural symptoms compared to placebo and was similar to the
reference arm lorazepam. </span><span lang=EN-GB style='color:black'>The
observed mean improvement from baseline on the PANSS Excitement Component score
at the primary 2-hour endpoint was 5.8 for placebo, 9.6 for lorazepam, and 8.7
for ABILIFY solution for injection. In subpopulation analyses on patients with
mixed episodes or on patients with severe agitation, a similar pattern of
efficacy to the overall population was observed but </span><span lang=EN-GB
style='color:black'>statistical significance could not be established due to a
reduced sample size.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Schizophrenia
with oral aripiprazole</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In three short-term
(4 to 6</span><span lang=EN-GB style='color:black'>&nbsp;</span><span
lang=EN-GB style='color:black'>weeks) placebo-controlled trials involving
1,228&nbsp;schizophrenic adult patients, presenting with positive or negative
symptoms, oral aripiprazole was associated with statistically significantly
greater improvements in psychotic symptoms compared to placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole is
effective in maintaining the clinical improvement during continuation therapy
in adult patients who have shown an initial treatment response. In a
haloperidol-controlled trial, the proportion of responder patients maintaining
response to medicinal product at 52&#8209;weeks was similar in both groups
(oral aripiprazole 77&nbsp;% and haloperidol 73&nbsp;%). The overall completion
rate was significantly higher for patients on oral aripiprazole (43&nbsp;%)
than for oral haloperidol (30&nbsp;%). Actual scores in rating scales used as
secondary endpoints, including PANSS and the Montgomery-&Aring;sberg Depression
Rating Scale <a name="_Hlk8900809">(MADRS)</a> showed a significant improvement
over haloperidol.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In a 26&#8209;week,
placebo-controlled trial in adult stabilised patients with chronic schizophrenia,
oral aripiprazole had significantly greater reduction in relapse rate, 34&nbsp;%
in oral aripiprazole group and 57&nbsp;% in placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Weight gain</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In clinical trials
oral aripiprazole has not been shown to induce clinically relevant weight gain.
In a 26&#8209;week, olanzapine-controlled, double-blind, multi-national study
of schizophrenia which included 314&nbsp;adult patients and where the primary
endpoint was weight gain, significantly less patients had at least 7&nbsp;%
weight gain over baseline (i.e. a gain of at least 5.6&nbsp;kg for a mean
baseline weight of ~80.5&nbsp;kg) on oral aripiprazole (n&nbsp;=&nbsp;18, or 13&nbsp;%
of evaluable patients), compared to oral olanzapine (n&nbsp;=&nbsp;45, or 33&nbsp;%
of evaluable patients).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Lipid parameters</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In a pooled analysis
on lipid parameters from placebo controlled clinical trials in adults,
aripiprazole has not been shown to induce clinically relevant alterations in
levels of total cholesterol, triglycerides, High Density Lipoprotein (HDL) and Low
Density Lipoprotein (LDL).</span></p>

<p class=EMEABodyText><i><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>Prolactin</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Prolactin levels were
evaluated in all trials of all doses of aripiprazole (n&nbsp;=&nbsp;28,242).
The incidence of hyperprolactinaemia or increased serum prolactin in patients
treated with aripiprazole (0.3&nbsp;%) was similar to that of placebo
(0.2&nbsp;%). For patients receiving aripiprazole, the median time to onset was
42&nbsp;days and median duration was 34&nbsp;days.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The incidence of
hypoprolactinaemia or decreased serum prolactin in patients treated with
aripiprazole was 0.4&nbsp;%, compared with 0.02&nbsp;% for patients treated
with placebo. For patients receiving aripiprazole, the median time to onset was
30&nbsp;days and median duration was 194&nbsp;days.</span></p>

<p class=EMEABodyText><i><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Manic episodes in
Bipolar I Disorder with oral aripiprazole</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In two<b> </b>3&#8209;week,
flexible-dose, placebo-controlled monotherapy trials involving<b> </b>patients
with a manic or mixed episode of Bipolar I Disorder, aripiprazole demonstrated
superior efficacy to placebo in reduction of manic symptoms over 3&nbsp;weeks.
These trials included patients with or without psychotic features and with or
without a rapid-cycling course.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In one 3&#8209;week,
fixed-dose, placebo-controlled monotherapy trial involving patients with a
manic or mixed episode of Bipolar I Disorder, aripiprazole failed to demonstrate
superior efficacy to placebo.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In two 12&#8209;week,
placebo- and active-controlled monotherapy trials in patients with a manic or
mixed episode of Bipolar I Disorder, with or without psychotic features,
aripiprazole demonstrated superior efficacy to placebo at week&nbsp;3 and a
maintenance of effect comparable to lithium or haloperidol at week&nbsp;12.
Aripiprazole also demonstrated a comparable proportion of patients in
symptomatic remission from mania as lithium or haloperidol at week&nbsp;12.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In a 6&#8209;week,
placebo-controlled trial involving patients with a manic or mixed episode of
Bipolar I Disorder, with or without psychotic features, who were partially
non-responsive to lithium or valproate monotherapy for 2&nbsp;weeks at
therapeutic serum levels, the addition of aripiprazole as adjunctive therapy
resulted in superior efficacy in reduction of manic symptoms than lithium or
valproate monotherapy.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In a 26&#8209;week,
placebo-controlled trial, followed by a 74&#8209;week extension, in manic
patients who achieved remission on aripiprazole during a stabilization phase
prior to randomisation, aripiprazole demonstrated superiority over placebo in
preventing bipolar recurrence, primarily in preventing recurrence into mania
but failed to demonstrate superiority over placebo in preventing recurrence
into depression.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In a 52&#8209;week,
placebo-controlled trial, in patients with a current manic or mixed episode of
Bipolar I Disorder who achieved sustained remission (Young Mania Rating Scale [YMRS]
and MADRS with total scores &#8804;&nbsp;12) on aripiprazole (10&nbsp;mg/day to
30&nbsp;mg/day) adjunctive to lithium or valproate for 12&nbsp;consecutive
weeks, adjunctive aripiprazole demonstrated superiority over placebo with a 46&nbsp;%
decreased risk (hazard ratio of 0.54) in preventing bipolar recurrence and a 65&nbsp;%
decreased risk (hazard ratio of 0.35) in preventing recurrence into mania over
adjunctive placebo but failed to demonstrate superiority over placebo in
preventing recurrence into depression. Adjunctive aripiprazole demonstrated
superiority over placebo on the secondary outcome measure in Clinical Global
Impression - Bipolar version (CGI-BP) Severity of Illness (SOI; mania) scores. In
this trial, patients were assigned by investigators with either open-label
lithium or valproate monotherapy to determine partial non-response. Patients
were stabilised for at least 12&nbsp;consecutive weeks with the combination of
aripiprazole and the same mood stabilizer. Stabilized patients were then
randomised to continue the same mood stabilizer with double-blind aripiprazole
or placebo. Four mood stabilizer subgroups were assessed in the randomised
phase: aripiprazole + lithium; aripiprazole + valproate; placebo + lithium;
placebo + valproate. The Kaplan-Meier rates for recurrence to any mood episode
for the adjunctive treatment arm were 16&nbsp;% in aripiprazole + lithium and
18&nbsp;% in aripiprazole + valproate compared to 45&nbsp;% in placebo +
lithium and 19&nbsp;% in placebo + valproate.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The European
Medicines Agency has deferred the obligation to submit the results of studies
with </span><span lang=EN-GB style='color:black'>ABILIFY i</span><span
lang=EN-GB style='color:black'>n one or more subsets of the paediatric
population in the treatment of schizophrenia and in the treatment of bipolar
affective disorder (see section&nbsp;4.2 for information on paediatric use).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic
properties</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Absorption</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole administered
intramuscularly as a single-dose to healthy subjects is well absorbed and has
an absolute bioavailability of 100&nbsp;%. The aripiprazole AUC in the first 2</span><span
lang=EN-GB style='color:black'>&nbsp;</span><span lang=EN-GB style='color:black'>hours
after an intramuscular injection was 90&nbsp;% greater than the AUC after the
same dose as a tablet; systemic exposure was generally similar between the 2</span><span
lang=EN-GB style='color:black'>&nbsp;</span><span lang=EN-GB style='color:black'>formulations.
In 2</span><span lang=EN-GB style='color:black'>&nbsp;</span><span lang=EN-GB
style='color:black'>studies in healthy subjects the median times to the peak
plasma concentrations were 1 and 3</span><span lang=EN-GB style='color:black'>&nbsp;</span><span
lang=EN-GB style='color:black'>hours after dosing.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Distribution</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><em><span lang=EN-GB style='color:black;font-style:normal'>Based
on results from trials with oral administration of aripiprazole</span></em><span
lang=EN-GB style='color:black'>, aripiprazole is widely distributed throughout
the body with an apparent volume of distribution of 4.9&nbsp;L/kg, indicating
extensive extravascular distribution. At therapeutic concentrations,
aripiprazole and dehydro-aripiprazole are greater than 99&nbsp;% bound to serum
proteins, binding primarily to albumin.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Biotransformation</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aripiprazole is
extensively metabolised by the liver primarily by three biotransformation
pathways: dehydrogenation, hydroxylation, and N-dealkylation. Based on <i>in&nbsp;vitro</i>
studies, CYP3A4 and CYP2D6 enzymes are responsible for dehydrogenation and
hydroxylation of aripiprazole, and N-dealkylation is catalysed by CYP3A4.
Aripiprazole is the predominant medicinal product moiety in systemic
circulation. At steady state, dehydro-aripiprazole, the active metabolite,
represents about 40&nbsp;% of aripiprazole AUC in plasma.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Elimination</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The mean elimination
half-lives for aripiprazole are approximately 75&nbsp;hours in extensive
metabolisers of CYP2D6 and approximately 146&nbsp;hours in poor metabolisers of
CYP2D6.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The total body
clearance of aripiprazole is 0.7&nbsp;mL/min/kg, which is primarily hepatic.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Following a single
oral dose of [<sup>14</sup>C]-labelled aripiprazole, approximately 27&nbsp;% of
the administered radioactivity was recovered in the urine and approximately 60&nbsp;%
in the faeces. Less than 1&nbsp;% of unchanged aripiprazole was excreted in the
urine and approximately 18&nbsp;% was recovered unchanged in the faeces.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Pharmacokinetics
in special patient groups</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Elderly</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>There are no
differences in the pharmacokinetics of aripiprazole between healthy elderly and
younger adult subjects, nor is there any detectable effect of age in a population
pharmacokinetic analysis in schizophrenic patients.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Gender</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>There are no
differences in the pharmacokinetics of aripiprazole between healthy male and
female subjects nor is there any detectable effect of gender in a population
pharmacokinetic analysis in schizophrenic patients.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><i><span lang=EN-GB
style='color:black'>Smoking</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Population pharmacokinetic evaluation of oral aripiprazole
has revealed no evidence of clinically relevant effects from smoking on the
pharmacokinetics of aripiprazole.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><i><span lang=EN-GB
style='color:black'>Race</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Population pharmacokinetic evaluation showed no evidence of
race&#8209;related differences on the pharmacokinetics of aripiprazole.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Renal impairment</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The pharmacokinetic
characteristics of aripiprazole and dehydro-aripiprazole were found to be
similar in patients with severe renal disease compared to young healthy
subjects.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>Hepatic
impairment</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>A single-dose study
in subjects with varying degrees of liver cirrhosis (Child&#8209;Pugh Classes
A, B, and&nbsp;C) did not reveal a significant effect of hepatic impairment on
the pharmacokinetics of aripiprazole and dehydro-aripiprazole, but the study
included only 3&nbsp;patients with Class&nbsp;C liver cirrhosis, which is
insufficient to draw conclusions on their metabolic capacity.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical safety
data</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Administration of ABILIFY
solution for injection was well tolerated and produced no direct target organ
toxicity in rats or monkeys after repeated dosing at systemic exposures (AUC)
that were 15 and 5</span><span lang=EN-GB style='color:black'>&nbsp;</span><span
lang=EN-GB style='color:black'>times, respectively, human exposure at the
maximum recommended human dose of 30&nbsp;mg intramuscular. In intravenous
reproductive toxicity studies, no new safety concerns were observed at maternal
exposures up to 15 (rat) and 29 (rabbit) times human exposure at 30&nbsp;mg.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Non-clinical data
reveal no special hazard for humans based on conventional oral aripiprazole studies
of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic
potential, toxicity to reproduction and development.</span></p>

<p class=EMEABodyText><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Toxicologically
significant effects were observed only at doses or exposures that were
sufficiently in excess of the maximum human dose or exposure, indicating that
these effects were limited or of no relevance to clinical use. These included:
dose-dependent adrenocortical toxicity (lipofuscin pigment accumulation and/or
parenchymal cell loss) in rats after 104&nbsp;weeks at&nbsp;20&nbsp;mg/kg/day
to 60&nbsp;mg/kg/day (3&nbsp;to 10&nbsp;times the mean steady-state AUC at the
maximum recommended human dose) and increased adrenocortical carcinomas and
combined adrenocortical adenomas/carcinomas in female rats at 60&nbsp;mg/kg/day
(10&nbsp;times the mean steady-state AUC at the maximum recommended human
dose). The highest nontumorigenic exposure in female rats was 7&nbsp;times the
human exposure at the recommended dose.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>An additional finding
was cholelithiasis as a consequence of precipitation of sulphate conjugates of
hydroxy metabolites of aripiprazole in the bile of monkeys after repeated oral
dosing at&nbsp;25&nbsp;mg/kg/day to 125&nbsp;mg/kg/day (1 to 3&nbsp;times the
mean steady-state AUC at the maximum recommended clinical dose or 16 to
81&nbsp;times the maximum recommended human dose based on&nbsp;mg/m<span
class=EMEASuperscript>2</span>). However, the concentrations of the sulphate
conjugates of hydroxy aripiprazole in human bile at the highest dose proposed,
30&nbsp;mg per day, were no more than 6&nbsp;% of the bile concentrations found
in the monkeys in the 39&#8209;week study and are well below (6&nbsp;%) their
limits of <i>in&nbsp;vitro</i> solubility.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>In repeat-dose studies
in juvenile rats and dogs, the toxicity profile of aripiprazole was comparable
to that observed in adult animals, and there was no evidence of neurotoxicity
or adverse reactions on development.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Based on results of
a full range of standard genotoxicity tests, aripiprazole was considered
non-genotoxic. Aripiprazole did not impair fertility in reproductive toxicity
studies. Developmental toxicity, including dose-dependent delayed foetal
ossification and possible teratogenic effects, were observed in rats at doses
resulting in subtherapeutic exposures (based on AUC) and in rabbits at doses
resulting in exposures 3 and 11&nbsp;times the mean steady-state AUC at the
maximum recommended clinical dose. Maternal toxicity occurred at doses similar
to those eliciting developmental toxicity.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>6.1&nbsp;&nbsp;&nbsp;&nbsp; List of excipients</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Sulfobutylether
&#946;-cyclodextrin (SBECD)</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Tartaric acid</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Sodium hydroxide</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Water for injections</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Not applicable.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf life</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>18&nbsp;months</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>After opening: use
product immediately.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>6.4&nbsp;&nbsp;&nbsp;&nbsp; Special precautions
for storage</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Keep the vial in the
outer carton in order to protect from light.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>For storage
conditions after first opening of the medicinal product, see section&nbsp;6.3.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>6.5&nbsp;&nbsp;&nbsp;&nbsp; Nature and contents
of container</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Each carton contains
one single-use type I glass vial with a rubber butyl stopper and a
&quot;tear-off&quot; aluminium seal.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>6.6&nbsp;&nbsp;&nbsp;&nbsp; Special precautions
for disposal</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Any unused medicinal
product or waste material should be disposed of in accordance with local
requirements.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Otsuka Pharmaceutical
Netherlands B.V.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Herikerbergweg 292</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>1101 CT, Amsterdam</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Netherlands</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>EU/1/04/276/036</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DATE OF
FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Date of first
authorisation: 04&nbsp;June&nbsp;2004</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Date of latest
renewal: 04&nbsp;June&nbsp;2009</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>10.&nbsp;&nbsp;&nbsp;&nbsp; DATE OF REVISION OF
THE TEXT</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>{MM/YYYY}</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Detailed information
on this medicinal product is available on the website of the European Medicines
Agency <a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a>.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEATitle style='page-break-after:auto'><span lang=EN-GB
style='color:black'>ANNEX II</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;page-break-after:auto'><span
lang=EN-GB style='color:black;text-transform:none'>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURERS
RESPONSIBLE FOR BATCH RELEASE</span></p>

<p class=EMEABodyText style='margin-left:85.05pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;page-break-after:auto'><span
lang=EN-GB style='color:black;text-transform:none'>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS
OR RESTRICTIONS REGARDING SUPPLY AND USE</span></p>

<p class=EMEABodyText style='margin-left:85.05pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;page-break-after:auto'><span
lang=EN-GB style='color:black;text-transform:none'>C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></p>

<p class=EMEABodyText style='margin-left:85.05pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;page-break-after:auto'><span
lang=EN-GB style='color:black;text-transform:none'>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS
OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=TitleB><span lang=EN-GB style='color:black'>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURERS
RESPONSIBLE FOR BATCH RELEASE</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>Name and address
of the manufacturers responsible for batch release</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR style='color:black'>Elaiapharm</span></p>

<p class=MsoNormal><span lang=FR style='color:black'>2881 Route des
Cr&ecirc;tes, Z.I. Les Bouilides-Sophia Antipolis,</span></p>

<p class=MsoNormal><span lang=FR style='color:black'>06560 Valbonne</span></p>

<p class=MsoNormal><span lang=FR style='color:black'>France</span></p>

<p class=MsoNormal><span lang=FR style='color:black'>&nbsp;</span></p>

<p class=NormalSingle><span lang=FR style='font-size:11.0pt'>Zambon S.p.A.</span></p>

<p class=NormalSingle><span lang=IT style='font-size:11.0pt'>Via della Chimica,
9</span></p>

<p class=NormalSingle><span lang=IT style='font-size:11.0pt'>I-36100
Vicenza(VI)</span></p>

<p class=NormalSingle><span lang=EN-GB style='font-size:11.0pt'>Italy</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The printed package
leaflet of the medicinal product must state the name and address of the
manufacturer responsible for the release of the concerned batch.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB style='color:black'>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS
OR RESTRICTIONS REGARDING SUPPLY AND USE</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Medicinal product
subject to medical prescription.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB style='color:black'>C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyTextIndent><a name="_Hlk13471350"><b><span lang=EN-GB
style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Periodic safety
update reports (PSURs)</span></b></a></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><a name="_Hlk13471388"><span lang=EN-GB style='color:
black'>The requirements for submission of PSURs for this medicinal product are
set out in the list of Union reference dates (EURD list) </span></a><span
lang=EN-GB style='color:black'>provided for under Article 107c(7) of Directive
2001/83/EC and any subsequent updates published on the European medicines
web-portal.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB style='color:black'>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS
OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL
PRODUCT</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyTextIndent><a name="_Hlk13471398"><b><span lang=EN-GB
style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Risk management
plan (RMP)</span></b></a></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><a name="_Hlk13471405"><span lang=EN-GB style='color:
black'>The marketing authorisation holder (MAH) shall perform the required
pharmacovigilance activities and interventions detailed in the agreed RMP
presented in Module 1.8.2 of the marketing authorisation and any agreed
subsequent updates of the RMP.</span></a></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>An updated RMP
should be submitted:</span></p>

<p class=EMEABodyTextIndent><b><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></b><span
lang=EN-GB style='color:black'>At the request of the European Medicines Agency;</span></p>

<p class=EMEABodyTextIndent><b><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></b><span
lang=EN-GB style='color:black'>Whenever the risk management system is modified,
especially as the result of new information being received that may lead to a
significant change to the benefit/risk profile or as the result of an important
(pharmacovigilance or risk minimisation) milestone being reached.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEATitle style='page-break-after:auto'><span lang=EN-GB
style='color:black'>ANNEX III</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEATitle style='page-break-after:auto'><span lang=EN-GB
style='color:black'>LABELLING AND PACKAGE LEAFLET</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB style='color:black'>A. LABELLING</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;text-transform:uppercase'><br clear=all style='page-break-before:
always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>OUTER CARTON</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY&nbsp;5&nbsp;mg
tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>aripiprazole</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Each tablet contains
5&nbsp;mg of aripiprazole.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Also contains:
lactose monohydrate.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>Tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>14&nbsp;&times;
1&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>28&nbsp;&times;
1&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>49&nbsp;&times;
1&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>56&nbsp;&times;
1&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>98&nbsp;&times;
1&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Read the package
leaflet before use.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Oral use.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Keep out of the
sight and reach of children.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Store in the
original package in order to protect from moisture.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Otsuka Pharmaceutical
Netherlands B.V.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Herikerbergweg 292</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>1101 CT, Amsterdam</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Netherlands</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt;color:black'>EU/1/04/276/001
<span style='background:silver'>(5&nbsp;mg, 14&nbsp;&times; 1 tablets)</span></span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt;color:black;
background:silver'>EU/1/04/276/002 (5&nbsp;mg, 28&nbsp;&times; 1 tablets)</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt;color:black;
background:silver'>EU/1/04/276/003 (5&nbsp;mg, 49&nbsp;&times; 1 tablets)</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt;color:black;
background:silver'>EU/1/04/276/004 (5&nbsp;mg, 56&nbsp;&times; 1 tablets)</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt;color:black;
background:silver'>EU/1/04/276/005 (5&nbsp;mg, 98&nbsp;&times; 1 tablets)</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Medicinal product
subject to medical prescription.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>abilify 5&nbsp;mg</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER
&#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode carrying
the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER
- HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<b><u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;text-transform:uppercase'><br clear=all style='page-break-before:
always'>
</span></u></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>MINIMUM PARTICULARS TO APPEAR ON
BLISTERS OR STRIPS</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>&nbsp;</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>BLISTERS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY 5&nbsp;mg
tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>aripiprazole</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Otsuka</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;text-transform:uppercase'><br clear=all style='page-break-before:
always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>OUTER CARTON</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY&nbsp;10&nbsp;mg
tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>aripiprazole</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Each tablet contains
10&nbsp;mg of aripiprazole.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Also contains:
lactose monohydrate.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>Tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>14&nbsp;&times;
1&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>28&nbsp;&times;
1&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>49&nbsp;&times;
1&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>56&nbsp;&times;
1&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>98&nbsp;&times;
1&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Read the package
leaflet before use.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Oral use.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Keep out of the
sight and reach of children.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Store in the
original package in order to protect from moisture.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Otsuka Pharmaceutical
Netherlands B.V.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Herikerbergweg 292</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>1101 CT, Amsterdam</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Netherlands</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt;color:black'>EU/1/04/276/006
<span style='background:silver'>(10&nbsp;mg, 14&nbsp;&times; 1 tablets)</span></span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt;color:black;
background:silver'>EU/1/04/276/007 (10&nbsp;mg, 28&nbsp;&times; 1 tablets)</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt;color:black;
background:silver'>EU/1/04/276/008 (10&nbsp;mg, 49&nbsp;&times; 1 tablets)</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt;color:black;
background:silver'>EU/1/04/276/009 (10&nbsp;mg, 56&nbsp;&times; 1 tablets)</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt;color:black;
background:silver'>EU/1/04/276/010 (10&nbsp;mg, 98&nbsp;&times; 1 tablets)</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Medicinal product
subject to medical prescription.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>abilify 10&nbsp;mg</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER
&#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER
- HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<b><u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;text-transform:uppercase'><br clear=all style='page-break-before:
always'>
</span></u></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>MINIMUM PARTICULARS TO APPEAR ON
BLISTERS OR STRIPS</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>&nbsp;</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>BLISTERS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY 10&nbsp;mg
tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>aripiprazole</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Otsuka</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;text-transform:uppercase'><br clear=all style='page-break-before:
always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>OUTER CARTON</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY&nbsp;15&nbsp;mg
tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>aripiprazole</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Each tablet contains
15&nbsp;mg of aripiprazole.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Also contains:
lactose monohydrate.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>Tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>14&nbsp;&times;
1&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>28&nbsp;&times;
1&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>49&nbsp;&times;
1&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>56&nbsp;&times;
1&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>98&nbsp;&times;
1&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Read the package
leaflet before use.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Oral use.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Keep out of the
sight and reach of children.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Store in the
original package in order to protect from moisture.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Otsuka Pharmaceutical
Netherlands B.V.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Herikerbergweg 292</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>1101 CT, Amsterdam</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Netherlands</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt;color:black'>EU/1/04/276/011
<span style='background:silver'>(15&nbsp;mg, 14&nbsp;&times; 1 tablets)</span></span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt;color:black;
background:silver'>EU/1/04/276/012 (15&nbsp;mg, 28&nbsp;&times; 1 tablets)</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt;color:black;
background:silver'>EU/1/04/276/013 (15&nbsp;mg, 49&nbsp;&times; 1 tablets)</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt;color:black;
background:silver'>EU/1/04/276/014 (15&nbsp;mg, 56&nbsp;&times; 1 tablets)</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt;color:black;
background:silver'>EU/1/04/276/015 (15&nbsp;mg, 98&nbsp;&times; 1 tablets)</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Medicinal product
subject to medical prescription.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>abilify 15&nbsp;mg</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER
&#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER
- HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<b><u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;text-transform:uppercase'><br clear=all style='page-break-before:
always'>
</span></u></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>MINIMUM PARTICULARS TO APPEAR ON
BLISTERS OR STRIPS</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>&nbsp;</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>BLISTERS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY 15&nbsp;mg
tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>aripiprazole</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Otsuka</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;text-transform:uppercase'><br clear=all style='page-break-before:
always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>OUTER CARTON</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY&nbsp;30&nbsp;mg
tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>aripiprazole</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Each tablet contains
30&nbsp;mg of aripiprazole.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Also contains:
lactose monohydrate.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>Tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>14&nbsp;&times;
1&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>28&nbsp;&times;
1&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>49&nbsp;&times;
1&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>56&nbsp;&times;
1&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>98&nbsp;&times;
1&nbsp;tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Read the package
leaflet before use.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Oral use.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Keep out of the
sight and reach of children.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Store in the
original package in order to protect from moisture.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Otsuka Pharmaceutical
Netherlands B.V.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Herikerbergweg 292</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>1101 CT, Amsterdam</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Netherlands</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt;color:black'>EU/1/04/276/016
<span style='background:silver'>(30&nbsp;mg, 14&nbsp;&times; 1 tablets)</span></span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt;color:black;
background:silver'>EU/1/04/276/017 (30&nbsp;mg, 28&nbsp;&times; 1 tablets)</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt;color:black;
background:silver'>EU/1/04/276/018 (30&nbsp;mg, 49&nbsp;&times; 1 tablets)</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt;color:black;
background:silver'>EU/1/04/276/019 (30&nbsp;mg, 56&nbsp;&times; 1 tablets)</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt;color:black;
background:silver'>EU/1/04/276/020 (30&nbsp;mg, 98&nbsp;&times; 1 tablets)</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Medicinal product
subject to medical prescription.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>abilify 30&nbsp;mg</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER
&#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER
- HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<b><u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;text-transform:uppercase'><br clear=all style='page-break-before:
always'>
</span></u></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>MINIMUM PARTICULARS TO APPEAR ON
BLISTERS OR STRIPS</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>&nbsp;</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>BLISTERS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY 30&nbsp;mg
tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>aripiprazole</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Otsuka</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;text-transform:uppercase'><br clear=all style='page-break-before:
always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>&nbsp;</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>OUTER CARTON</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY 10&nbsp;mg
orodispersible tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>aripiprazole</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Each tablet contains
10&nbsp;mg of aripiprazole.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Contains aspartame
and lactose. See package leaflet for further information.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>Orodispersible
tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>14&nbsp;&times; 1
orodispersible tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>28&nbsp;&times;
1 orodispersible tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>49&nbsp;&times;
1 orodispersible tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Read the package
leaflet before use.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Oral use.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'><img border=0
width=261 height=76 src="Abilify-h-471-e_files/image001.gif"></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Keep out of the
sight and reach of children.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Store in the
original package in order to protect from moisture.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Otsuka Pharmaceutical Netherlands
B.V.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Herikerbergweg 292</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>1101 CT, Amsterdam</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Netherlands</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EU/1/04/276/024 <span
style='background:silver'>(10&nbsp;mg, 14&nbsp;&times; 1 orodispersible
tablets)</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:silver'>EU/1/04/276/025
(10&nbsp;mg, 28&nbsp;&times; 1 orodispersible tablets)</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:silver'>EU/1/04/276/026
(10&nbsp;mg, 49&nbsp;&times; 1 orodispersible tablets)</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Medicinal product
subject to medical prescription.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>abilify 10&nbsp;mg</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER
&#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode carrying
the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER
- HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>MINIMUM PARTICULARS TO APPEAR ON
BLISTERS OR STRIPS</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>&nbsp;</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>BLISTERS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY&nbsp;10&nbsp;mg
orodispersible tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>aripiprazole</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Otsuka</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;text-transform:uppercase'><br clear=all style='page-break-before:
always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>&nbsp;</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>OUTER CARTON</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY 15&nbsp;mg
orodispersible tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>aripiprazole</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Each tablet contains
15&nbsp;mg of aripiprazole.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Contains aspartame
and lactose. See package leaflet for further information.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>Orodispersible
tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>14&nbsp;&times; 1
orodispersible tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>28&nbsp;&times;
1 orodispersible tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>49&nbsp;&times;
1 orodispersible tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Read the package
leaflet before use.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Oral use.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'><img border=0
width=261 height=76 src="Abilify-h-471-e_files/image001.gif"></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Keep out of the
sight and reach of children.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Store in the
original package in order to protect from moisture.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Otsuka Pharmaceutical
Netherlands B.V.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Herikerbergweg 292</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>1101 CT, Amsterdam</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Netherlands</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EU/1/04/276/027 <span
style='background:silver'>(15&nbsp;mg, 14&nbsp;&times; 1 orodispersible
tablets)</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:silver'>EU/1/04/276/028
(15&nbsp;mg, 28&nbsp;&times; 1 orodispersible tablets)</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:silver'>EU/1/04/276/029
(15&nbsp;mg, 49&nbsp;&times; 1 orodispersible tablets)</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Medicinal product
subject to medical prescription.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>abilify 15&nbsp;mg</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER
&#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER
- HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>MINIMUM PARTICULARS TO APPEAR ON BLISTERS
OR STRIPS</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>&nbsp;</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>BLISTERS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY&nbsp;15&nbsp;mg
orodispersible tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>aripiprazole</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Otsuka</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;text-transform:uppercase'><br clear=all style='page-break-before:
always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>&nbsp;</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>OUTER CARTON</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY 30&nbsp;mg
orodispersible tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>aripiprazole</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Each tablet contains
30&nbsp;mg of aripiprazole.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Contains aspartame
and lactose. See package leaflet for further information.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>Orodispersible
tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>14&nbsp;&times; 1
orodispersible tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>28&nbsp;&times;
1 orodispersible tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>49&nbsp;&times;
1 orodispersible tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Read the package
leaflet before use.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Oral use.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'><img border=0
width=261 height=76 src="Abilify-h-471-e_files/image001.gif"></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Keep out of the
sight and reach of children.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Store in the
original package in order to protect from moisture.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Otsuka Pharmaceutical
Netherlands B.V.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Herikerbergweg 292</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>1101 CT, Amsterdam</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Netherlands</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EU/1/04/276/030 <span
style='background:silver'>(30&nbsp;mg, 14&nbsp;&times; 1 orodispersible
tablets)</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:silver'>EU/1/04/276/031
(30&nbsp;mg, 28&nbsp;&times; 1 orodispersible tablets)</span></p>

<p class=MsoNormal><span lang=FR style='color:black;background:silver'>EU/1/04/276/032
(30&nbsp;mg, 49&nbsp;</span><span lang=EN-GB style='color:black;background:
silver'>&times;</span><span lang=FR style='color:black;background:silver'> 1
orodispersible tablets)</span></p>

<p class=EMEABodyText><span lang=FR style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Medicinal product
subject to medical prescription.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>abilify 30&nbsp;mg</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER
&#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER
- HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>MINIMUM PARTICULARS TO APPEAR ON BLISTERS
OR STRIPS</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>&nbsp;</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>BLISTERS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY&nbsp;30&nbsp;mg
orodispersible tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>aripiprazole</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Otsuka</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;text-transform:uppercase'><br clear=all style='page-break-before:
always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING AND THE IMMEDIATE PACKAGING</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>&nbsp;</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>OUTER CARTON AND BOTTLE LABEL</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY&nbsp;1&nbsp;mg/mL
oral solution</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>aripiprazole</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Each mL contains
1&nbsp;mg of aripiprazole.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Contains fructose,
sucrose, E218, and E216.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR style='color:black;background:silver'>Oral
solution</span></p>

<p class=EMEABodyText><span lang=FR style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR style='color:black'>50&nbsp;mL oral
solution</span></p>

<p class=EMEABodyText><span lang=FR style='color:black;background:silver'>150&nbsp;mL
oral solution</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>480&nbsp;mL
oral solution</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Read the package
leaflet before use.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Oral use.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Keep out of the
sight and reach of children.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Use within
6&nbsp;months after first opening.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>Outer
carton:</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Otsuka Pharmaceutical
Netherlands B.V.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Herikerbergweg 292</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>1101 CT, Amsterdam</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Netherlands</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR style='color:black'>EU/1/04/276/033 <span
style='background:silver'>- 50&nbsp;mL bottle</span></span></p>

<p class=EMEABodyText><span lang=FR style='color:black;background:silver'>EU/1/04/276/034
- 150&nbsp;mL bottle</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>EU/1/04/276/035
- 480&nbsp;mL bottle</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Medicinal product
subject to medical prescription.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR style='color:black;background:silver'>Outer
carton:</span><span lang=FR style='color:black'> abilify 1&nbsp;mg/mL</span></p>

<p class=MsoNormal><span lang=FR style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=FR>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER
&#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER
- HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;text-transform:uppercase'><br clear=all style='page-break-before:
always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>&nbsp;</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>OUTER CARTON</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY&nbsp;7.5&nbsp;mg/mL
solution for injection</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>aripiprazole</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Each mL contains
7.5&nbsp;mg of aripiprazole. A vial provides 9.75&nbsp;mg in 1.3&nbsp;mL.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Also contains
sulfobutylether b-cyclodextrin, tartaric acid, sodium hydroxide, and water for
injections.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>Solution
for injection</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>1&nbsp;vial</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>9.75&nbsp;mg /
1.3&nbsp;mL</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Read the package
leaflet before use.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Intramuscular use.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Keep out of the
sight and reach of children.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Keep the vial in the
outer carton in order to protect from light.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Otsuka Pharmaceutical
Netherlands B.V.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Herikerbergweg 292</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>1101 CT, Amsterdam</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Netherlands</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>EU/1/04/276/036</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Medicinal product
subject to medical prescription.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:silver'>Justification
for not including Braille accepted.</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER
&#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER
- HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;text-transform:uppercase'><br clear=all style='page-break-before:
always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>MINIMUM PARTICULARS TO APPEAR ON SMALL
IMMEDIATE PACKAGING UNITS</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>&nbsp;</span></p>

<p class=EMEATitlePAC style='page-break-after:auto'><span lang=EN-GB
style='color:black;text-transform:none'>VIAL LABEL</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY&nbsp;7.5&nbsp;mg/mL
solution for injection</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>aripiprazole</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>IM use</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
OF ADMINISTRATION</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>9.75&nbsp;mg /
1.3&nbsp;mL</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:auto'><span lang=EN-GB style='color:black;text-transform:none'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB style='color:black'>B. PACKAGE LEAFLET</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=EMEATitle style='page-break-after:auto'><span lang=EN-GB
style='color:black'>Package leaflet: Information for the user</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEATitle style='page-break-after:auto'><span lang=EN-GB
style='color:black'>ABILIFY 5&nbsp;mg tablets</span></p>

<p class=EMEATitle style='page-break-after:auto'><span lang=EN-GB
style='color:black'>ABILIFY 10&nbsp;mg tablets</span></p>

<p class=EMEATitle style='page-break-after:auto'><span lang=EN-GB
style='color:black'>ABILIFY 15&nbsp;mg tablets</span></p>

<p class=EMEATitle style='page-break-after:auto'><span lang=EN-GB
style='color:black'>ABILIFY 30&nbsp;mg tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEATitle style='page-break-after:auto'><span lang=EN-GB
style='color:black;font-weight:normal'>aripiprazole</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Read all of this
leaflet carefully before you start taking this medicine because it contains
important information for you.</span></b></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep
this leaflet. You may need to read it again.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If
you have any further questions, ask your doctor or pharmacist.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This
medicine has been prescribed for you only. Do not pass it on to others. It may harm
them, even if their signs of illness are the same as yours.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If
you get any side effects, talk to your doctor or pharmacist. This includes any
possible side effects not listed in this leaflet. See section&nbsp;4.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>What is in this
leaflet</span></b></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
ABILIFY is and what it is used for</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you
need to know before you take ABILIFY</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to take
ABILIFY</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side
effects</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store ABILIFY</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
ABILIFY is and what it is used for</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><em><span lang=EN-GB style='color:black;font-style:normal'>ABILIFY
contains the active substance aripiprazole and belong to a group of medicines
called antipsychotics.</span></em><span lang=EN-GB style='color:black'> It<b> </b>is
used to treat adults and adolescents aged 15&nbsp;years and older who suffer
from a disease characterised by symptoms such as hearing, seeing or sensing
things which are not there, suspiciousness, mistaken beliefs, incoherent speech
and behaviour and emotional flatness. People with this condition may also feel
depressed, guilty, anxious or tense.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY is used to
treat adults and adolescents aged 13&nbsp;years and older who suffer from a
condition with symptoms such as feeling &quot;high&quot;, having excessive
amounts of energy, needing much less sleep than usual, talking very quickly
with racing ideas and sometimes severe irritability. In adults it also prevents
this condition from returning in patients who have responded to the treatment
with ABILIFY.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you
need to know before you take ABILIFY</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Do not take ABILIFY</span></b></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if
you are allergic to aripiprazole or any of the other ingredients of this
medicine (listed in section&nbsp;6).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Warnings and
precautions</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Talk to your doctor
before taking ABILIFY.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>Suicidal
thoughts and behaviours have been reported during aripiprazole treatment. Tell
your doctor immediately if you are having any thoughts or feelings about
hurting yourself.</span></em></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><em><span lang=EN-GB style='font-style:normal'>Before
treatment with </span></em><span lang=EN-GB>ABILIFY<em><span style='font-style:
normal'>, tell your doctor</span></em> if you suffer from</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>high blood sugar (characterised by symptoms such as
excessive thirst, passing of large amounts of urine, increase in appetite and
feeling weak) or family history of diabetes</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>fits (seizures) since your doctor may want to monitor
you more closely</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>involuntary, irregular muscle movements, especially
in the face</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>cardiovascular diseases (diseases of the heart and
circulation), family history of cardiovascular disease, stroke or
&quot;mini&quot; stroke, abnormal blood pressure</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>blood clots, or family history of blood clots, as
antipsychotics have been associated with formation of blood clots</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>past experience with excessive gambling</span></em></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If you notice you
are gaining weight, develop unusual movements, experience somnolence that interferes
with normal daily activities, any difficulty in swallowing or allergic
symptoms, please tell your doctor.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If you are an
elderly patient suffering from dementia (loss of memory and other mental
abilities), you or your carer/relative should tell your doctor if you have ever
had a stroke or &quot;mini&quot; stroke.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Tell your doctor
immediately if you are having any thoughts or feelings about hurting yourself.
Suicidal thoughts and behaviours have been reported during aripiprazole treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Tell your doctor immediately
if you suffer from muscle stiffness or inflexibility with high fever, sweating,
altered mental status, or very rapid or irregular heartbeat.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Tell your doctor if you or your
family/carer notices that you are developing urges or cravings to behave in
ways that are unusual for you and you cannot resist the impulse, drive or
temptation to carry out certain activities that could harm yourself or others.
These are called impulse control disorders and can include behaviours such as
addictive gambling, excessive eating or spending, an abnormally high sex drive
or preoccupation with an increase in sexual thoughts or feelings.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Your doctor may need to adjust or
stop your dose.</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Aripiprazole
may cause sleepiness, fall in blood pressure when standing up, dizziness and
changes in your ability to move and balance, which may lead to falls. Caution
should be taken, particularly if you are an elderly patient or have some
debility.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Children and
adolescents</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Do not use this
medicine in children and adolescents under 13 years of age. It is not known if
it is safe and effective in these patients.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Other medicines and
ABILIFY</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Tell your doctor or
pharmacist if you are taking, have recently taken or might take any other
medicines</span><span lang=EN-GB style='color:black'>, including medicines
obtained without a prescription.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Blood
pressure-lowering medicines: ABILIFY may increase the effect of medicines used
to lower the blood pressure. Be sure to tell your doctor if you take a medicine
to keep your blood pressure under control.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>Taking </span></em><span
lang=EN-GB>ABILIFY <em><span style='font-style:normal'>with some medicines may
mean the doctor will need to change your dose of </span></em>ABILIFY<em><span
style='font-style:normal'> or the other medicines. It is especially important
to mention the following to your doctor:</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>medicines to correct heart rhythm (such as quinidine,
amiodarone, flecainide)</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>antidepressants or herbal remedy used to treat
depression and anxiety</span></em><span class=berschrift4Zchn><span
style='font-style:normal'> </span></span><span class=berschrift4Zchn><span
style='font-weight:normal'>(</span></span><em><span style='font-style:normal'>such
as fluoxetine, paroxetine, venlafaxine, St. John's Wort)</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>antifungal medicines (such as ketoconazole,
itraconazole)</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>certain medicines to treat HIV infection (such as
efavirenz, nevirapine, an protease inhibitors e.g. indinavir, ritonavir)</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>anticonvulsants used to treat epilepsy (such as </span></em><span
class=BMSHeading3Char><span style='color:windowtext;font-weight:normal'>carbamazepine,
phenytoin,</span></span><span class=BMSHeading3Char><i><span style='color:windowtext'>
</span></i></span><em><span style='font-style:normal'>phenobarbital)</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>certain antibiotics used to treat tuberculosis
(rifabutin, rifampicin)</span></em></span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>These medicines may increase the risk of
side effects or reduce the effect of ABILIFY; if you get any unusual symptom
taking any of these medicines together with ABILIFY you should see your doctor.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Medicines that increase the level of
serotonin <span class=BMSHeading3Char><span style='color:windowtext;font-weight:
normal'>are typically used in conditions including </span></span><a
href="http://en.wikipedia.org/wiki/Major_depressive_disorder"
title="Major depressive disorder"><span class=BMSHeading3Char><span
style='color:windowtext;font-weight:normal;text-decoration:none'>depression</span></span></a><span
class=BMSHeading3Char><span style='color:windowtext;font-weight:normal'>, </span></span><a
href="http://en.wikipedia.org/wiki/Generalized_anxiety_disorder"
title="Generalized anxiety disorder"><span class=BMSHeading3Char><span
style='color:windowtext;font-weight:normal;text-decoration:none'>generalised
anxiety disorder</span></span></a><span class=BMSHeading3Char><span
style='color:windowtext;font-weight:normal'>, <a name="_Hlk7774171">obsessive-compulsive
disorder </a>(OCD) and </span></span><a
href="http://en.wikipedia.org/wiki/Social_anxiety_disorder"
title="Social anxiety disorder"><span class=BMSHeading3Char><span
style='color:windowtext;font-weight:normal;text-decoration:none'>social phobia</span></span></a><span
class=BMSHeading3Char><span style='color:windowtext;font-weight:normal'> as
well as migraine and pain</span></span>:</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; triptans, tramadol
and tryptophan used for conditions including depression, generalised anxiety
disorder, obsessive compulsive disorder (OCD) and social phobia as well as
migraine and pain</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; selective-serotonin-reuptake-inhibitors
(SSRIs) (such as paroxetine and fluoxetine) used for depression, OCD, panic and
anxiety</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other
anti-depressants (such as venlafaxine and tryptophan) used in major depression</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tricyclic&#8217;s
(such as clomipramine and amitriptyline) used for depressive illness</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St John&#8217;s
Wort (<i>Hypericum perforatum</i>) used as a herbal remedy for mild depression</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain killers (such
as tramadol and pethidine) used for pain relief</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; triptans (such as
sumatriptan and zolmitripitan) used for treating migraine</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>&nbsp;</span></em></p>

<p class=EMEABodyText><span lang=EN-GB>These medicines may increase the risk of
side effects; if you get any unusual symptom taking any of these medicines
together with ABILIFY, you should see your doctor.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>ABILIFY with food,
drink and alcohol</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>This medicine can be
taken regardless of meals.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Alcohol should be
avoided.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Pregnancy,
breast-feeding and fertility</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If you are pregnant
or breast-feeding, think you may be pregnant or are planning to have a baby,
ask your doctor for advice before taking this medicine.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The following
symptoms may occur in newborn babies, of mothers that have used ABILIFY in the
last trimester (last three months of their pregnancy): shaking, muscle stiffness
and/or weakness, sleepiness, agitation, breathing problems, and difficulty in
feeding. If your baby develops any of these symptoms you may need to contact
your doctor.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>If you are
taking </span></em><span lang=EN-GB>ABILIFY<em><span style='font-style:normal'>,
your doctor will discuss with you whether you should breast&#8209;feed
considering the benefit to you of your therapy and the benefit to your baby of
breast&#8209;feeding. You should not do both. Talk to your doctor about the
best way to feed your baby if you are taking </span></em>this medicine<em><span
style='font-style:normal'>.</span></em></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Driving and using
machines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Dizziness and vision problems may occur
during treatment with this medicine (see section&nbsp;4).</span></p>

<p class=MsoNormal><span lang=EN-GB>This should be considered in cases where
full alertness is required, e.g. when driving a car or handling machines.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>ABILIFY contains
lactose</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If you have been
told by your doctor that you have an intolerance to some sugars, contact your
doctor before taking this medicine.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to
take ABILIFY</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Always take this
medicine exactly as your doctor or pharmacist has told you. Check with your
doctor or pharmacist if you are not sure.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB style='color:black;layout-grid-mode:
line'>The recommended dose for adults is 15&nbsp;mg once a day.</span></b><span
lang=EN-GB style='color:black;layout-grid-mode:line'> </span><span lang=EN-GB
style='color:black'>However<span style='layout-grid-mode:line'> your doctor may
prescribe a lower or higher dose to a maximum of 30&nbsp;mg once a day.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Use in children and
adolescents</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>This medicinal
product may be started at a low dose with the oral solution (liquid) form.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The dose may be
gradually increased to<b> the recommended dose for adolescents of 10&nbsp;mg
once a day</b>. However your doctor may prescribe a lower or higher dose to a
maximum of 30&nbsp;mg once a day.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If you have the
impression that the effect of ABILIFY is too strong or too weak, talk to your
doctor or pharmacist.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB style='color:black'>Try to take ABILIFY
at the same time each day.</span></b><span lang=EN-GB style='color:black'> It
does not matter whether you take it with or without food. Always take the
tablet with water and swallow it whole.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB style='color:black'>Even if you feel
better,</span></b><span lang=EN-GB style='color:black'> do not alter or
discontinue the daily dose of ABILIFY without first consulting your doctor.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>If you take more
ABILIFY than you should</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If you realise you
have taken more ABILIFY than your doctor has recommended (or if someone else
has taken some of your ABILIFY), contact your doctor right away. If you cannot
reach your doctor, go to the nearest hospital and take the pack with you.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>Patients who
have taken too much aripiprazole have experienced the following symptoms:</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>rapid heartbeat, agitation/aggressiveness, problems
with speech.</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>unusual movements (especially of the face or tongue)
and reduced level of consciousness.</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>Other
symptoms may include:</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>acute confusion, seizures (epilepsy), coma, a
combination of fever, faster breathing, sweating,</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>muscle stiffness, and drowsiness or sleepiness,
slower breathing, choking, high or low blood pressure, abnormal rhythms of the
heart.</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>Contact your
doctor or hospital immediately if you experience any of the above.</span></em></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>If you forget to
take ABILIFY</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If you miss a dose,
take the missed dose as soon as you remember but do not take two doses in one
day.</span></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></b></em></p>

<p class=MsoNormal><em><b><span lang=EN-GB style='color:black;font-style:normal'>If
you stop taking </span></b></em><b><span lang=EN-GB style='color:black'>ABILIFY</span></b></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Do
not stop your treatment just because you feel better. It is important that you
carry on taking </span></em><span lang=EN-GB style='color:black'>ABILIFY<em><span
style='font-style:normal'> for as long as your doctor has told you to.</span></em></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If you have any
further questions on the use of this medicine, ask your doctor or pharmacist.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></b></p>

<p class=EMEAHeading1 style='margin-left:0in;text-indent:0in;page-break-after:
auto'><span lang=EN-GB style='color:black;font-weight:normal'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Like all medicines,
this medicine can cause side effects, although not everybody gets them.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
style='color:black;font-style:normal'>Common side effects (may affect up to 1
in 10&nbsp;people):</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB>diabetes mellitus,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>difficulty sleeping,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>feeling anxious,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>feeling restless and unable to keep still,
difficulty sitting still,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>akathisia (an uncomfortable feeling of inner
restlessness and a compelling need to move constantly),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>uncontrollable twitching, jerking or writhing
movements,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>trembling,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>headache,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>tiredness,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleepiness,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>light-headedness,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>shaking and blurred vision,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased
number of or difficulty making bowel movements,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; indigestion,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling
sick,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>more saliva in mouth than normal,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>vomiting,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling
tired.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Uncommon
side effects (may affect up to 1 in 100&nbsp;people):</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased
blood levels of the hormone prolactin</span></em><em><span lang=EN-GB
style='color:black;font-style:normal'>,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; too
much sugar in the blood,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>depression,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>altered or increased sexual
interest</span></em><em><span lang=EN-GB style='color:black;font-style:normal'>,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><span
lang=EN-GB>uncontrollable movements of mouth, tongue and limbs (tardive
dyskinesia),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle
disorder causing twisting movements (dystonia),</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><span
lang=EN-GB style='color:black'>restless legs,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; double
vision</span></em><em><span lang=EN-GB style='color:black;font-style:normal'>,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eye
sensitivity to light,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast
heart</span></em><em><span lang=EN-GB style='color:black;font-style:normal'>beat,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a
fall in blood pressure on standing up which causes dizziness, light-headedness
or fainting,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hiccups</span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>The
following side effects have been reported since the marketing of oral
aripiprazole but the frequency for them to occur is not known:</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>low levels of white blood
cells,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low
levels of blood platelets,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>allergic reaction (e.g.
swelling in the mouth, tongue, face and throat, itching, hives),</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; onset
or worsening of diabetes, ketoacidosis (ketones in the blood and urine) or
coma,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high
blood sugar,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; not
enough sodium in the blood,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss
of appetite (anorexia),</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight
loss,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight
gain,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thoughts
of suicide, suicide attempt and suicide,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling
aggressive,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; agitation,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nervousness,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; combination
of fever, muscle stiffness, faster breathing, sweating, reduced consciousness
and sudden changes in blood pressure and heart rate, fainting (neuroleptic
malignant syndrome),</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seizure,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serotonin
syndrome (a reaction which may cause feelings of great happiness, drowsiness,
clumsiness, restlessness, feeling of being drunk, fever, sweating or rigid
muscles),</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; speech
disorder,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><span
lang=EN-GB style='color:black'>fixation of the eyeballs in one position,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><span
lang=EN-GB>sudden unexplained death,</span></p>

<p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><span
lang=EN-GB style='color:black'>life-threatening irregular heartbeat,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart
attack,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; slower
heartbeat,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>blood clots in the veins
especially in the legs (symptoms include swelling, pain and redness in the
leg), which may travel through blood vessels to the lungs causing chest pain
and difficulty in breathing (if you notice any of these symptoms, seek medical
advice immediately),</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high
blood pressure,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; accidental
inhalation of food with risk of pneumonia (lung infection),</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>spasm of the muscles around
the voice box,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>inflammation of the pancreas,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>difficulty swallowing,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal
discomfort,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach
discomfort,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver
failure,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation
of the liver,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellowing
of the skin and white part of eyes,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reports
of abnormal liver tests values,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>skin rash,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin
sensitivity to light,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; baldness,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; excessive
sweating,</span></em></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;text-autospace:
none'><span lang=EN-GB>&#8226;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>serious allergic reactions such as Drug Reaction
with Eosinophilia and Systemic Symptoms (DRESS). DRESS appears initially as
flu-like symptoms with a rash on the face and then with an extended rash, high
temperature, enlarged lymph nodes, increased levels of liver enzymes seen in
blood tests and an increase in a type of white blood cell (eosinophilia),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal
muscle breakdown which can lead to kidney problems,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle
pain,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stiffness,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>involuntary loss of urine
(incontinence),</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty
in passing urine,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; withdrawal
symptoms in newborn babies in case of exposure during pregnancy,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>prolonged and/or painful
erection,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>difficulty controlling core
body temperature or overheating,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>chest pain,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling
of hands, ankles or feet,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in
blood tests: increased or fluctuating blood sugar, increased </span></em><span
lang=EN-GB>glycosylated haemoglobin.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><span
lang=EN-GB style='color:black'>Inability to resist the impulse, drive or
temptation to perform an action that could be harmful to you or others, which
may include:</span></p>

<p class=EMEABodyText style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; strong
impulse to gamble excessively despite serious personal or family consequences</span></p>

<p class=EMEABodyText style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; altered
or increased sexual interest and behaviour of significant concern to you or to
others, for example, an increased sexual drive</span></p>

<p class=EMEABodyText style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; uncontrollable
excessive shopping</span></p>

<p class=EMEABodyText style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; binge
eating (eating large amounts of food in a short time period) or compulsive
eating (eating more food than normal and more than is needed to satisfy your
hunger)</span></p>

<p class=EMEABodyText style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB>a tendency to wander away.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt'><span lang=EN-GB
style='color:black'>Tell your doctor if you experience any of these behaviours;
he/she will discuss ways of managing or reducing the symptoms.</span></p>

<p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
style='color:black'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>In elderly patients
with dementia, more fatal cases have been reported while taking aripiprazole.
In addition, cases of stroke or &quot;mini&quot; stroke have been reported.</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Additional side
effects in children and adolescents</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Adolescents aged
13&nbsp;years and older experienced side effects that were similar in frequency
and type to those in adults except that sleepiness, uncontrollable twitching or
jerking movements, restlessness, and tiredness were very common (greater than
1&nbsp;in 10&nbsp;patients) and upper abdominal pain, dry mouth, increased
heart rate, weight gain, increased appetite, muscle twitching, uncontrolled
movements of the limbs, and feeling dizzy, especially when getting up from a
lying or sitting position, were common (greater than 1&nbsp;in
100&nbsp;patients).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Reporting of side
effects</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If you get any side
effects, talk to your doctor or pharmacist. This includes any possible side
effects not listed in this leaflet. You can also report side effects directly
via <span style='background:silver'>the national reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a></span>. By reporting side effects you can help provide more information
on the safety of this medicine.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to
store ABILIFY</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Keep this medicine
out of the sight and reach of children.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Do not use this medicine
after the expiry date which is stated on the blister and on the carton after
EXP. The expiry date refers to the last day of that month.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Store in the
original package in order to protect from moisture.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Do not throw away
any medicines via wastewater or household waste. Ask your pharmacist how to
throw away medicines you no longer use. These measures will help protect the
environment.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>What ABILIFY contains</span></b></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The
active substance is aripiprazole.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each
tablet contains 5&nbsp;mg of aripiprazole.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each
tablet contains 10&nbsp;mg of aripiprazole.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each
tablet contains 15&nbsp;mg of aripiprazole.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each
tablet contains 30&nbsp;mg of aripiprazole.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The
other ingredients are lactose monohydrate, maize starch, microcrystalline
cellulose, hydroxypropylcellulose</span><span lang=EN-GB style='color:black'>
and</span><span lang=EN-GB style='color:black'> magnesium stearate.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt'><u><span lang=NO-BOK
style='color:black'>Tablet coat</span></u></p>

<p class=EMEABodyText style='margin-left:28.35pt'><span lang=NO-BOK
style='color:black'>ABILIFY 5&nbsp;mg tablets:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Indigo
carmine aluminium lake (E&nbsp;132)</span></p>

<p class=EMEABodyText style='margin-left:28.35pt'><span lang=ES
style='color:black'>ABILIFY 10&nbsp;mg tablets:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Red
iron oxide&nbsp;(E&nbsp;172)</span></p>

<p class=EMEABodyText style='margin-left:28.35pt'><span lang=EN-GB
style='color:black'>ABILIFY 15&nbsp;mg tablets:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yellow
iron oxide&nbsp;(E&nbsp;172)</span></p>

<p class=EMEABodyText style='margin-left:28.35pt'><span lang=ES
style='color:black'>ABILIFY 30&nbsp;mg tablets:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Red
iron oxide&nbsp;(E&nbsp;172)</span></p>

<p class=EMEABodyText><span lang=ES style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>What ABILIFY looks
like and contents of the pack</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY&nbsp;5&nbsp;mg
tablets are rectangular and blue, marked with &#8216;A-007&#8217; and
&#8216;5&#8217; on one side.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY&nbsp;10&nbsp;mg
tablets are rectangular and pink, marked with &#8216;A-008&#8217; and
&#8216;10&#8217; on one side.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY&nbsp;15&nbsp;mg
tablets are round and yellow, marked with &#8216;A-009&#8217; and
&#8216;15&#8217; on one side.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY&nbsp;30&nbsp;mg
tablets are round and pink, marked with &#8216;A-011&#8217; and
&#8216;30&#8217; on one side.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY tablets are supplied
in perforated unit dose blisters packed in cartons containing 14&nbsp;&times;&nbsp;1,
28&nbsp;&times;&nbsp;1, 49&nbsp;&times;&nbsp;1, 56&nbsp;&times;&nbsp;1, or 98&nbsp;&times;&nbsp;1
tablets.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Not all pack sizes
may be marketed.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>Marketing Authorisation Holder</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Otsuka Pharmaceutical
Netherlands B.V.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Herikerbergweg 292</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>1101 CT, Amsterdam</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Netherlands</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Manufacturer</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Elaiapharm</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>2881 Route des
Cr&ecirc;tes, Z.I. Les Bouilides-Sophia Antipolis,</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>06560 Valbonne</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>France</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>For any information
about this medicine, please contact the local representative of the Marketing
Authorisation Holder:</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=614
 style='border-collapse:collapse'>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><a name="_Hlk12953200"><b><span lang=EN-GB>Belgi&euml;/Belgique/Belgien</span></b></a></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=DE>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=DE>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#268;esk&aacute; republika</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Magyarorsz&aacute;g</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Danmark</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharma Scandinavia AB</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tlf: +46&nbsp;(0)&nbsp;8&nbsp;545&nbsp;286&nbsp;60</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Malta</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=DE>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=DE>Otsuka Pharma GmbH</span></p>
  <p class=MsoNormal><span lang=DE>Tel: +49&nbsp;(0)&nbsp;69&nbsp;1700&nbsp;860</span></p>
  <p class=MsoNormal><span lang=DE>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Nederland</span></b></p>
  <p class=MsoNormal><span lang=ES>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Eesti</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Norge</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharma Scandinavia AB</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tlf: +46&nbsp;(0)&nbsp;8&nbsp;545&nbsp;286&nbsp;60</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&Ouml;sterreich</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=ES>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal><span lang=ES>Otsuka Pharmaceutical</span><span lang=ES>,
  S.A.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +34 93 550 01 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Polska</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=FR>France</span></b></p>
  <p class=MsoNormal><span lang=FR>Otsuka Pharmaceutical France SAS</span></p>
  <p class=MsoNormal><span lang=FR>T&eacute;l: +33 (0)1 47 08 00 00</span></p>
  <p class=MsoNormal><b><span lang=FR>&nbsp;</span></b></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=PT>Portugal</span></b></p>
  <p class=MsoNormal><span lang=PT>Lundbeck Portugal Lda</span></p>
  <p class=MsoNormal><span lang=PT>Tel: +351 (0) 21 00 45 900</span></p>
  <p class=MsoNormal><span lang=PT>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=PT>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=PT>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=PT>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=PT>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=PT>Rom&acirc;nia</span></b></p>
  <p class=MsoNormal><span lang=PT>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=PT>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&Iacute;sland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Vistor hf.</span></p>
  <p class=MsoNormal><span lang=EN-GB>S&iacute;mi: +354 (0) 535 7000</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Slovensk&aacute; republika</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Italia</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Italy S.r.l.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +39 (0) 2 0063 2710</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=IT>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=IT>Otsuka Pharma Scandinavia AB</span></p>
  <p class=MsoNormal><span lang=EN-GB>Puh/Tel: +46&nbsp;(0)&nbsp;8&nbsp;545&nbsp;286&nbsp;60</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Sverige</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharma Scandinavia AB</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +46&nbsp;(0)&nbsp;8&nbsp;545&nbsp;286&nbsp;60</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Latvija</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>United Kingdom</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceuticals (UK) Ltd.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +44 (0) 203 747 5300</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black;font-weight:normal'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>This leaflet was
last revised in {MM/YYYY}</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='color:black'>Other sources of information</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=EMEABodyText style='page-break-after:avoid'><em><span lang=EN-GB
style='color:black;font-style:normal'>Detailed information on this medicine is
available on the European Medicines Agency web site: </span></em><span
lang=EN-GB style='color:black'><a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a><em><span
style='font-style:normal'>.</span></em></span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=EMEABodyText align=center style='text-align:center'><b><span
lang=EN-GB style='color:black'>Package leaflet: Information for the user</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEATitle style='page-break-after:auto'><span lang=EN-GB
style='color:black'>ABILIFY 10&nbsp;mg orodispersible tablets</span></p>

<p class=EMEATitle style='page-break-after:auto'><span lang=EN-GB
style='color:black'>ABILIFY 15&nbsp;mg orodispersible tablets</span></p>

<p class=EMEATitle style='page-break-after:auto'><span lang=EN-GB
style='color:black'>ABILIFY 30&nbsp;mg orodispersible tablets</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEATitle style='page-break-after:auto'><span lang=EN-GB
style='color:black;font-weight:normal'>aripiprazole</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Read all of this
leaflet carefully before you start taking this medicine because it contains
important information for you.</span></b></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep
this leaflet. You may need to read it again.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If
you have any further questions, ask your doctor or pharmacist.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This
medicine has been prescribed for you only. Do not pass it on to others. It may
harm them, even if their signs of illness are the same as yours.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If
you get any side effects, talk to your doctor or pharmacist. This includes any
possible side effects not listed in this leaflet. See section&nbsp;4.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>What is in this
leaflet</span></b></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
ABILIFY is and what it is used for</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you
need to know before you take ABILIFY</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to
take ABILIFY</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store ABILIFY</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
ABILIFY is and what it is used for</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><em><span lang=EN-GB style='color:black;font-style:normal'>ABILIFY
contains the active substance aripiprazole and belong to a group of medicines
called antipsychotics.</span></em><span lang=EN-GB style='color:black'> It<b> </b>is
used to treat adults and adolescents aged 15&nbsp;years and older who suffer
from a disease characterised by symptoms such as hearing, seeing or sensing
things which are not there, suspiciousness, mistaken beliefs, incoherent speech
and behaviour and emotional flatness. People with this condition may also feel
depressed, guilty, anxious or tense.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY is used to
treat adults and adolescents aged 13&nbsp;years and older who suffer from a
condition with symptoms such as feeling &quot;high&quot;, having excessive
amounts of energy, needing much less sleep than usual, talking very quickly
with racing ideas and sometimes severe irritability. In adults it also prevents
this condition from returning in patients who have responded to the treatment
with ABILIFY.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you
need to know before you take ABILIFY</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Do not take ABILIFY</span></b></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if
you are allergic to aripiprazole or any of the other ingredients of this
medicine (listed in section&nbsp;6).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Warnings and
precautions</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Talk to your doctor
before taking ABILIFY.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>Suicidal
thoughts and behaviours have been reported during aripiprazole treatment. Tell
your doctor immediately if you are having any thoughts or feelings about hurting
yourself.</span></em></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><em><span lang=EN-GB style='font-style:normal'>Before
treatment with </span></em><span lang=EN-GB>ABILIFY<em><span style='font-style:
normal'>, tell your doctor</span></em> if you suffer from</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>high blood sugar (characterised by symptoms such as
excessive thirst, passing of large amounts of urine, increase in appetite and
feeling weak) or family history of diabetes</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>fits (seizures) since your doctor may want to monitor
you more closely</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>involuntary, irregular muscle movements, especially
in the face</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>cardiovascular diseases (diseases of the heart and
circulation), family history of cardiovascular disease, stroke or
&quot;mini&quot; stroke, abnormal blood pressure</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>blood clots, or family history of blood clots, as
antipsychotics have been associated with formation of blood clots</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>past experience with excessive gambling</span></em></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If you notice you
are gaining weight, develop unusual movements, experience somnolence that
interferes with normal daily activities, any difficulty in swallowing or
allergic symptoms, please tell your doctor.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If you are an
elderly patient suffering from dementia (loss of memory and other mental
abilities), you or your carer/relative should tell your doctor if you have ever
had a stroke or &quot;mini&quot; stroke.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Tell your doctor
immediately if you are having any thoughts or feelings about hurting yourself.
Suicidal thoughts and behaviours have been reported during aripiprazole
treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Tell your doctor
immediately if you suffer from muscle stiffness or inflexibility with high
fever, sweating, altered mental status, or very rapid or irregular heartbeat.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Tell your doctor if you or your
family/carer notices that you are developing urges or cravings to behave in
ways that are unusual for you and you cannot resist the impulse, drive or
temptation to carry out certain activities that could harm yourself or others.
These are called impulse control disorders and can include behaviours such as addictive
gambling, excessive eating or spending, an abnormally high sex drive or
preoccupation with an increase in sexual thoughts or feelings.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Your doctor may need to adjust or
stop your dose.</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Aripiprazole
may cause sleepiness, fall in blood pressure when standing up, dizziness and
changes in your ability to move and balance, which may lead to falls. Caution
should be taken, particularly if you are an elderly patient or have some
debility.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Children and
adolescents</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Do not use this medicine
in children and adolescents under 13 years of age. It is not known if it is
safe and effective in these patients</span><span lang=EN-GB style='color:black'>.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Other medicines and
ABILIFY</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Tell your doctor or
pharmacist if you are taking, have recently taken or might take any other medicines</span><span
lang=EN-GB style='color:black'>, including medicines obtained without a
prescription.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Blood
pressure-lowering medicines: ABILIFY may increase the effect of medicines used
to lower the blood pressure. Be sure to tell your doctor if you take a medicine
to keep your blood pressure under control.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>Taking </span></em><span
lang=EN-GB>ABILIFY<em><span style='font-style:normal'> with some medicines may
mean the doctor will need to change your dose of </span></em>ABILIFY<em><span
style='font-style:normal'> or the other medicines. It is especially important
to mention the following to your doctor:</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>medicines to correct heart rhythm (such as quinidine,
amiodarone, flecainide)</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>antidepressants or herbal remedy used to treat
depression and anxiety</span></em><span class=berschrift4Zchn><span
style='font-style:normal'> </span></span><span class=berschrift4Zchn><span
style='font-weight:normal;font-style:normal'>(</span></span><em><span
style='font-style:normal'>such as fluoxetine, paroxetine, venlafaxine, St.
John's Wort)</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>antifungal medicines (such as ketoconazole,
itraconazole)</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>certain medicines to treat HIV infection (such as
efavirenz, nevirapine, an protease inhibitors e.g. indinavir, ritonavir)</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>anticonvulsants used to treat epilepsy (such as </span></em><span
class=BMSHeading3Char><span style='color:windowtext;font-weight:normal'>carbamazepine,
phenytoin,</span></span><span class=BMSHeading3Char><i><span style='color:windowtext'>
</span></i></span><em><span style='font-style:normal'>phenobarbital)</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>certain antibiotics used to treat tuberculosis
(rifabutin, rifampicin)</span></em></span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>These medicines may increase the risk of
side effects or reduce the effect of ABILIFY; if you get any unusual symptom
taking any of these medicines together with ABILIFY you should see your doctor.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Medicines that increase the level of
serotonin <span class=BMSHeading3Char><span style='color:windowtext;font-weight:
normal'>are typically used in conditions including </span></span><a
href="http://en.wikipedia.org/wiki/Major_depressive_disorder"
title="Major depressive disorder"><span class=BMSHeading3Char><span
style='color:windowtext;font-weight:normal;text-decoration:none'>depression</span></span></a><span
class=BMSHeading3Char><span style='color:windowtext;font-weight:normal'>, </span></span><a
href="http://en.wikipedia.org/wiki/Generalized_anxiety_disorder"
title="Generalized anxiety disorder"><span class=BMSHeading3Char><span
style='color:windowtext;font-weight:normal;text-decoration:none'>generalised
anxiety disorder</span></span></a><span class=BMSHeading3Char><span
style='color:windowtext;font-weight:normal'>, obsessive-compulsive disorder (OCD)
and </span></span><a href="http://en.wikipedia.org/wiki/Social_anxiety_disorder"
title="Social anxiety disorder"><span class=BMSHeading3Char><span
style='color:windowtext;font-weight:normal;text-decoration:none'>social phobia</span></span></a><span
class=BMSHeading3Char><span style='color:windowtext;font-weight:normal'> as
well as migraine and pain</span></span>:</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; triptans, tramadol
and tryptophan used for conditions including depression, generalised anxiety
disorder, obsessive compulsive disorder (OCD) and social phobia as well as
migraine and pain</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; selective-serotonin-reuptake-inhibitors
(SSRIs) (such as paroxetine and fluoxetine) used for depression, OCD, panic and
anxiety</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other
anti-depressants (such as venlafaxine and tryptophan) used in major depression</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tricyclic&#8217;s
(such as clomipramine and amitriptyline) used for depressive illness</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St John&#8217;s
Wort (<i>Hypericum perforatum</i>) used as a herbal remedy for mild depression</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain killers (such
as tramadol and pethidine) used for pain relief</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; triptans (such as
sumatriptan and zolmitripitan) used for treating migraine</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>&nbsp;</span></em></p>

<p class=EMEABodyText><span lang=EN-GB>These medicines may increase the risk of
side effects; if you get any unusual symptom taking any of these medicines
together with ABILIFY, you should see your doctor.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>ABILIFY with food,
drink and alcohol</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>This medicine can be
taken regardless of meals.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Alcohol should be
avoided.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Pregnancy,
breast-feeding and fertility</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If you are pregnant
or breast-feeding, think you may be pregnant or are planning to have a baby,
ask your doctor for advice before taking this medicine.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The following symptoms
may occur in newborn babies, of mothers that have used ABILIFY in the last
trimester (last three months of their pregnancy): shaking, muscle stiffness
and/or weakness, sleepiness, agitation, breathing problems, and difficulty in
feeding. If your baby develops any of these symptoms you may need to contact
your doctor.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>If you are
taking </span></em><span lang=EN-GB>ABILIFY<em><span style='font-style:normal'>,
your doctor will discuss with you whether you should breast&#8209;feed considering
the benefit to you of your therapy and the benefit to your baby of breast&#8209;feeding.
You should not do both. Talk to your doctor about the best way to feed your
baby if you are taking </span></em>this medicine<em><span style='font-style:
normal'>.</span></em></span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Driving and using
machines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Dizziness and vision problems may occur
during treatment with this medicine (see section 4).</span></p>

<p class=MsoNormal><span lang=EN-GB>This should be considered in cases where
full alertness is required, e.g., when driving a car or handling machines.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>ABILIFY contains
aspartame</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY 10 mg
orodispersible tablets: This medicine contains 2&nbsp;mg aspartame in each
tablet.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY 15 mg
orodispersible tablets: This medicine contains 3&nbsp;mg aspartame in each
tablet.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY 30 mg
orodispersible tablets: This medicine contains 6&nbsp;mg aspartame in each
tablet.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Aspartame is a
source of phenylalanine. <b>It may be harmful if you have phenylketonuria (PKU)</b>,
a rare genetic disorder in which phenylalanine builds up because the body
cannot remove it properly.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>ABILIFY contains
lactose</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If you have been
told by your doctor that you have an intolerance to some sugars, contact your
doctor before taking this medicine.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB style='color:black'>ABILIFY contains sodium</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>This medicine
contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per tablet, that is to say
essentially &#8216;sodium-free&#8217;.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to
take ABILIFY</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Always take this
medicine exactly as your doctor or pharmacist has told you. Check with your
doctor or pharmacist if you are not sure.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB style='color:black'>The<span
style='layout-grid-mode:line'> recommended dose for adults is 15&nbsp;mg once a
day.</span></span></b><span lang=EN-GB style='color:black;layout-grid-mode:
line'> However your doctor may prescribe a lower or higher dose to a maximum of
30&nbsp;mg once a day.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Use in children and
adolescents</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>This medicinal
product may be started at a low dose with the oral solution (liquid) form.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The dose may be
gradually increased to <b>the recommended dose for adolescents of 10&nbsp;mg
once a day</b>. However your doctor may prescribe a lower or higher dose to a
maximum of 30&nbsp;mg once a day.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If you have the
impression that the effect of ABILIFY is too strong or too weak, talk to your
doctor or pharmacist.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB style='color:black'>Try to take
ABILIFY at the same time each day.</span></b><span lang=EN-GB style='color:
black'> It does not matter whether you take it with or without food.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Do not open the
blister until ready to administer. For single tablet removal, open the package
and peel back the foil on the blister to expose the tablet. Do not push the
tablet through the foil because this could damage the tablet. Immediately upon
opening the blister, using dry hands, remove the tablet and place the entire
orodispersible tablet on the tongue. Tablet disintegration occurs rapidly in
saliva. The orodispersible tablet can be taken with or without liquid.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Alternatively,
disperse the tablet in water and drink the resulting suspension.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB style='color:black'>Even if you feel
better,</span></b><span lang=EN-GB style='color:black'> do not alter or
discontinue the daily dose of ABILIFY without first consulting your doctor.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>If you take more
ABILIFY than you should</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If you realise you
have taken more ABILIFY than your doctor has recommended (or if someone else
has taken some of your ABILIFY), contact your doctor right away. If you cannot
reach your doctor, go to the nearest hospital and take the pack with you.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>Patients who
have taken too much aripiprazole have experienced the following symptoms:</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>rapid heartbeat, agitation/aggressiveness, problems
with speech.</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>unusual movements (especially of the face or tongue)
and reduced level of consciousness.</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>Other
symptoms may include:</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>acute confusion, seizures (epilepsy), coma, a
combination of fever, faster breathing, sweating,</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>muscle stiffness, and drowsiness or sleepiness,
slower breathing, choking, high or low blood pressure, abnormal rhythms of the
heart.</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>Contact your
doctor or hospital immediately if you experience any of the above.</span></em></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>If you forget to
take ABILIFY</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If you miss a dose,
take the missed dose as soon as you remember but do not take two doses in one
day.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><em><b><span lang=EN-GB style='color:black;font-style:
normal'>If you stop taking </span></b></em><b><span lang=EN-GB
style='color:black'>ABILIFY</span></b></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Do
not stop your treatment just because you feel better. It is important that you
carry on taking </span></em><span lang=EN-GB style='color:black'>ABILIFY <em><span
style='font-style:normal'>for as long as your doctor has told you to.</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If you have any
further questions on the use of this medicine, ask your doctor or pharmacist.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Like all medicines,
this medicine can cause side effects, although not everybody gets them.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
style='color:black;font-style:normal'>Common side effects (may affect up to 1
in 10&nbsp;people):</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB>diabetes mellitus,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>difficulty sleeping,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>feeling anxious,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>feeling restless and unable to keep still,
difficulty sitting still,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>akathisia (an uncomfortable feeling of inner
restlessness and a compelling need to move constantly),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>uncontrollable twitching, jerking or writhing
movements,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>trembling,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>headache,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>tiredness,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleepiness,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>light-headedness,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>shaking and blurred vision,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased
number of or difficulty making bowel movements,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; indigestion,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling
sick,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>more saliva in mouth than normal,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>vomiting,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling
tired.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Uncommon
side effects (may affect up to 1 in 100&nbsp;people):</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased
blood levels of the hormone prolactin</span></em><em><span lang=EN-GB
style='color:black;font-style:normal'>,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; too
much sugar in the blood,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>depression,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>altered or increased sexual
interest</span></em><em><span lang=EN-GB style='color:black;font-style:normal'>,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><span
lang=EN-GB>uncontrollable movements of mouth, tongue and limbs (tardive
dyskinesia),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle
disorder causing twisting movements (dystonia),</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>restless legs,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; double
vision</span></em><em><span lang=EN-GB style='color:black;font-style:normal'>,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eye
sensitivity to light,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast
heart</span></em><em><span lang=EN-GB style='color:black;font-style:normal'>beat,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a
fall in blood pressure on standing up which causes dizziness, light-headedness
or fainting,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hiccups</span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>The
following side effects have been reported since the marketing of oral
aripiprazole but the frequency for them to occur is not known:</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>low levels of white blood
cells,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low
levels of blood platelets,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>allergic reaction (e.g.
swelling in the mouth, tongue, face and throat, itching, hives),</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; onset
or worsening of diabetes, ketoacidosis (ketones in the blood and urine) or
coma,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high
blood sugar,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; not
enough sodium in the blood,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss
of appetite (anorexia),</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight
loss,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight
gain,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thoughts
of suicide, suicide attempt and suicide,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling
aggressive,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; agitation,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nervousness,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; combination
of fever, muscle stiffness, faster breathing, sweating, reduced consciousness
and sudden changes in blood pressure and heart rate, fainting (neuroleptic
malignant syndrome),</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seizure,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serotonin
syndrome (a reaction which may cause feelings of great happiness, drowsiness,
clumsiness, restlessness, feeling of being drunk, fever, sweating or rigid
muscles),</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; speech
disorder,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><span
lang=EN-GB style='color:black'>fixation of the eyeballs in one position,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><span
lang=EN-GB>sudden unexplained death,</span></p>

<p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><span
lang=EN-GB style='color:black'>life-threatening irregular heartbeat,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart
attack,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; slower
heartbeat,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>blood clots in the veins
especially in the legs (symptoms include swelling, pain and redness in the
leg), which may travel through blood vessels to the lungs causing chest pain
and difficulty in breathing (if you notice any of these symptoms, seek medical
advice immediately),</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high
blood pressure,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; accidental
inhalation of food with risk of pneumonia (lung infection),</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>spasm of the muscles around
the voice box,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>inflammation of the pancreas,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>difficulty swallowing,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal
discomfort,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach
discomfort,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver
failure,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation
of the liver,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellowing
of the skin and white part of eyes,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reports
of abnormal liver tests values,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>skin rash,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin
sensitivity to light,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; baldness,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; excessive
sweating,</span></em></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;text-autospace:
none'><span lang=EN-GB>&#8226;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>serious allergic reactions such as Drug Reaction
with Eosinophilia and Systemic Symptoms (DRESS). DRESS appears initially as
flu-like symptoms with a rash on the face and then with an extended rash, high
temperature, enlarged lymph nodes, increased levels of liver enzymes seen in
blood tests and an increase in a type of white blood cell (eosinophilia),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal
muscle breakdown which can lead to kidney problems,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle
pain,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stiffness,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>involuntary loss of urine
(incontinence),</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty
in passing urine,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; withdrawal
symptoms in newborn babies in case of exposure during pregnancy,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>prolonged and/or painful
erection,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>difficulty controlling core
body temperature or overheating,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>chest pain,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling
of hands, ankles or feet,</span></em></p>

<p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in
blood tests: increased or fluctuating blood sugar, increased </span></em><span
lang=EN-GB>glycosylated haemoglobin.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><span
lang=EN-GB style='color:black'>Inability to resist the impulse, drive or
temptation to perform an action that could be harmful to you or others, which
may include:</span></p>

<p class=EMEABodyText style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; strong
impulse to gamble excessively despite serious personal or family consequences</span></p>

<p class=EMEABodyText style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; altered
or increased sexual interest and behaviour of significant concern to you or to
others, for example, an increased sexual drive</span></p>

<p class=EMEABodyText style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; uncontrollable
excessive shopping</span></p>

<p class=EMEABodyText style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; binge
eating (eating large amounts of food in a short time period) or compulsive
eating (eating more food than normal and more than is needed to satisfy your
hunger)</span></p>

<p class=EMEABodyText style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB>a tendency to wander away.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt'><span lang=EN-GB
style='color:black'>Tell your doctor if you experience any of these behaviours;
he/she will discuss ways of managing or reducing the symptoms.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In elderly patients
with dementia, more fatal cases have been reported while taking aripiprazole.
In addition, cases of stroke or &quot;mini&quot; stroke have been reported.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Additional side
effects in children and adolescents</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Adolescents aged
13&nbsp;years and older experienced side effects that were similar in frequency
and type to those in adults except that sleepiness, uncontrollable twitching or
jerking movements, restlessness, and tiredness were very common (greater than
1&nbsp;in 10&nbsp;patients) and upper abdominal pain, dry mouth, increased
heart rate, weight gain, increased appetite, muscle twitching, uncontrolled
movements of the limbs, and feeling dizzy, especially when getting up from a
lying or sitting position, were common (greater than 1&nbsp;in
100&nbsp;patients).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Reporting of side
effects</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If you get any side
effects, talk to your doctor or pharmacist. This includes any possible side
effects not listed in this leaflet. You can also report side effects directly via
<span style='background:silver'>the national reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a></span>. By reporting side effects you can help provide more information
on the safety of this medicine.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to
store ABILIFY</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Keep this medicine
out of the sight and reach of children.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Do not use this
medicine after the expiry date which is stated on the blister and on the carton
after EXP. The expiry date refers to the last day of that month.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Store in the
original package in order to protect from moisture.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Do not throw away
any medicines via wastewater or household waste. Ask your pharmacist how to
throw away medicines you no longer use. These measures will help protect the
environment.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>What ABILIFY contains</span></b></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The
active substance is aripiprazole.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each
orodispersible tablet contains 10&nbsp;mg of aripiprazole.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each
orodispersible tablet contains 15&nbsp;mg of aripiprazole.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each
orodispersible tablet contains 30&nbsp;mg of aripiprazole.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The
other ingredients are calcium silicate, croscarmellose sodium, crospovidone,
silicon dioxide, xylitol, microcrystalline cellulose, aspartame, acesulfame
potassium, vanilla flavour (contains lactose), tartaric acid </span><span
lang=EN-GB style='color:black'>and</span><span lang=EN-GB style='color:black'> magnesium
stearate.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt'><u><span lang=EN-GB
style='color:black'>Tablet coat</span></u></p>

<p class=EMEABodyText style='margin-left:28.35pt'><span lang=ES
style='color:black'>ABILIFY 10&nbsp;mg orodispersible tablets:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Red
iron oxide&nbsp;(E&nbsp;172)</span></p>

<p class=EMEABodyText style='margin-left:28.35pt'><span lang=ES
style='color:black'>ABILIFY 15&nbsp;mg orodispersible tablets:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yellow
iron oxide&nbsp;(E&nbsp;172)</span></p>

<p class=EMEABodyText style='margin-left:28.35pt'><span lang=ES
style='color:black'>ABILIFY 30&nbsp;mg orodispersible tablets:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Red
iron oxide&nbsp;(E&nbsp;172)</span></p>

<p class=EMEABodyTextIndent style='text-indent:0in'><span lang=ES
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>What ABILIFY looks
like and contents of the pack</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY&nbsp;10&nbsp;mg<b>
</b>orodispersible tablets are round and pink, marked with &#8216;&quot;A&quot;
over &quot;640&quot;&#8217; on one side and &#8216;10&#8217; on the other.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY&nbsp;15&nbsp;mg<b>
</b>orodispersible tablets are round and yellow, marked with
&#8216;&quot;A&quot; over &quot;641&quot;&#8217; on one side and
&#8216;15&#8217; on the other.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY&nbsp;30&nbsp;mg<b>
</b>orodispersible tablets are round and pink, marked with &#8216;&quot;A&quot;
over &quot;643&quot;&#8217; on one side and &#8216;30&#8217; on the other.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY
orodispersible tablets are supplied in perforated unit dose blisters packed in cartons
containing 14&nbsp;&times;&nbsp;1, 28&nbsp;&times;&nbsp;1, or 49&nbsp;&times;&nbsp;1
orodispersible tablets.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Not all pack sizes
may be marketed.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Marketing
Authorisation Holder</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Otsuka Pharmaceutical
Netherlands B.V.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Herikerbergweg 292</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>1101 CT, Amsterdam</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Netherlands</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Manufacturer</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Elaiapharm</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>2881 Route des
Cr&ecirc;tes, Z.I. Les Bouilides-Sophia Antipolis,</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>06560 Valbonne</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>France</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>For any information
about this medicine, please contact the local representative of the Marketing
Authorisation Holder:</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=614
 style='border-collapse:collapse'>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Belgi&euml;/Belgique/Belgien</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=DE>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=DE>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#268;esk&aacute; republika</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Magyarorsz&aacute;g</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Danmark</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharma Scandinavia AB</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tlf: +46&nbsp;(0)&nbsp;8&nbsp;545&nbsp;286&nbsp;60</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Malta</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=DE>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=DE>Otsuka Pharma GmbH</span></p>
  <p class=MsoNormal><span lang=DE>Tel: +49&nbsp;(0)&nbsp;69&nbsp;1700&nbsp;860</span></p>
  <p class=MsoNormal><span lang=DE>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Nederland</span></b></p>
  <p class=MsoNormal><span lang=ES>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Eesti</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Norge</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharma Scandinavia AB</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tlf: +46&nbsp;(0)&nbsp;8&nbsp;545&nbsp;286&nbsp;60</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&Ouml;sterreich</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=ES>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal><span lang=ES>Otsuka Pharmaceutical</span><span lang=ES>,
  S.A.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +34 93 550 01 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Polska</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=FR>France</span></b></p>
  <p class=MsoNormal><span lang=FR>Otsuka Pharmaceutical France SAS</span></p>
  <p class=MsoNormal><span lang=FR>T&eacute;l: +33 (0)1 47 08 00 00</span></p>
  <p class=MsoNormal><b><span lang=FR>&nbsp;</span></b></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=PT>Portugal</span></b></p>
  <p class=MsoNormal><span lang=PT>Lundbeck Portugal Lda</span></p>
  <p class=MsoNormal><span lang=PT>Tel: +351 (0) 21 00 45 900</span></p>
  <p class=MsoNormal><span lang=PT>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=PT>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=PT>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=PT>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=PT>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=PT>Rom&acirc;nia</span></b></p>
  <p class=MsoNormal><span lang=PT>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=PT>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&Iacute;sland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Vistor hf.</span></p>
  <p class=MsoNormal><span lang=EN-GB>S&iacute;mi: +354 (0) 535 7000</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Slovensk&aacute; republika</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Italia</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Italy S.r.l.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +39 (0) 2 0063 2710</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=IT>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=IT>Otsuka Pharma Scandinavia AB</span></p>
  <p class=MsoNormal><span lang=EN-GB>Puh/Tel: +46&nbsp;(0)&nbsp;8&nbsp;545&nbsp;286&nbsp;60</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Sverige</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharma Scandinavia AB</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +46&nbsp;(0)&nbsp;8&nbsp;545&nbsp;286&nbsp;60</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Latvija</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>United Kingdom</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceuticals (UK) Ltd.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +44 (0) 203 747 5300</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black;font-weight:normal'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>This leaflet was
last revised in {MM/YYYY}</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='color:black'>Other sources of information</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=EMEABodyText style='page-break-after:avoid'><em><span lang=EN-GB
style='color:black;font-style:normal'>Detailed information on this medicine is
available on the European Medicines Agency web site: </span></em><span
lang=EN-GB style='color:black'><a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a><em><span
style='font-style:normal'>.</span></em></span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=EMEABodyText align=center style='text-align:center'><b><span
lang=EN-GB style='color:black'>Package leaflet: Information for the user</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEATitle style='page-break-after:auto'><span lang=EN-GB
style='color:black'>ABILIFY 1&nbsp;mg/mL oral solution</span></p>

<p class=EMEATitle style='page-break-after:auto'><span lang=EN-GB
style='color:black;font-weight:normal'>aripiprazole</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Read all of this
leaflet carefully before you start taking this medicine because it contains
important information for you.</span></b></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep
this leaflet. You may need to read it again.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If
you have any further questions, ask your doctor or pharmacist.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This
medicine has been prescribed for you only. Do not pass it on to others. It may
harm them, even if their signs of illness are the same as yours.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If
you get any side effects, talk to your doctor or pharmacist. This includes any
possible side effects not listed in this leaflet. See section&nbsp;4.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>What is in this
leaflet</span></b></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
ABILIFY is and what it is used for</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you
need to know before you take ABILIFY</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to
take ABILIFY</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store ABILIFY</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
ABILIFY is and what it is used for</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><em><span lang=EN-GB style='color:black;font-style:normal'>ABILIFY
contains the active substance aripiprazole and belongs to a group of medicines
called antipsychotics.</span></em><span lang=EN-GB style='color:black'> It<b> </b>is
used to treat adults and adolescents aged 15&nbsp;years and older who suffer
from a disease characterised by symptoms such as hearing, seeing or sensing
things which are not there, suspiciousness, mistaken beliefs, incoherent speech
and behaviour and emotional flatness. People with this condition may also feel
depressed, guilty, anxious or tense.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY is used to
treat adults and adolescents aged 13&nbsp;years and older who suffer from a
condition with symptoms such as feeling &quot;high&quot;, having excessive
amounts of energy, needing much less sleep than usual, talking very quickly
with racing ideas and sometimes severe irritability. In adults it also prevents
this condition from returning in patients who have responded to the treatment
with ABILIFY.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you take ABILIFY</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Do not take ABILIFY</span></b></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if
you are allergic to aripiprazole or any of the other ingredients of this
medicine (listed in section&nbsp;6).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Warnings and
precautions</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Talk to your doctor
before taking ABILIFY.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>Suicidal
thoughts and behaviours have been reported during aripiprazole treatment. Tell
your doctor immediately if you are having any thoughts or feelings about
hurting yourself.</span></em></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><em><span lang=EN-GB style='font-style:normal'>Before
treatment with </span></em><span lang=EN-GB>ABILIFY<em><span style='font-style:
normal'>, tell your doctor</span></em> if you suffer from</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>high blood sugar (characterised by symptoms such as
excessive thirst, passing of large amounts of urine, increase in appetite and
feeling weak) or family history of diabetes</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>fits (seizures) since your doctor may want to monitor
you more closely</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>involuntary, irregular muscle movements, especially
in the face</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>cardiovascular diseases (diseases of the heart and
circulation), family history of cardiovascular disease, stroke or
&quot;mini&quot; stroke, abnormal blood pressure</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>blood clots, or family history of blood clots, as
antipsychotics have been associated with formation of blood clots</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>past experience with excessive gambling</span></em></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If you notice you
are gaining weight, develop unusual movements, experience somnolence that
interferes with normal daily activities, any difficulty in swallowing or
allergic symptoms, please tell your doctor.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If you are an
elderly patient suffering from dementia (loss of memory and other mental
abilities), you or your carer/relative should tell your doctor if you have ever
had a stroke or &quot;mini&quot; stroke.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Tell your doctor
immediately if you are having any thoughts or feelings about hurting yourself.
Suicidal thoughts and behaviours have been reported during aripiprazole
treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Tell your doctor
immediately if you suffer from muscle stiffness or inflexibility with high
fever, sweating, altered mental status, or very rapid or irregular heartbeat.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Tell your doctor if you or your
family/carer notices that you are developing urges or cravings to behave in
ways that are unusual for you and you cannot resist the impulse, drive or
temptation to carry out certain activities that could harm yourself or others.
These are called impulse control disorders and can include behaviours such as
addictive gambling, excessive eating or spending, an abnormally high sex drive
or preoccupation with an increase in sexual thoughts or feelings.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Your doctor may need to adjust or
stop your dose.</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Aripiprazole
may cause sleepiness, fall in blood pressure when standing up, dizziness and
changes in your ability to move and balance, which may lead to falls. Caution
should be taken, particularly if you are an elderly patient or have some
debility.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Children and
adolescents</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Do not use this
medicine in children and adolescents under 13&nbsp;years of age. It is not
known if it is safe and effective in these patients.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Other medicines and
ABILIFY</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Tell your doctor or
pharmacist if you are taking, have recently taken or might take any other
medicines</span><span lang=EN-GB style='color:black'>, including medicines
obtained without a prescription.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Blood pressure-lowering
medicines: ABILIFY may increase the effect of medicines used to lower the blood
pressure. Be sure to tell your doctor if you take a medicine to keep your blood
pressure under control.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>Taking </span></em><span
lang=EN-GB>ABILIFY <em><span style='font-style:normal'>with some medicines may
mean the doctor will need to change your dose of </span></em>ABILIFY<em><span
style='font-style:normal'> or the other medicines. It is especially important
to mention the following to your doctor:</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>medicines to correct heart rhythm (such as quinidine,
amiodarone, flecainide)</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>antidepressants or herbal remedy used to treat
depression and anxiety</span></em><span class=berschrift4Zchn><span
style='font-style:normal'> </span></span><span class=berschrift4Zchn><span
style='font-weight:normal'>(</span></span><em><span style='font-style:normal'>such
as fluoxetine, paroxetine, venlafaxine, St. John's Wort)</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>antifungal medicines (such as ketoconazole,
itraconazole)</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>certain medicines to treat HIV infection (such as
efavirenz, nevirapine, an protease inhibitors e.g. indinavir, ritonavir)</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>anticonvulsants used to treat epilepsy (such as </span></em><span
class=BMSHeading3Char><span style='color:windowtext;font-weight:normal'>carbamazepine,
phenytoin,</span></span><span class=BMSHeading3Char><i><span style='color:windowtext'>
</span></i></span><em><span style='font-style:normal'>phenobarbital)</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>certain antibiotics used to treat tuberculosis
(rifabutin, rifampicin)</span></em></span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>These medicines may increase the risk of
side effects or reduce the effect of ABILIFY; if you get any unusual symptom
taking any of these medicines together with ABILIFY you should see your doctor.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Medicines that increase the level of
serotonin <span class=BMSHeading3Char><span style='color:windowtext;font-weight:
normal'>are typically used in conditions including </span></span><a
href="http://en.wikipedia.org/wiki/Major_depressive_disorder"
title="Major depressive disorder"><span class=BMSHeading3Char><span
style='color:windowtext;font-weight:normal;text-decoration:none'>depression</span></span></a><span
class=BMSHeading3Char><span style='color:windowtext;font-weight:normal'>, </span></span><a
href="http://en.wikipedia.org/wiki/Generalized_anxiety_disorder"
title="Generalized anxiety disorder"><span class=BMSHeading3Char><span
style='color:windowtext;font-weight:normal;text-decoration:none'>generalised
anxiety disorder</span></span></a><span class=BMSHeading3Char><span
style='color:windowtext;font-weight:normal'>, obsessive-compulsive disorder
(OCD) and </span></span><a
href="http://en.wikipedia.org/wiki/Social_anxiety_disorder"
title="Social anxiety disorder"><span class=BMSHeading3Char><span
style='color:windowtext;font-weight:normal;text-decoration:none'>social phobia</span></span></a><span
class=BMSHeading3Char><span style='color:windowtext;font-weight:normal'> as
well as migraine and pain</span></span>:</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; triptans, tramadol
and tryptophan used for conditions including depression, generalised anxiety
disorder, obsessive compulsive disorder (OCD) and social phobia as well as
migraine and pain</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span
style='color:black'>selective-serotonin-reuptake-inhibitors</span> (SSRIs)
(such as paroxetine and fluoxetine) used for depression, OCD, panic and anxiety</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other
anti-depressants (such as venlafaxine and tryptophan) used in major depression</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tricyclic&#8217;s
(such as clomipramine and amitriptyline) used for depressive illness</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St John&#8217;s
Wort (<i>Hypericum perforatum</i>) used as a herbal remedy for mild depression</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain killers (such
as tramadol and pethidine) used for pain relief</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; triptans (such as
sumatriptan and zolmitripitan) used for treating migraine</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><span lang=EN-GB>These medicines may increase the risk of
side effects; if you get any unusual symptom taking any of these medicines
together with ABILIFY, you should see your doctor.</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>ABILIFY with food,
drink and alcohol</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>This medicine can be
taken regardless of meals. However, the oral solution should not be diluted
with other liquids or mixed with any food prior to administration.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Alcohol should be
avoided.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Pregnancy, breast-feeding
and fertility</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If you are pregnant
or breast-feeding, think you may be pregnant or are planning to have a baby,
ask your doctor for advice before taking this medicine.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The following
symptoms may occur in newborn babies, of mothers that have used ABILIFY in the
last trimester (last three months of their pregnancy): shaking, muscle
stiffness and/or weakness, sleepiness, agitation, breathing problems, and
difficulty in feeding. If your baby develops any of these symptoms you may need
to contact your doctor.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>If you are
taking </span></em><span lang=EN-GB>ABILIFY<em><span style='font-style:normal'>,
your doctor will discuss with you whether you should breast&#8209;feed considering
the benefit to you of your therapy and the benefit to your baby of breast&#8209;feeding.
You should not do both. Talk to your doctor about the best way to feed your
baby if you are taking </span></em>this medicine<em><span style='font-style:
normal'>.</span></em></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Driving and using machines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Dizziness and vision problems may occur
during treatment with this medicine (see section 4).</span></p>

<p class=MsoNormal><span lang=EN-GB>This should be considered in cases where
full alertness is required, e.g., when driving a car or handling machines.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>ABILIFY contains
fructose and sucrose</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>This medicine contains
200&nbsp;mg of fructose and 400&nbsp;mg of sucrose in each mL. If you have been
told by your doctor that you have an intolerance to some sugars, contact your
doctor before taking this medicine. Fructose may damage teeth.</span><span
lang=EN-GB> Sucrose m</span><span lang=EN-GB style='color:black'>ay be harmful
to the teeth.</span></p>

<p class=EMEABodyText><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB style='color:black'>ABILIFY contains parahydroxybenzoates</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>May cause allergic
reactions (possibly delayed).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB style='color:black'>ABILIFY contains
sodium</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>This medicine
contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dosage unit, that is to
say essentially &#8216;sodium-free&#8217;.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to take
ABILIFY</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>Always take this medicine exactly as your doctor or pharmacist has told
you. Check with your doctor or pharmacist if you are not sure.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB style='color:black;layout-grid-mode:
line'>The recommended dose for adults is 15&nbsp;mL solution (corresponding to
15&nbsp;mg aripiprazole) once a day.</span></b><span lang=EN-GB
style='color:black;layout-grid-mode:line'> However your doctor may prescribe a
lower or higher dose to a maximum of 30&nbsp;mg (i.e. 30&nbsp;mL) once a day.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Use in children and
adolescents</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB style='color:black;layout-grid-mode:
line'>The recommended dose for adolescents is 10&nbsp;mL solution
(corresponding to 10&nbsp;mg aripiprazole) once a day.</span></b><span
lang=EN-GB style='color:black;layout-grid-mode:line'> However your doctor may
prescribe a lower or higher dose to a maximum of 30&nbsp;mL (i.e. 30&nbsp;mg)
once a day.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The dose of ABILIFY must
be measured using the calibrated cup or the 2 mL calibrated dropping pipette supplied
in the carton.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If you have the
impression that the effect of ABILIFY is too strong or too weak, talk to your
doctor or pharmacist.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB style='color:black'>Try to take ABILIFY
at the same time each day.</span></b><span lang=EN-GB style='color:black'> It
does not matter whether you take it with or without food. However, you should
not dilute with other liquids or mix with other food prior to taking ABILIFY
oral solution.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB style='color:black'>Even if you feel
better,</span></b><span lang=EN-GB style='color:black'> do not alter or
discontinue the daily dose of ABILIFY without first consulting your doctor.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>If you take more
ABILIFY than you should</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If you realise you
have taken more ABILIFY than your doctor has recommended (or if someone else
has taken some of your ABILIFY), contact your doctor right away. If you cannot
reach your doctor, go to the nearest hospital and take the pack with you.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>Patients who
have taken too much aripiprazole have experienced the following symptoms:</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>rapid heartbeat, agitation/aggressiveness, problems
with speech.</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>unusual movements (especially of the face or tongue)
and reduced level of consciousness.</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>Other
symptoms may include:</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>acute confusion, seizures (epilepsy), coma, a combination
of fever, faster breathing, sweating,</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>muscle stiffness, and drowsiness or sleepiness,
slower breathing, choking, high or low blood pressure, abnormal rhythms of the
heart.</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>Contact your
doctor or hospital immediately if you experience any of the above.</span></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>If you forget to
take ABILIFY</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If you miss a dose,
take the missed dose as soon as you remember but do not take two doses in one
day.</span></p>

<p class=EMEABodyText><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB style='color:black'>If you stop
taking </span></b><b><span lang=EN-GB style='color:black'>ABILIFY</span></b></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Do
not stop your treatment just because you feel better. It is important that you
carry on taking </span></em><span lang=EN-GB style='color:black'>ABILIFY <em><span
style='font-style:normal'>for as long as your doctor has told you to.</span></em></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If you have any
further questions on the use of this medicine, ask your doctor or pharmacist.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Like all medicines,
this medicine can cause side effects, although not everybody gets them.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
style='color:black;font-style:normal'>Common side effects (may affect up to 1
in 10&nbsp;people):</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB>diabetes mellitus,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>difficulty sleeping,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>feeling anxious,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>feeling restless and unable to keep still,
difficulty sitting still,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>akathisia (an uncomfortable feeling of inner
restlessness and a compelling need to move constantly),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>uncontrollable twitching, jerking or writhing
movements,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>trembling,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>headache,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>tiredness,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleepiness,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>light-headedness,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>shaking and blurred vision,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased
number of or difficulty making bowel movements,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; indigestion,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling
sick,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>more saliva in mouth than normal,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>vomiting,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling
tired.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Uncommon
side effects (may affect up to 1 in 100&nbsp;people):</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased
blood levels of the hormone prolactin</span></em><em><span lang=EN-GB
style='color:black;font-style:normal'>,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; too
much sugar in the blood,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>depression,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>altered or increased sexual
interest</span></em><em><span lang=EN-GB style='color:black;font-style:normal'>,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><span
lang=EN-GB>uncontrollable movements of mouth, tongue and limbs (tardive
dyskinesia),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle
disorder causing twisting movements (dystonia),</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>restless legs,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; double
vision</span></em><em><span lang=EN-GB style='color:black;font-style:normal'>,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eye
sensitivity to light,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast
heart</span></em><em><span lang=EN-GB style='color:black;font-style:normal'>beat,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a
fall in blood pressure on standing up which causes dizziness, light-headedness
or fainting,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hiccups</span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>.</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>The
following side effects have been reported since the marketing of oral
aripiprazole but the frequency for them to occur is not known:</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>low levels of white blood
cells,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low
levels of blood platelets,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>allergic reaction (e.g.
swelling in the mouth, tongue, face and throat, itching, hives),</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; onset
or worsening of diabetes, ketoacidosis (ketones in the blood and urine) or coma,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high
blood sugar,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; not
enough sodium in the blood,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss
of appetite (anorexia),</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight
loss,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight
gain,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thoughts
of suicide, suicide attempt and suicide,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling
aggressive,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; agitation,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nervousness,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; combination
of fever, muscle stiffness, faster breathing, sweating, reduced consciousness
and sudden changes in blood pressure and heart rate, fainting (neuroleptic
malignant syndrome),</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seizure,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serotonin
syndrome (a reaction which may cause feelings of great happiness, drowsiness,
clumsiness, restlessness, feeling of being drunk, fever, sweating or rigid
muscles),</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; speech
disorder,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><span
lang=EN-GB style='color:black'>fixation of the eyeballs in one position,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><span
lang=EN-GB>sudden unexplained death,</span></p>

<p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><span
lang=EN-GB style='color:black'>life-threatening irregular heartbeat,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart
attack,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; slower
heartbeat,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>blood clots in the veins
especially in the legs (symptoms include swelling, pain and redness in the
leg), which may travel through blood vessels to the lungs causing chest pain
and difficulty in breathing (if you notice any of these symptoms, seek medical
advice immediately),</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high
blood pressure,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; accidental
inhalation of food with risk of pneumonia (lung infection),</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>spasm of the muscles around
the voice box,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>inflammation of the pancreas,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>difficulty swallowing,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal
discomfort,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach
discomfort,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver
failure,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation
of the liver,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellowing
of the skin and white part of eyes,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reports
of abnormal liver tests values,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>skin rash,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin
sensitivity to light,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; baldness,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; excessive
sweating,</span></em></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;text-autospace:
none'><span lang=EN-GB>&#8226;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>serious allergic reactions such as Drug Reaction
with Eosinophilia and Systemic Symptoms (DRESS). DRESS appears initially as
flu-like symptoms with a rash on the face and then with an extended rash, high
temperature, enlarged lymph nodes, increased levels of liver enzymes seen in
blood tests and an increase in a type of white blood cell (eosinophilia),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal
muscle breakdown which can lead to kidney problems,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle
pain,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stiffness,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>involuntary loss of urine
(incontinence),</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty
in passing urine,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; withdrawal
symptoms in newborn babies in case of exposure during pregnancy,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>prolonged and/or painful
erection,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>difficulty controlling core
body temperature or overheating,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><em><span
lang=EN-GB style='color:black;font-style:normal'>chest pain,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling
of hands, ankles or feet,</span></em></p>

<p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in
blood tests: increased or fluctuating blood sugar, increased </span></em><span
lang=EN-GB>glycosylated haemoglobin.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><span
lang=EN-GB style='color:black'>Inability to resist the impulse, drive or
temptation to perform an action that could be harmful to you or others, which
may include:</span></p>

<p class=EMEABodyText style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; strong
impulse to gamble excessively despite serious personal or family consequences</span></p>

<p class=EMEABodyText style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; altered
or increased sexual interest and behaviour of significant concern to you or to
others, for example, an increased sexual drive</span></p>

<p class=EMEABodyText style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; uncontrollable
excessive shopping</span></p>

<p class=EMEABodyText style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; binge
eating (eating large amounts of food in a short time period) or compulsive
eating (eating more food than normal and more than is needed to satisfy your
hunger)</span></p>

<p class=EMEABodyText style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB>a tendency to wander away.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt'><span lang=EN-GB
style='color:black'>Tell your doctor if you experience any of these behaviours;
he/she will discuss ways of managing or reducing the symptoms.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In elderly patients
with dementia, more fatal cases have been reported while taking aripiprazole. In
addition, cases of stroke or &quot;mini&quot; stroke have been reported.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Additional side
effects in children and adolescents</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Adolescents aged
13&nbsp;years and older experienced side effects that were similar in frequency
and type to those in adults except that sleepiness, uncontrollable twitching or
jerking movements, restlessness, and tiredness were very common (greater than
1&nbsp;in 10&nbsp;patients) and upper abdominal pain, dry mouth, increased
heart rate, weight gain, increased appetite, muscle twitching, uncontrolled
movements of the limbs, and feeling dizzy, especially when getting up from a
lying or sitting position, were common (greater than 1&nbsp;in
100&nbsp;patients).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Reporting of side
effects</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If you get any side
effects, talk to your doctor or pharmacist. This includes any possible side
effects not listed in this leaflet. You can also report side effects directly via
<span style='background:silver'>the national reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a></span>. By reporting side effects you can help provide more information
on the safety of this medicine.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to
store ABILIFY</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Keep this medicine
out of the sight and reach of children.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Do not use this
medicine after the expiry date which is stated on the bottle and on the carton
after EXP. The expiry date refers to the last day of that month.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>This medicine does
not require any special storage conditions.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Use within
6&nbsp;months after first opening.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Do not throw away
any medicines via wastewater or household waste. Ask your pharmacist how to
throw away medicines you no longer use. These measures will help protect the
environment.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>What ABILIFY
contains</span></b></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The
active substance is aripiprazole.</span></p>

<p class=EMEABodyTextIndent style='text-indent:0in'><span lang=EN-GB
style='color:black'>Each&nbsp;mL contains 1&nbsp;mg of aripiprazole.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The
other ingredients are disodium edetate, fructose, glycerin, lactic acid, methyl
parahydroxybenzoate (E218), propylene glycol, propyl parahydroxybenzoate
(E216), sodium hydroxide, sucrose, purified water, and orange flavour.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB style='color:black'>What ABILIFY
looks like and contents of the pack</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY&nbsp;1&nbsp;mg/mL
oral solution is a clear, colourless to light yellow liquid supplied in bottles
with polypropylene child-resistant closure containing 50&nbsp;mL, 150&nbsp;mL
or 480&nbsp;mL per bottle.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Each carton contains
one bottle and both a calibrated polypropylene measuring cup and a calibrated
polypropylene low-density polyethylene dropping pipette.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Not all pack sizes may
be marketed.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Marketing
Authorisation Holder</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Otsuka Pharmaceutical
Netherlands B.V.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Herikerbergweg 292</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>1101 CT, Amsterdam</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Netherlands</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Manufacturer</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Elaiapharm</span></p>

<p class=MsoNormal><span lang=FR style='color:black'>2881 Route des
Cr&ecirc;tes, Z.I. Les Bouilides-Sophia Antipolis,</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>06560 Valbonne</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>France</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>For any information
about this medicine, please contact the local representative of the Marketing
Authorisation Holder:</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=614
 style='border-collapse:collapse'>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Belgi&euml;/Belgique/Belgien</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=DE>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=DE>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#268;esk&aacute; republika</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Magyarorsz&aacute;g</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Danmark</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharma Scandinavia AB</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tlf: +46&nbsp;(0)&nbsp;8&nbsp;545&nbsp;286&nbsp;60</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Malta</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=DE>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=DE>Otsuka Pharma GmbH</span></p>
  <p class=MsoNormal><span lang=DE>Tel: +49&nbsp;(0)&nbsp;69&nbsp;1700&nbsp;860</span></p>
  <p class=MsoNormal><span lang=DE>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Nederland</span></b></p>
  <p class=MsoNormal><span lang=ES>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Eesti</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Norge</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharma Scandinavia AB</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tlf: +46&nbsp;(0)&nbsp;8&nbsp;545&nbsp;286&nbsp;60</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&Ouml;sterreich</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=ES>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal><span lang=ES>Otsuka Pharmaceutical</span><span lang=ES>,
  S.A.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +34 93 550 01 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Polska</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=FR>France</span></b></p>
  <p class=MsoNormal><span lang=FR>Otsuka Pharmaceutical France SAS</span></p>
  <p class=MsoNormal><span lang=FR>T&eacute;l: +33 (0)1 47 08 00 00</span></p>
  <p class=MsoNormal><b><span lang=FR>&nbsp;</span></b></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=PT>Portugal</span></b></p>
  <p class=MsoNormal><span lang=PT>Lundbeck Portugal Lda</span></p>
  <p class=MsoNormal><span lang=PT>Tel: +351 (0) 21 00 45 900</span></p>
  <p class=MsoNormal><span lang=PT>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=PT>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=PT>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=PT>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=PT>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=PT>Rom&acirc;nia</span></b></p>
  <p class=MsoNormal><span lang=PT>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=PT>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&Iacute;sland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Vistor hf.</span></p>
  <p class=MsoNormal><span lang=EN-GB>S&iacute;mi: +354 (0) 535 7000</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Slovensk&aacute; republika</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Italia</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Italy S.r.l.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +39 (0) 2 0063 2710</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=IT>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=IT>Otsuka Pharma Scandinavia AB</span></p>
  <p class=MsoNormal><span lang=EN-GB>Puh/Tel: +46&nbsp;(0)&nbsp;8&nbsp;545&nbsp;286&nbsp;60</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Sverige</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharma Scandinavia AB</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +46&nbsp;(0)&nbsp;8&nbsp;545&nbsp;286&nbsp;60</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Latvija</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>United Kingdom</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceuticals (UK) Ltd.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +44 (0) 203 747 5300</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black;font-weight:normal'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>This leaflet was
last revised in {MM/YYYY}</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='color:black'>Other sources of information</span></b></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><em><span lang=EN-GB
style='color:black;font-style:normal'>Detailed information on this medicine is
available on the European Medicines Agency web site: </span></em><span
lang=EN-GB style='color:black'><a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a><em><span
style='font-style:normal'>.</span></em></span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=EMEATitle style='page-break-after:auto'><span lang=EN-GB
style='color:black'>Package leaflet: Information for the user</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><b><span
lang=EN-GB style='color:black'>ABILIFY 7.5&nbsp;mg/mL solution for injection</span></b></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>aripiprazole</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Read all of this
leaflet carefully before you receive this medicine because it contains
important information for you.</span></b></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep
this leaflet. You may need to read it again.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If
you have any further questions, ask your doctor or pharmacist.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This
medicine has been prescribed for you only. Do not pass it on to others. It may
harm them, even if their signs of illness are the same as yours.</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If
you get any side effects, talk to your doctor or pharmacist. This includes any
possible side effects not listed in this leaflet. See section&nbsp;4.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>What is in this
leaflet</span></b></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
ABILIFY is and what it is used for</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you
need to know before you are given ABILIFY</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
ABILIFY is given</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to
store ABILIFY</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
ABILIFY is and what it is used for</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><em><span lang=EN-GB style='color:black;font-style:normal'>ABILIFY
contains the active substance aripiprazole and belongs to a group of medicines
called antipsychotics. </span></em><span lang=EN-GB style='color:black'>ABILIFY
is used to treat quickly symptoms of agitation and distressing behaviour that
may occur in a disease characterised by symptoms such as:</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hearing,
seeing or sensing things which are not there, suspiciousness, mistaken beliefs,
incoherent speech and behaviour and emotional flatness. People with this
condition may also feel depressed, guilty, anxious or tense.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling
&quot;high&quot;, having excessive amounts of energy, needing much less sleep
than usual, talking very quickly with racing ideas and sometimes severe
irritability.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>ABILIFY is given
when treatment with oral formulations is not appropriate. Your doctor will
change your treatment to oral ABILIFY as soon as appropriate.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you
need to know before you are given ABILIFY</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Do not use ABILIFY</span></b></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if
you are allergic to aripiprazole or any of the other ingredients of this
medicine (listed in section&nbsp;6).</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Warnings and
precautions</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Talk to your doctor
before you are given ABILIFY.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>Suicidal
thoughts and behaviours have been reported during aripiprazole treatment. Tell
your doctor immediately if you are having any thoughts or feelings about hurting
yourself.</span></em></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><em><span lang=EN-GB style='font-style:normal'>Before
treatment with </span></em><span lang=EN-GB>ABILIFY<em><span style='font-style:
normal'>, tell your doctor</span></em> if you suffer from</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>high blood sugar (characterised by symptoms such as
excessive thirst, passing of large amounts of urine, increase in appetite and
feeling weak) or family history of diabetes</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>fits (seizures) since your doctor may want to monitor
you more closely</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>involuntary, irregular muscle movements, especially
in the face</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>cardiovascular diseases (diseases of the heart and
circulation), family history of cardiovascular disease, stroke or
&quot;mini&quot; stroke, abnormal blood pressure</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>blood clots, or family history of blood clots, as
antipsychotics have been associated with formation of blood clots</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>past experience with excessive gambling</span></em></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If you notice you
are gaining weight, develop unusual movements, experience somnolence that interferes
with normal daily activities, any difficulty in swallowing or allergic
symptoms, please tell your doctor.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If you are an
elderly patient suffering from dementia (loss of memory and other mental
abilities), you or your carer/relative should tell your doctor if you have ever
had a stroke or &quot;mini&quot; stroke.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Tell the doctor or
nurse if you feel dizzy or faint after the injection. You will probably need to
lie down until you feel better. The doctor may also want to measure your blood
pressure and pulse.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Tell your doctor
immediately if you are having any thoughts or feelings about hurting yourself.
Suicidal thoughts and behaviours have been reported during aripiprazole
treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Tell your doctor
immediately if you suffer from muscle stiffness or inflexibility with high
fever, sweating, altered mental status, or very rapid or irregular heartbeat.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Tell your doctor if you or your
family/carer notices that you are developing urges or cravings to behave in
ways that are unusual for you and you cannot resist the impulse, drive or
temptation to carry out certain activities that could harm yourself or others.
These are called impulse control disorders and can include behaviours such as
addictive gambling, excessive eating or spending, an abnormally high sex drive
or preoccupation with an increase in sexual thoughts or feelings.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB>Your doctor may need to adjust or
stop your dose.</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Aripiprazole
may cause sleepiness, fall in blood pressure when standing up, dizziness and
changes in your ability to move and balance, which may lead to falls. Caution
should be taken, particularly if you are an elderly patient or have some
debility.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black'>Children and adolescents</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Do not use this
medicine in children and adolescents under 18&nbsp;years of age. It is not
known if it is safe and effective in these patients.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Other medicines and
ABILIFY</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:white'>Tell
your doctor or </span><span lang=EN-GB style='color:black'>pharmacist<span
style='background:white'> if you are taking, have recently taken or might take
any other medicines.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Blood
pressure-lowering medicines: ABILIFY may increase the effect of medicines used
to lower the blood pressure. Be sure to tell your doctor if you take a medicine
to keep your blood pressure under control.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Receiving </span><span
lang=EN-GB>ABILIFY <em><span style='font-style:normal'>with some medicines may
mean the doctor will need to change your dose of </span></em>ABILIFY<em><span
style='font-style:normal'> or the other medicines. It is especially important
to mention the following to your doctor:</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>medicines to correct heart rhythm (such as quinidine,
amiodarone, flecainide)</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>antidepressants or herbal remedy used to treat
depression and anxiety</span></em><span class=berschrift4Zchn><span
style='font-style:normal'> </span></span><span class=berschrift4Zchn><span
style='font-weight:normal'>(</span></span><em><span style='font-style:normal'>such
as fluoxetine, paroxetine, venlafaxine, St. John's Wort)</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>antifungal medicines (such as ketoconazole,
itraconazole)</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>certain medicines to treat HIV infection (such as
efavirenz, nevirapine, an protease inhibitors e.g. indinavir, ritonavir)</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>anticonvulsants used to treat epilepsy (such as </span></em><span
class=BMSHeading3Char><span style='color:windowtext;font-weight:normal'>carbamazepine,
phenytoin,</span></span><span class=BMSHeading3Char><i><span style='color:windowtext'>
</span></i></span><em><span style='font-style:normal'>phenobarbital)</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>certain antibiotics used to treat tuberculosis
(rifabutin, rifampicin)</span></em></span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>These medicines may increase the risk of
side effects or reduce the effect of ABILIFY; if you get any unusual symptom
taking any of these medicines together with ABILIFY you should see your doctor.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Medicines that increase the level of
serotonin <span class=BMSHeading3Char><span style='color:windowtext;font-weight:
normal'>are typically used in conditions including </span></span><a
href="http://en.wikipedia.org/wiki/Major_depressive_disorder"
title="Major depressive disorder"><span class=BMSHeading3Char><span
style='color:windowtext;font-weight:normal;text-decoration:none'>depression</span></span></a><span
class=BMSHeading3Char><span style='color:windowtext;font-weight:normal'>, </span></span><a
href="http://en.wikipedia.org/wiki/Generalized_anxiety_disorder"
title="Generalized anxiety disorder"><span class=BMSHeading3Char><span
style='color:windowtext;font-weight:normal;text-decoration:none'>generalised
anxiety disorder</span></span></a><span class=BMSHeading3Char><span
style='color:windowtext;font-weight:normal'>, obsessive-compulsive disorder
(OCD) and </span></span><a
href="http://en.wikipedia.org/wiki/Social_anxiety_disorder"
title="Social anxiety disorder"><span class=BMSHeading3Char><span
style='color:windowtext;font-weight:normal;text-decoration:none'>social phobia</span></span></a><span
class=BMSHeading3Char><span style='color:windowtext;font-weight:normal'> as
well as migraine and pain</span></span>:</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; triptans, tramadol
and tryptophan used for conditions including depression, generalised anxiety
disorder, obsessive compulsive disorder (OCD) and social phobia as well as
migraine and pain</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span
style='color:black'>selective-serotonin-reuptake-inhibitors</span> (SSRIs)
(such as paroxetine and fluoxetine) used for depression, OCD, panic and anxiety</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other anti-depressants
(such as venlafaxine and tryptophan) used in major depression</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tricyclic&#8217;s
(such as clomipramine and amitriptyline) used for depressive illness</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St John&#8217;s
Wort (<i>Hypericum perforatum</i>) used as a herbal remedy for mild depression</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain killers (such
as tramadol and pethidine) used for pain relief</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; triptans (such as
sumatriptan and zolmitripitan) used for treating migraine</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>&nbsp;</span></em></p>

<p class=EMEABodyText><span lang=EN-GB>These medicines may increase the risk of
side effects; if you get any unusual symptom taking any of these medicines
together with ABILIFY, you should see your doctor.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>A combination of
ABILIFY with medicines taken for anxiety might make you feel drowsy or dizzy.
Only take other medicines while you are on ABILIFY if your doctor tells you
that you can.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>ABILIFY with food,
drink and alcohol</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>This medicine can be
given regardless of meals.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Alcohol should be
avoided.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Pregnancy,
breast-feeding and fertility</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If you are pregnant
or breast-feeding, think you may be pregnant or are planning to have a baby,
ask your doctor for advice before taking this medicine.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The following
symptoms may occur in newborn babies, of mothers that have used ABILIFY in the
last trimester (last three months of their pregnancy): shaking, muscle
stiffness and/or weakness, sleepiness, agitation, breathing problems, and
difficulty in feeding. If your baby develops any of these symptoms you may need
to contact your doctor.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>If you are receiving
</span></em><span lang=EN-GB>ABILIFY<em><span style='font-style:normal'>, your
doctor will discuss with you whether you should breast&#8209;feed considering
the benefit to you of your therapy and the benefit to your baby of breast&#8209;feeding.
You should not do both. Talk to your doctor about the best way to feed your
baby if you are receiving </span></em>this medicine<em><span style='font-style:
normal'>.</span></em></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Driving and using
machines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Dizziness and vision problems may occur
during treatment with this medicine (see section 4).</span></p>

<p class=MsoNormal><span lang=EN-GB>This should be considered in cases where
full alertness is required, e.g., when driving a car or handling machines.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB style='color:black'>ABILIFY contains sodium</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>This medicine
contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dosage unit, that is to
say essentially &#8216;sodium-free&#8217;.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
ABILIFY is given</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>Your doctor will decide how much ABILIFY you need and how long you need
it for. The recommended dose is 9.75&nbsp;mg (1.3&nbsp;mL) for the first
injection. Up to three injections in 24&nbsp;hours may be given. The total dose
of ABILIFY (all formulations) should not exceed 30&nbsp;mg per day.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>ABILIFY is ready to use. The correct amount of solution will be injected
into your muscle by your doctor or nurse.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>If you are given
more </span></b><b><span lang=EN-GB style='color:black'>ABILIFY than you need</span></b></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>This
medicine will be given to you under medical supervision; it is therefore
unlikely that you will be given too much. If you see more than one doctor, be
sure to tell them that you are receiving </span></em><span lang=EN-GB
style='color:black'>ABILIFY.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>Patients who
have been given too much aripiprazole have experienced the following symptoms:</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>rapid heartbeat, agitation/aggressiveness, problems
with speech.</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>unusual movements (especially of the face or tongue)
and reduced level of consciousness.</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>Other
symptoms may include:</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>acute confusion, seizures (epilepsy), coma, a
combination of fever, faster breathing, sweating,</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em><span
style='font-style:normal'>muscle stiffness, and drowsiness or sleepiness,
slower breathing, choking, high or low blood pressure, abnormal rhythms of the
heart.</span></em></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='font-style:normal'>Contact your
doctor or hospital immediately if you experience any of the above.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>If you miss an
injection of ABILIFY</span></b></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>It
is important not to miss your dose. If you miss an injection, you should
contact your doctor to arrange your next injection as soon as you can.</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>If you stop
receiving </span></b><b><span lang=EN-GB style='color:black'>ABILIFY</span></b></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Do
not stop your treatment just because you feel better. It is important that you
carry on receiving </span></em><span lang=EN-GB style='color:black'>ABILIFY
solution for injection<b> </b><em><span style='font-style:normal'>for as long
as your doctor has told you to.</span></em></span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>If
you have any further questions on the use of this medicine, ask your doctor or
nurse.</span></em></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Like all medicines,
this medicine can cause side effects, although not everybody gets them.</span></p>

<p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
style='color:black;font-style:normal'>Common side effects (may affect up to 1
in 10&nbsp;people):</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB>diabetes mellitus,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>difficulty sleeping,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>feeling anxious,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>feeling restless and unable to keep still,
difficulty sitting still,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>akathisia (an uncomfortable feeling of inner
restlessness and a compelling need to move constantly),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB>uncontrollable twitching, jerking or writhing movements,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>trembling,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>headache,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>tiredness,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleepiness,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>light-headedness,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>shaking and blurred vision,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased
number of or difficulty making bowel movements,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; indigestion,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling
sick,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>more saliva in mouth than normal,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>vomiting,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling
tired.</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>Uncommon
side effects (may affect up to 1 in 100&nbsp;people):</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased
blood levels of the hormone prolactin,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; too
much sugar in the blood,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depression,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; altered
or increased sexual interest,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><span
lang=EN-GB>uncontrollable movements of mouth, tongue and limbs (tardive
dyskinesia),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle
disorder causing twisting movements (dystonia),</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='color:black'>restless legs,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; double
vision,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eye
sensitivity to light,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast
heartbeat,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased
diastolic blood pressure,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a
fall in blood pressure on standing up which causes dizziness, light-headedness
or fainting,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hiccups,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry
mouth.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>The
following side effects have been reported since the marketing of oral
aripiprazole but the frequency for them to occur is not known:</span></em></p>

<p class=MsoNormal><em><span lang=EN-GB style='color:black;font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low
levels of white blood cells,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low
levels of blood platelets,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic
reaction (e.g. swelling in the mouth, tongue, face and throat, itching, hives),</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; onset
or worsening of diabetes, ketoacidosis (ketones in the blood and urine) or
coma,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high
blood sugar,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; not
enough sodium in the blood,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss
of appetite (anorexia),</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight
loss,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight
gain,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thoughts
of suicide, suicide attempt and suicide,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling
aggressive,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; agitation,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nervousness,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; combination
of fever, muscle stiffness, faster breathing, sweating, reduced consciousness
and sudden changes in blood pressure and heart rate, fainting (neuroleptic
malignant syndrome),</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seizure,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serotonin
syndrome (a reaction which may cause feelings of great happiness, drowsiness,
clumsiness, restlessness, feeling of being drunk, fever, sweating or rigid
muscles),</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; speech
disorder,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><span
lang=EN-GB style='color:black'>fixation of the eyeballs in one position,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><span
lang=EN-GB>sudden unexplained death,</span></p>

<p class=MsoNormal style='text-autospace:none'><em><span lang=EN-GB
style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><span
lang=EN-GB style='color:black'>life-threatening irregular heartbeat,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart
attack,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; slower
heartbeat,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood
clots in the veins especially in the legs (symptoms include swelling, pain and
redness in the leg), which may travel through blood vessels to the lungs
causing chest pain and difficulty in breathing (if you notice any of these
symptoms, seek medical advice immediately),</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high
blood pressure,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; accidental
inhalation of food with risk of pneumonia (lung infection),</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; spasm
of the muscles around the voice box,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation
of the pancreas,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty
swallowing,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal
discomfort,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach
discomfort,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver
failure,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation
of the liver,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellowing
of the skin and white part of eyes,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reports
of abnormal liver tests values,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin
rash,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin
sensitivity to light,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; baldness,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; excessive
sweating,</span></em></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;text-autospace:
none'><span lang=EN-GB>&#8226;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>serious allergic reactions such as Drug Reaction
with Eosinophilia and Systemic Symptoms (DRESS). DRESS appears initially as flu-like
symptoms with a rash on the face and then with an extended rash, high
temperature, enlarged lymph nodes, increased levels of liver enzymes seen in
blood tests and an increase in a type of white blood cell (eosinophilia),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal
muscle breakdown which can lead to kidney problems,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle
pain,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stiffness,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; involuntary
loss of urine (incontinence),</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty
in passing urine,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; withdrawal
symptoms in newborn babies in case of exposure during pregnancy,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; prolonged
and/or painful erection,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty
controlling core body temperature or overheating,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest
pain,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling
of hands, ankles or feet,</span></em></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><em><span lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in
blood tests: increased or fluctuating blood sugar, increased </span></em><span
lang=EN-GB>glycosylated haemoglobin.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><em><span
lang=EN-GB style='color:black;font-style:normal'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></em><span
lang=EN-GB style='color:black'>Inability to resist the impulse, drive or
temptation to perform an action that could be harmful to you or others, which
may include:</span></p>

<p class=EMEABodyText style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; strong
impulse to gamble excessively despite serious personal or family consequences</span></p>

<p class=EMEABodyText style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; altered
or increased sexual interest and behaviour of significant concern to you or to
others, for example, an increased sexual drive</span></p>

<p class=EMEABodyText style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; uncontrollable
excessive shopping</span></p>

<p class=EMEABodyText style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; binge
eating (eating large amounts of food in a short time period) or compulsive
eating (eating more food than normal and more than is needed to satisfy your
hunger)</span></p>

<p class=EMEABodyText style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB>a tendency to wander away.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt'><span lang=EN-GB
style='color:black'>Tell your doctor if you experience any of these behaviours;
he/she will discuss ways of managing or reducing the symptoms.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>In elderly patients
with dementia, more fatal cases have been reported while taking aripiprazole.
In addition, cases of stroke or &quot;mini&quot; stroke have been reported.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Reporting of side
effects</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If you get any side
effects, talk to your doctor or pharmacist. This includes any possible side effects
not listed in this leaflet. You can also report side effects directly via <span
style='background:silver'>the national reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a></span>. By reporting side effects you can help provide more information
on the safety of this medicine.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to
store ABILIFY</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Keep this medicine
out of the sight and reach of children.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Do not use this
medicine after the expiry date which is stated on the carton and on the vial
after EXP. The expiry date refers to the last day of that month.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Keep the vial in the
outer carton in order to protect from light.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Do not throw away
any medicines via wastewater or household waste. Ask your pharmacist how to
throw away medicines you no longer use. These measures will help protect the
environment.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='color:black'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>What ABILIFY contains</span></b></p>

<p class=EMEABodyTextIndent><span lang=EN-GB style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The
active substance is aripiprazole.</span></p>

<p class=EMEABodyTextIndent style='text-indent:0in'><span lang=EN-GB
style='color:black'>Each&nbsp;mL contains 7.5&nbsp;mg aripiprazole.</span></p>

<p class=EMEABodyTextIndent style='text-indent:0in'><span lang=PT
style='color:black'>A vial contains 9.75&nbsp;mg (1.3&nbsp;mL) aripiprazole.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=PT style='color:black'>&nbsp;</span></p>

<p class=EMEABodyTextIndent><span lang=PT style='color:black'>&#8226;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span
style='background:white'>The other ingredients are </span>sulfobutylether </span><span
lang=EN-GB style='color:black'>&#946;</span><span lang=PT style='color:black'>-cyclodextrin
(SBECD), tartaric acid, sodium hydroxide, and water for injections.</span></p>

<p class=EMEABodyText><span lang=PT style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>What ABILIFY looks
like and contents of the pack</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The ABILIFY solution
for injection is a clear, colourless, aqueous solution.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Each carton contains
one single-use type I glass vial with a rubber butyl stopper and a
&quot;tear-off&quot; aluminium seal.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Marketing
Authorisation Holder</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Otsuka Pharmaceutical
Netherlands B.V.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Herikerbergweg 292</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>1101 CT, Amsterdam</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Netherlands</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Manufacturer</span></b></p>

<p class=NormalSingle><span lang=EN-GB style='font-size:11.0pt'>Zambon S.p.A.</span></p>

<p class=NormalSingle><span lang=EN-GB style='font-size:11.0pt'>Via della
Chimica, 9</span></p>

<p class=EMEABodyText><span lang=EN-GB>I-36100 Vicenza(VI)</span></p>

<p class=EMEABodyText><span lang=EN-GB>Italy</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>For any information
about this medicine, please contact the local representative of the Marketing
Authorisation Holder:</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=614
 style='border-collapse:collapse'>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Belgi&euml;/Belgique/Belgien</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=DE>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=DE>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#268;esk&aacute; republika</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Magyarorsz&aacute;g</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Danmark</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharma Scandinavia AB</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tlf: +46&nbsp;(0)&nbsp;8&nbsp;545&nbsp;286&nbsp;60</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Malta</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=DE>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=DE>Otsuka Pharma GmbH</span></p>
  <p class=MsoNormal><span lang=DE>Tel: +49&nbsp;(0)&nbsp;69&nbsp;1700&nbsp;860</span></p>
  <p class=MsoNormal><span lang=DE>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Nederland</span></b></p>
  <p class=MsoNormal><span lang=ES>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Eesti</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Norge</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharma Scandinavia AB</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tlf: +46&nbsp;(0)&nbsp;8&nbsp;545&nbsp;286&nbsp;60</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&Ouml;sterreich</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=ES>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal><span lang=ES>Otsuka Pharmaceutical</span><span lang=ES>,
  S.A.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +34 93 550 01 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Polska</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=FR>France</span></b></p>
  <p class=MsoNormal><span lang=FR>Otsuka Pharmaceutical France SAS</span></p>
  <p class=MsoNormal><span lang=FR>T&eacute;l: +33 (0)1 47 08 00 00</span></p>
  <p class=MsoNormal><b><span lang=FR>&nbsp;</span></b></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=PT>Portugal</span></b></p>
  <p class=MsoNormal><span lang=PT>Lundbeck Portugal Lda</span></p>
  <p class=MsoNormal><span lang=PT>Tel: +351 (0) 21 00 45 900</span></p>
  <p class=MsoNormal><span lang=PT>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=PT>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=PT>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=PT>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=PT>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=PT>Rom&acirc;nia</span></b></p>
  <p class=MsoNormal><span lang=PT>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=PT>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&Iacute;sland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Vistor hf.</span></p>
  <p class=MsoNormal><span lang=EN-GB>S&iacute;mi: +354 (0) 535 7000</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Slovensk&aacute; republika</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Italia</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Italy S.r.l.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +39 (0) 2 0063 2710</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=IT>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=IT>Otsuka Pharma Scandinavia AB</span></p>
  <p class=MsoNormal><span lang=EN-GB>Puh/Tel: +46&nbsp;(0)&nbsp;8&nbsp;545&nbsp;286&nbsp;60</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Sverige</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharma Scandinavia AB</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +46&nbsp;(0)&nbsp;8&nbsp;545&nbsp;286&nbsp;60</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width=303 valign=top style='width:227.2pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Latvija</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceutical Netherlands B.V.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +31 (0) 20 85 46 555</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=311 valign=top style='width:233.5pt;padding:0in 0in 0in 0in;
  height:1.0pt'>
  <p class=MsoNormal><b><span lang=EN-GB>United Kingdom</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Otsuka Pharmaceuticals (UK) Ltd.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +44 (0) 203 747 5300</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=EMEAHeading2 style='page-break-after:auto'><span lang=EN-GB
style='color:black;font-weight:normal'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>This leaflet was
last revised in {MM/YYYY}</span></b></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Other sources of
information</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=EMEABodyText><em><span lang=EN-GB style='color:black;font-style:normal'>Detailed
information on this medicine is available on the European Medicines Agency web
site: </span></em><span lang=EN-GB style='color:blue'><a
href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a></span><em><span
lang=EN-GB style='color:black;font-style:normal'>.</span></em></p>

</div>

</body>

</html>
